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The murine hybridoma CRL1606 was found to be dependent on insulin for 
proliferation in serum-free conditions.  A novel insulin-free medium, developed by zinc-
supplementation, could support cell growth and antibody production to the same extent as the 
original insulin-supplemented medium.  No adaptation into the new medium was necessary.  
The effects of these media on the transcriptional response of the cells were investigated using a 
7524-element microarray based on the Compugen basic mouse oligolibrary.  Analysis via 
pathway visualization suggested that zinc could have insulin-mimetic effects in insulin-free, 
zinc-supplemented CRL1606 culture via the up-regulation of PUR-1 and CD19 (which then 
imparts survival signals via the Pi3k-dependent pathway), as well as through the down-
regulation of the apoptotic adaptor FADD (that eventually inhibits apoptosis via the caspase 8 
cascade).  Taken together, the microarray results suggest that Pi3k may be important in 
integrating zinc-induced signaling with the insulin-mimetic effects observed in zinc-
supplemented insulin-free CRL1606 cultures.   
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Optimal growth of hybridoma cells has been routinely achieved in chemically defined 
basal media supplemented with relatively high levels of animal-derived components (e.g. 
serum and insulin).  To help comply with increasingly stringent regulatory requirements, a 
well-defined production process based on protein-free media is desirable for the production of 
monoclonal antibodies of consistent quality.  This thesis, part of a project to develop a protein-
free medium for a murine hybridoma cell line CRL1606, was undertaken in 2 stages to (i) 
identify a non-proteinaceous substitute for insulin, and to (ii) study the differential gene 
expression profile in zinc- and insulin-supplemented cultures. 
CRL1606 was found to be significantly dependent on insulin for proliferation under 
serum-free conditions.  Growth rate and peak cell density varied with different insulin dosages.  
Although cells grown in either insulin-supplemented or insulin-free media were capable of 
producing similar final antibody titers (at varying specific productivities), repeated passaging 
in insulin-free medium resulted in unstable growth and viability profiles.  Based on previous 
studies detailing the insulin-mimetic properties of zinc, a novel insulin-free medium was 
developed through the addition of ZnSO4·7H2O (at a relatively high concentration of 1.5mg/L).  
This medium restored the growth of insulin-free cultures without the need for adaptation.  
Prolonged maintenance in the new medium showed good culture stability in terms of growth, 
viability and antibody production.  Inductively coupled plasma-optical emission (ICP-OE) 
measurements of extracellular zinc ion concentration in batch zinc-supplemented cultures 
suggested significant biosorption and/or cellular uptake of zinc under insulin-free conditions. 
The effect of insulin- and zinc-supplemented media on the transcriptional response of 
CRL1606 cells was investigated using oligonucleotide microarrays.  Comparative analysis 
revealed that 0.7% of the Compugen (Jamesburg, USA) basic mouse oligolibrary (7524 genes) 
showed at least 2-fold differential expression (n = 3, 95% confidence).   The majority of the 
  vii
differentially expressed genes was signal transduction and transcription-related.  Several 
candidate genes that could be involved in the insulin-mimetic effects of zinc were identified 
for further studies.  They include PUR-1 (an insulin transcription regulator), RAD (a repressor 
of glucose uptake), and CD19 (a survival signal transducer).  To further characterize the effects 
of zinc supplementation on gene expression under insulin-free conditions, a comparative study 
of low-zinc (0.2mg-ZnSO4·7H2O/L) and zinc-supplemented (1.5mg-ZnSO4·7H2O/L) cultures 
was carried out.  49 genes (0.65% of 7524 genes) showed at least 2-fold differential expression 
(n = 3, 95% confidence) in the study.  Candidate genes identified through the study for further 
investigations include GRB10 (which regulates insulin and Igf-1 signaling), PAX6 (a 
transcription factor that binds to insulin promoters) and EIF4EBP1/PHAS1 (an insulin-
stimulated mediator of protein synthesis).  Taken together, the microarray results suggest that 
Pi3k (a well-known downstream effector of insulin-related substrates) may be important in 
integrating zinc-induced signaling with the insulin-mimetic effects observed in zinc-
supplemented insulin-free CRL1606 cultures.  The identification of the above-mentioned 







N.1 General Abbreviations and Nomenclature 
3.0e5  3.0 x 105 
AAA  quantitative amino acid analysis 
Ai  total intensity / hybridization strength of the ith element on microarray 
AMP  ArrayWoRx Microtiter Plate 
ATCC  American Type Culture Collection 
ATP  adenosine tri-phosphate 
BSA  bovine serum albumin 
CCD  charge coupled device 
cDNA  complementary DNA 
CG  correction factor for Cy3 channel 
CHO   Chinese Hamster Ovary 
CR   correction factor for Cy5 channel 
CRL1606 a murine hybridoma cell line (ATCC-CRL1606) 
Cy  cyanine 
DMEM  Dulbecco's Modified Eagle Medium 
DMSO  dimethyl sulfoxide 
DPEC  diethyl pyro-carbonate 
ELISA  Enzyme Linked ImmunoSorbent Assay 
EST  expressed sequence tag 
GenMAPP Gene Microarray Pathway Profiler 
Gi  measured signal minus background intensity of Cy3 channel (ith element) 
GSH  glutathione 




ICP-OE inductive coupled plasma-optical emission 
IMDM  Iscove’s Modified Dulbecco’s Medium 
lowess  locally weighted linear regression 
IVCD  integrated viable cell density 
log2  logarithm (common, base 2) 
Mab  monoclonal antibody 
MAPP  Microarray Pathway Profiler (platform files for GenMAPP analysis) 
mgZn/L mg of ZnSO4·7H2O per liter (or mg-ZnSO4·7H2O/L) 
mgZn2+/L mg of elemental zinc ion per liter 
Mi  normalized expression ratio for the ith element 
Mnorm,i   lowess-corrected expression ratio 
mRNA  messenger RNA 
n  number of replicate experiments 
Narray  number of unique elements in the microarray 
Ntotal  normalization factor 
r  Pearson's correlation coefficient 
Ri  measured signal minus background intensity of Cy5 channel (ith element) 
R’i  normalised signal minus background intensity of Cy5 channel (ith element) 
ROI  region of interest 
RT  reverse transcription 
SDDC  semi-automatic DNA dispensing cell 
SDS  sodium dodecyl sulfate 
SMP  stealth micro spotting pin 
SSC  sodium chloride/sodium citrate 




w.r.t.  with respect to 
w/w  weight/weight (concentration) 
Zn  zinc 
µ  specific growth rate 
[ x ]  with reference to x 
~ y mL  approximately to be y mL 
 
N.2 Gene and Protein Name Abbreviations 
Gene name abbreviations are shown in capital letters and italics (e.g. MAZ, IR).  
Protein name abbreviations are shown in capital letters without italics for 2-letter abbreviations 
(e.g. IR, MT), or a combination of both capital and small letters without italics for 3-letter 
abbreviations (e.g. pRB, ZnT, Maz), depending on the prevailing convention.  The following, 
listed as proteins, are mentioned in the text of this thesis: 
Akt/PkB protein kinase B 
Bax  Bcl2-associated X 
Bcl  B-cell leukemia/lymphoma 
Bcr  B-cell antigen receptor 
Cdc42   cell division cycle 42 
Clca1  chloride channel calcium activated 1 
Eif4ebp1 eukaryotic translation initiation factor 4E binding protein (also known as Phas1) 
Fadd  Fas-associating protein with death domain 
Ghr/Ghbp growth hormone receptor/growth hormone-binding protein 
Glut4  glucose transporter 4 
Grb10  growth factor receptor bound protein 10 






Igf  insulin-like growth factor 
IR  insulin receptor 
Irs  insulin receptor substrate 
Map  mitogen-activated protein 
Maz  Myc-associated zinc finger protein 
Myc  oncogene of the MC29 avian myelocytomatosis virus. 
MT  metallothionein 
Mtf  metal-response element-binding transcription factor 
Pax6  paired box gene 6 
Pi3k  phosphoinositide 3-kinase 
pRB  retinoblastoma 
Pur-1  purine binding factor-1 
Tak1  transforming growth factor (Tgf) ß-activated kinase 1 
Tgf  transforming growth factor 
Tnfr-1  tumor necrosis factor receptor-1 
ZnT  zinc-transporter 
 
N.3 In-House Media Formulations 
The following lists the in-house media formulations described in this thesis.  
‘BITTE’ refers to IMDM-based culture medium with insulin-supplementation (10mg 
insulin/L).  This medium is also named ‘insulin-supplemented’ medium.  IMDM 
(Iscove's Modified Dulbecco's Medium) is a basal medium supplied by Invitrogen, 
California).  The exact formulation of this medium shown in Table 3.1.   
‘IF’ is obtained by removing insulin from BITTE-formulation without any replacement-










‘IF+0.2mgZn/L’ is a variation of BITTE by replacing insulin with 0.2mg-ZnSO4·7H2O/L 
(i.e. 0.045mgZn2+/L).  This medium is also named ‘low-zinc’ medium. 
‘IF+ x mgZn/L’ is a variation of BITTE by replacing insulin with x mg-ZnSO4·7H2O/L. 
‘IF+Z’ is a variation of BITTE by replacing insulin with 1.5mg-ZnSO4·7H2O/L (i.e. 
0.34mgZn2+/L).  This medium is equivalent to ‘IF+1.5mgZn/L’, is also named as 
‘optimal-zinc’ medium in Section 4.5. 
Note: ‘mgZn’ is equivalent to ‘mg-ZnSO4·7H2O’, while ‘mgZn2+’ specifically refers to ionic zinc only. 
 
N.4. Microarray Terms 
The following lists the microarray terms mentioned in the thesis. 
A ‘comparative study’ refers to an experiment set-up that calls for a comparison of gene 
expression patterns between two populations (i.e. ‘test’ vs. ‘control’).  Two dyes with non-
overlapping spectra are used to separately label each population of targets.  A mixture of 
the two fluorescent target populations is then hybridized with the probes on the array.  
Relative gene expression patterns can then be obtained, based on the ratio of fluorescent 
intensities of the two dyes. 
‘Dye-swap experiments’ refers to reverse-labeled microarray experiments in which each 
of the two samples to be compared is divided into two aliquots and labeled with the two 
different Cy dyes (i.e. Cy3 and Cy5) in separate steps.  Two hybridization experiments 
(‘dye-swap’ of each other) are then performed.  In the ideal case, the differential 
expression data in these two experiments should be symmetrical (in the opposite direction 
of each other). 
‘Expression ratio’ refers to values of Cy5 signal intensity (of the test sample) divided by 








Based on a pre-determined cut-off (e.g. 2-fold change), the expression ratios were used to 
determine which elements were ‘up-regulated’ and ‘down-regulated’. 
‘Cut off’ refers to a fold-change of differential expression, exceeding which the gene 
would be considered as being differentially expressed (i.e. ‘up-regulated’ or ‘down-
regulated’). 
‘Up-regulation’ or ‘induction’ of a gene refers to increased transcript expression of the 
gene in a test sample, compared to a control sample in a microarray comparative study.  
‘Down-regulation’ or ‘repression’ of a gene refers to decreased transcript expression of 
the gene in a test sample, compared to a control sample in a microarray comparative study. 
‘Z2’ and ‘B2’ [Appendixes C to E] refers to zinc-supplemented (1.5mg-ZnSO4·7H2O/L or 
0.34mgZn2+/L, Day-2) and insulin supplemented (10mg-insulin/L, Day-2) CRL1606 
culture samples respectively.  Not all of the ‘Z2 vs. B2’ microarray comparative studies 
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1.1 Monoclonal Antibody Production 
Monoclonal antibodies (Mabs) have been extensively used in clinical diagnostics, 
therapy and purification of biomolecules.  Analysts have predicted that biopharmaceutical 
drugs (of which monoclonal antibodies are a major constituent) could contribute up to 18% of 
all new medicines in the period of 2002-2007 [Ashton, 2001].  At the turn of the century, 
monoclonal antibody drugs represented about 20% of all the biotechnology drugs in clinical 
trials, according to a survey released in 2000 by the trade group Pharmaceutical Research and 
Manufacturers of America (PhRMA, Washington) [Garber, 2001].  Datamonitor Market 
Consultancy (London, UK) has also revealed that the sales of monoclonal antibody drugs 
stood at US$2.9 billion in 2001 and could grow to as much as US$12.1 billion by 2010 
[Bennett et al, 2001]. 
It was only possible to produce polyclonal antibodies prior to 1975.  In 1975, Kohler 
and Milstein [1975] developed a method to produce monoclonal antibodies by fusing a B 
lymphocyte cell (from the spleen of an immunized animal) with a myeloma cell.  The resulting 
hybridoma cells have the capacity for unlimited proliferation.  Optimal growth of hybridoma 
cells has since been routinely achieved in defined basal media supplemented with relatively 
high levels of animal-derived additives (e.g. serum [Xie and Wang, 1994]) and protein 
supplements (e.g. insulin and transferrin [Follstad et al., 1999]).   
To produce monoclonal antibodies of consistent quality, a well-defined production 
process based on fully (chemically) defined protein-free media would be highly desirable.  
Non animal-derived media supplements can improve product biosafety by avoiding the danger 




offers the important advantage of lot-to-lot consistency.  Furthermore, protein-free media may 
facilitate downstream processing  (e.g. Mab may then be directly purified from the culture 
media by affinity chromatography with protein G [Akerstrom et al., 1985]), and thus help to 
reduce production cost.  Using a medium with a well-defined chemical composition limits the 
potential for unexpected results or side effects, which could be caused by using complex 
mixtures like serum or hydrolysates.  Overall, the improvements provided by protein-free 
media on the biomanufacturing process and product biosafety would help to comply with 
increasingly stringent regulatory requirements.  A fully defined medium also facilitates process 
development and optimization studies (e.g. cellular response to specific media components) by 
eliminating spurious results originating from unknown or ill-defined media components. 
Several protein-free media are currently available from commercial media companies.  
However the exact formulations for these media are proprietary, and the lack of this vital 
information would hinder process optimisation and characterization studies for further 
production improvement.  Although cells can be engineered [Renner et al, 1995] or adapted 
[Zang et al., 1995] to grow in protein-free media, the processes can be time-consuming and 
unpredictable. 
 
1.2 Thesis Scope 
This thesis, part of a project to develop a protein-free medium for a murine hybridoma 
cell line CRL1606, was undertaken in 2 stages outlined in Sections 1.2.1 and 1.2.2: 
1.2.1 Effects of Zinc as an Insulin Substitute 
CRL1606 cultures have been previously adapted to serum-free conditions, in part by 
insulin supplementation (10mg/L).  In fact, insulin is a very common growth-promoting 




1995].  But since insulin is commonly derived from animals and has a tendency to degrade 
under certain conditions, its removal from the media formulation is much preferred.  Although 
recombinant insulin from E. coli has been used, it is a costly option.  On the other hand, the 
insulin-replacement must preserve the original culture growth rate and viability.  A reduced 
growth rate would lengthen the culture duration and thus increase the overall running cost.  
Lower culture viability could also reduce product quality because of the proteases and 
glycosidases that are released by the lysed cells.  This could in turn induce the need for a more 
stringent downstream purification regime. 
To develop an insulin-free medium, the effects of zinc were investigated as a possible 
substitute for insulin.  A number of previous studies have suggested that zinc may have 
insulin-mimetic properties in various cell cultures and whole animals [May and Contoreggi, 
1982; Korohoda et al., 1993; Price et al., 1998].  In particular, zinc (together with other trace-
metal constituents) has been suggested as a probable substitute for insulin in the development 
of a protein-free cell culture medium [Cleveland and Erlanger, 1988; Jayme and Smith, 2000].   
In this thesis, the effects of zinc as an insulin replacement were studied in a series of 
dose-response cell culture experiments.  Subsequently, the long-term effect of the new insulin-
free medium was examined by comparing the characteristics of insulin-free and insulin-
supplemented cultures under prolonged maintenance.  Cell growth, viability, nutrient uptake, 
metabolite, and Mab production profiles were monitored to understand the effects of the test 
medium on cellular response. 
1.2.2 Effects of Zinc and Insulin on Global Genetic Expression 
As insulin is known to trigger signal transduction along several pathways [Bevan, 
2001], we hypothesized that zinc may also affect key genes along some of these pathways, 
leading to its insulin-mimetic effect.  DNA microarray was used to analyze the transcriptome 




range of genes (including those involved in metabolism, protein synthesis/degradation, cell 
cycle, signal transduction and apoptosis) were monitored.   
This knowledge may be useful for the subsequent design of a medium that caters more 
closely to cellular requirements and thus improve cell growth, product formation and 
productivity.  Findings from these studies may also help to identify potential targets for genetic 
manipulation and metabolic engineering to overcome the dependence of these cells on protein-
based media supplements.   
1.2.3 Thesis Organization 
Chapter 2 starts with a brief overview of serum- and protein-free media development 
for hybridoma cell lines, followed by reviews of insulin and zinc functions, as well as zinc-
insulin interactions.  The discussion of insulin functions focuses mainly on cell culture 
applications, while a sub-section is devoted to the current understanding of insulin structure.  
Zinc and zinc-insulin functions are reviewed more broadly (both cell culture and whole animal 
studies are discussed) because the specific functions of zinc have not been well established in 
the cell culture literature.  Chapter 3 describes the materials and methods of cell culture, 
microarray and other analytical techniques used.  Chapter 4 presents the results and 
discussions of various cell culture and microarray experiments on zinc- and insulin-
supplemented CRL1606 cultures.  The results from dose-response experiments for zinc and 
insulin are presented, and from these the cell culture effects of zinc and insulin are compared.  
Microarray analysis results of various zinc- and insulin-supplemented cultures are also shown 
and discussed in Chapter 4.  The concluding chapter, Chapter 5, provides a summary of the 
main conclusions, and recommends some areas for future studies. 
Appendixes A and B list out the materials, equipment and software mentioned in 
Chapter 3.  Appendixes C to E provide a contemporary background (in terms of data analysis, 




provides an overview of the pre-screened differential regulation profiles, while Appendix G 
lists out the secondary differential expression data (n = 3, <95% confidence) from the 
comparative studies detailed in Chapter 4.  Appendix H discusses the clustering of microarray 
data presented in Section 4.4.  Appendix I shows the pathway visualization of microarray data 
presented in Section 4.5.  Appendix J presents sample calculations for normalization, screening 






2. LITERATURE REVIEW 
            
2.1 Media Development for Hybridoma Cell Culture 
The first successful development of a monoclonal antibody (Mab)-secreting 
hybridoma cell line by Kohler and Milstein in 1975 [Kohler and Milstein, 1975] occurred at a 
time when the pioneering serum-free culture media formulations (first described by Ham in 
1965 [Ham, 1965]) were being developed in rapid succession.  Since hybridomas secrete their 
antibodies directly into the culture medium, the advantages of using a serum-free formulation 
were immediately apparent.  Serum contains many ill-defined components (e.g. various 
stimulatory and inhibitory factors).  As serum is derived from animals, it also carries the risk 
of contamination by virus, mycoplasma and prions.  Furthermore, serum is costly 
(~US$400/L*), and is subject to lot-to-lot variability as well as supply/demand constraints.   
In addition to the small-molecule nutrients, serum-free media are typically 
supplemented with one or more specific proteins that the cells require in order to survive and 
proliferate in culture [Hayashi and Sato, 1976]. These include growth factors that stimulate cell 
proliferation (e.g. insulin) and iron-carriers (e.g. transferrin).   However the protein-based 
additives have to be replaced with non-proteinaceous substitutes in order to achieve protein-
free media formulations.  Past attempts at the development of protein-free media for the 
cultivation of mammalian cells had varying levels of success [Barnes and Sato, 1980; Stoll, 
1996 and references therein].  It is only in recent years that commercially available serum- and 
protein-free media for hybridomas are becoming increasingly prevalent [Table 2.1]. 
 






Table 2.1 Survey of commercially available serum- and protein-free hybridoma media 
 
 
Serum-free / Protein-free 
Hybridoma Media Reference Remarks 
CD Hydridoma Medium 
(Gibco, Invitrogen) 
http://www.invitrogen.com Free of animal-derived 
components and proteins. 
Hybri-Max 
(Sigma) 
http://www.the-scientist.com Both serum-free and protein-
free formulations are 
available. 
HYGM-6 and HYGM-7 
(PromoCell) 
http://www.promocell.com HYGM-7 is protein free; 




Federspiel et al., 1991 Serum-free.  Contains 






Serum-free.  Contains 




http://www.jrhbio.com Serum-free.  Contains 
11mg/L of undisclosed 
proteins. 
IS-MAB-V, HB-GRO and 
HB-PRO 
(Metachem Diagnostics) 
http://www.metachem.co.uk Serum-free.  Contains ~1 to 
50mg/L of undisclosed 
proteins 
Note: Many cell lines previously grown in the presence of abundant serum and protein are unable to 
survive an abrupt transition into serum- or protein-free media.  These cells must be first be weaned into 




2.2.1 Insulin in Cell Culture 
Insulin (C254H377N65O75S6) is an important protein additive that has been commonly 
used in serum-free mammalian cell cultures [Barnes, 1987; Zhou and Hu, 1995 and references 






serum-free Chinese hamster ovary (CHO) cell cultures, and is also commonly added as a 
growth-promoting supplement in serum-free media for hybridoma cultures [Bottenstein et al., 
1979; Zhou and Hu, 1995; Chung et al., 1998; Follstad et al., 1999].  In particular, Chung et 
al. [1998] has shown that the withdrawal of insulin leads to a reduction in viable cell density 
and viability in the hybridoma line CRL1606. 
2.2.1.1 Insulin in Serum-Free Hybridoma Culture 
The optimal insulin concentrations in serum-free media formulations for hybridoma 
cultures usually range from 5-10mg/L [Barnes and Sato, 1980], a level much higher than the 
physiological concentration in the blood (0.03-0.06mg/L) [Guyton, 1991].  Earlier studies of 
the effect of insulin on mammalian cell cultures were limited to evaluating the influence of its 
initial concentration on cell growth in batch cultures [Suzuki et al., 1989; Murakami et al., 
1988; Chen et al., 1993].  In fact, insulin concentration in most pioneering serum-free 
hybridoma cell culture media have been empirically optimized using cell proliferation results 
from batch cultures.   
Recent insulin-supplementation studies focus more on insulin kinetics in bioreactor 
cultures and its effects on cellular metabolism.  Balcarcel [1999] has found that presence of 
insulin dramatically extended viable proliferation from 25-50 hrs in CRL1606 fed-batch 
cultures, where the dominant effect of insulin was to enhance metabolic capacity.  Working on 
murine VO208 hybridoma cells, Martial et al. [1994] investigated the effect of various insulin 
dosages on insulin utilization kinetics in continuous culture systems.  Finding no signs of 
insulin degradation, they concluded that specific insulin utilization increases with higher 
starting levels of insulin in the culture medium, both in batch and continuous bioreactor 






To improve hybridoma cell growth, Ljunggren and Haggstrom [1995] investigated the 
effect of insulin-supplementation on specific growth rate (µ) through various dosage response 
tests based on serum and insulin.  They observed that: 
• In serum- and insulin-free batch culture, µ increased initially, then decreased. 
• In serum-supplemented batch culture, µ also increased initially, then decreased. 
• In fed-batch culture with intermittent serum or insulin addition, µ remained high until the 
exhaustion of glucose.  
• In fed-batch culture with intermittent serum and insulin addition, the final antibody titer 
was 4x higher compared to the same amount of nutrients supplied to batch culture. 
The above observations showed that while insulin was essential for growth in batch serum-free 
hybridoma culture, it needed to be constantly replenished for continued growth.  Chung et al. 
[1998] reported that CRL1606 cells grown in nutrient-rich, serum-free media deprived of 
insulin (or in a low-serum environment) exhibited “abortive proliferation”, whereby 
continuous proliferation occurred in the presence of continuous death.  They suggested that the 
phenomenon of abortive proliferation was a consequence of inappropriate cell cycle entry in a 
survival factor limited environment.  Chung then concluded that insulin, together with Bcl-2, 
were the essential survival factors since they could rescue cells from the abortive proliferation 
pathway.   
On the other hand, Zhou and Hu [1995] found that the presence of insulin in a mouse-
mouse hybridoma culture increased glucose consumption with no beneficial effect on cell 
growth and antibody production.  They suggested that the elimination of insulin from the 
medium could result in higher final antibody titers than in insulin-supplemented cultures, 
although the specific antibody productivities could be similar in both cultures.  It is noted that 
the basal medium used in the study, DMEM/F12 (ratio 1:1) (Invitrogen, California), contained 






differences, that cells in insulin-supplemented cultures formed clumps or aggregates at the end 
of cultivation, while those in insulin-free cultures remained as single cells. 
2.2.1.2 Insulin Degradation During Culture 
 Zhou and Hu [1995] have demonstrated that extracellular insulin concentration 
decreased gradually during the exponential growth stage of a mouse-mouse hybridoma culture, 
and then the remaining insulin were quickly depleted when the cell density approached its 
maximum.  Deeks et al. [1988] also observed depletion of extracellular insulin (5% w/w per 
day, at 37oC) in rat cell culture, and suggested that high bovine serum albumin (BSA) 
concentrations (near 2.5g/L) could help prevent insulin degradation.  Interestingly, Schneider 
[1989] had reported spontaneous loss of insulin (25% loss w/w per day) in a cell-free medium 
due to binding on the reactor wall. 
 On the contrary, Martial et al. [1994] observed stable insulin hormone concentration 
and activity in their cell-free serum-free medium for more than 5 days at 37oC.  They found 
that insulin was stable during the initial lag phase of a batch culture that has been inoculated at 
low cell density.  Furthermore, degradation activity was found to be negligible at the end of the 
death phase.  It should be noted that the BSA stabilizing effect (around 2.5g/L) suggested by 
Deeks [Deeks et al., 1988] could not be effective in Martial’s culture, in which the BSA 
concentration was 0.2g/L. 
Cellular uptake, processing, and degradation of insulin are complex processes with 
multiple intracellular pathways.  A number of evidences support the insulin-degrading enzyme 
(Ide), a 110-kDa metalloendopeptidase, as being instrumental in the primary degradative 
mechanism [Duckworth, 1998, and references therein].  Ide has been reported to be a zinc-
requiring metalloproteinase with a distinct zinc-binding site [Duckworth et al., 1998].  
Duckworth has also shown that zinc is essential for insulin degradation via Ide, and that zinc-






activity, but lost their proteolytic activity.  Other divalent cations (e.g. Mn2+, Co2+, and Ca2+) 
may also affect the activity of Ide [Duckworth et al., 1998, and references therein].  ATP has 
also been found to inhibit the insulin degradation activity of Ide [Camberos et al., 2001].  
Camberos’ results show that ATP (at micromolar concentrations) is an allosteric inhibitor of 
Ide, and thus could directly regulate intracellular insulin levels (depending on cell metabolic 
status).  The mechanisms that terminate signals from activated receptors also have the potential 
to influence insulin degradation, as well as the magnitude and nature of cellular responses to 
insulin [Bevan et al., 2000].  It is not known whether the cellular degradation products of 
insulin could play a role in the post-receptor processing of insulin action.  This issue could be 
studied by examining insulin analogs resistant to degradation.   
The complexities of the insulin degradation mechanisms would hinder the comparison 
of insulin-related results between separate experiments whose test conditions could not be 
entirely similar (e.g. when different stock insulin additives were used).  Another concern 
stemming from insulin degradation activities is potential wastage, since high levels of insulin-
supplementation (5-10mg/L) are needed for optimal growth in serum-free cultures [Barnes and 
Sato, 1980].  One possible way of overcoming this problem is to introduce known insulin-
stabilizers (e.g. ~2.5 g-BSA/L, trace amounts of zinc) to insulin-supplemented cultures [Deeks 
et al., 1988].  It is also a good practice to use insulin that was freshly reconstituted from 
lyophilized preparations for experiments [Sigma product descriptions; Section 3.1.2.1]. 
2.2.2 Insulin-Mediated Signaling Pathways 
Insulin is known to exert profound stimulatory effects on anabolic processes - 
including monosaccharide and amino acid transport, fat and protein synthesis, and 
phosphorylation of many metabolic intermediates and vitamins [Mohan et al., 1989, and 
references therein].  Insulin plays a crucial role in the process of cell division [Khan, 1985], 






It is also important in controlling glucose homeostasis, via the translocation of an insulin-
sensitive glucose transporter (Glut4) from intracellular storage vesicles to the cell surface 
[Olson and Knight, 2003]. 
Insulin mediates its biological effects by binding to transmembrane insulin-receptors 
(IR) on the surface of target cells [Bevan, 2001].  The binding results in autophosphorylation 
of tyrosine residues and the subsequent tyrosine phosphorylation of insulin receptor substrates 
(Irs) by the insulin receptor tyrosine kinase.  This triggers a broad intracellular pathway 
cascade that is responsible for many known insulin-related responses [Bevan, 2001].  Signal 
transduction by insulin is not limited to IR activation at the cell surface.  Mohan et al. [1989] 
had demonstrated that insulin could enter the cell via 2 stages - by first combining with plasma 
membrane IR, and then ‘internalization’ of the activated ligand-receptor complex from cell 
surface into endosomes.  This process is dependent on tyrosine autophosphorylation.   The 
lifetime of a ligand-receptor complex within the endosomal compartment may be an important 
factor influencing the types of response produced.  This could be the reason why insulin 
(which has a relatively short endosomal residence) primarily elicits acute metabolic effects, 
whereas Igf-1 (which has longer endosomal residence) elicits mitogenic responses [Cheatham 
and Kahn, 1995; Bevan. 2001].  However, Bevan [2001] has reported that both insulin and Igf-
1 suppressed apoptosis via the Pi3k-Akt pathway (without affecting the expression of the BCL-
2 gene). 
2.2.3 The Structure of Insulin 
Insulin naturally exists as a mixture of monomer, dimer, tetramer, hexamer and higher 
aggregates in a solution free of metal ions [Sanger and Tuppy, 1951a, 1951b; Sanger and 
Thompson, 1953a, 1953b].  The ability of the insulin molecule to adopt different 
conformations may be an important factor in the expression of its biological activity.  Sanger 






chain and B chain [Sanger and Tuppy, 1951a, 1951b; Sanger and Thompson, 1953a, 1953b; 




Figure 2.1 The peptide chains of the insulin molecule shown as primary sequences of 
amino acids [Sanger and Tuppy, 1951a, 1951b; Sanger and Thompson, 1953a, 1953b] 
(top) and macromolecular structure view [RasMol] (bottom)  
Note: RasMol is a free molecular visualization resource authored by Salye R., 
dedicated to research and educational purposes. 
 
A and B chains are linked together by two disulfide bonds, with an additional disulfide 
bond formed within the A chain.  In most insulin molecules, the A chain consists of 21 amino 
acids and the B chain consists of 30 amino acids. 
Although the amino acid sequence of insulin varies among different species, certain 
segments of the molecule are highly conserved [Brange and Langkjoer, 1993].  This include 
the position of the three disulfide bonds, both ends of the A chain, and the C-terminal residues 






highly similar across different species.  In fact, insulin from one animal is likely to be 
biologically active in other species (e.g. bovine and porcine insulin has been widely used to 
treat human patients).  Conlon [2001] has observed that the amino acid residues that interact 
directly with the insulin receptor (IR), as well as those that maintain this receptor-binding 
domain in its correct conformation have been remarkably conserved in the insulin molecule.  
Insulin molecules have a tendency to form dimers in solution due to hydrogen bonding 
between the C-termini of their B chains [Yao et al., 1999].  In the presence of stabilizing ions 
(such as Zn2+ and Cl- [Manallack et al., 1985; Rahuel-Clermont et al., 1997]), insulin 
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Figure 2.4 Insulin dimer [RasMol]
 
The presence of zinc ions at pH 7.0 results in the predominance of the hexamer species 
[Milthorpe et al., 1977; Brange et al., 1986; Brange and Langkjoer, 1993; Figure 2.5], which is 
the basic unit that is utilized in insulin preparations for cell culture and whole animal therapy. 
 
Figure 2.5 The insulin hexamer shown as a trimer 






In fact, zinc-induced hexamerisation is closely related to some of the processes in 
insulin biosynthesis and storage [Dodson and Steiner, 1998].  This unique interaction of zinc 
with the insulin structure could directly contribute to observed insulin-mimetic properties of 
zinc in some applications [Section 2.4.2]. 
 
2.3 Zinc 
Zinc ( ) can be found in over 300 enzymes and proteins that are involved in a 
wide range of cellular functions.  More than 200 of these enzymes require zinc as a functional 
component, and these enzymes affect most known metabolic processes [Coleman, 1992, and 
references therein].  The following is an overview of the key functions of zinc. 
30
65.39Zn
2.3.1 Major Functions of Zinc in Cell Culture 
2.3.1.1 Growth 
Zinc is required in cell cycling and is thus essential for cell proliferation [Falchuk et 
al., 1975; Prasad, 1983].  Zinc also affects the levels of many growth hormones (including Igf-
1), which in turn influences somatic growth [MacDonald, 2000].  Mitogenic hormone signal 
pathways that specifically direct cell proliferation are also dependent on zinc for optimal 
signaling [MacDonald, 2000].  Truong-Tran et al. [2000] has also shown that zinc helps to 
regulate mitosis (as well as homeostasis and apoptosis) in response to toxins.  On the other 
hand, the exposure of rat hepatocytes to excessive zinc (50µmol/L) for 24 hours decreased 
IGF-I, GHR, GHBP and albumin expression, while stimulating metallothionein (MT) 
expression [Lefebvre et al., 1998].   
2.3.1.2 Transcription and Zinc Fingers 
Zinc is present in the cell nucleus, nucleolus and chromosomes.  It is a key cofactor (or 
metalloenzyme) component that is needed to activate and transport transcription factors [Wu 






expression, which then regulates a variety of cellular processes (including cell division, nucleic 
acid metabolism, and protein synthesis).  Zinc also stabilizes the structure of DNA, RNA and 
ribosomes [Wu and Wu, 1987].  Many zinc-related metalloenzymes are known to be 
associated with DNA and RNA synthesis.  These include RNA polymerase [Wu et al., 1992], 
DNA polymerase [Prasad, 1983], various reverse transcriptases and transcription factors [Wu 
and Wu, 1987].  Zinc is tightly bound to the molecular structure of these metalloenzymes, and 
helps to form a variety of structures that are functionally important to the enzymes [Chesters, 
1991].   
One example of a common and biologically important zinc-related structure is the zinc 
finger domain.  In each zinc finger domain, the zinc ion forms a loop in the polypeptide chain 
by creating a bridge between cysteine and histidine residues, forming a finger-like protrusion.  
Zinc finger proteins represent an important group of nucleic acid regulatory binding proteins, 
and are among the most abundant proteins in eukaryotic genomes [Laity et al., 2001].  Zinc 
finger-related functions are extraordinarily diverse and include DNA recognition, RNA 
packaging, transcriptional activation, regulation of apoptosis, lipid binding, protein folding and 
assembly [Laity et al., 2001].   
Zinc fingers extend from some transcription factors and bind to the major wide groove 
of a DNA molecule [Vallee and Auld, 1995].  Many guanosine-rich strands of DNA also 
contain zinc fingers [Frederickson et al., 2000].  In fact, about 1% of the DNA in the human 
genome requires zinc fingers to be functional [Frederickson et al., 2000].  Zinc finger proteins 
also regulate ribonucleic acids in retroviruses [Pabo and Sauer, 1992].  Some of the important 












WT-1 WT-1 binds to the regulatory regions of several genes and is also thought to 
suppress the expression of certain growth factors (e.g.: insulin-like factor II). 
[Drummond et al., 1992; Werner et al., 1995].  
Krox 20   A zinc finger transcription factor that regulates gene expression in the developing 
hindbrain [Gilardi et al., 1991]. 
Egr-1 Egr-1 (early growth response-1) is associated with G0 to G1 transition in murine B 
lymphocyte and is involved in protein kinase C mediated transmembrane 
signaling [Seyfert et al., 1990]. 
p53 p53 acts as a tumor suppressor, and is considered to be the most frequently 
mutated transcript in human cancer [Werner et al., 1996; Kihara et al., 2000] 
Mtf-1 Mtf-1 (Mre-binding transcription factor-1) is a six zinc-finger transcription factor 
that plays a central role in transcription activation of the metallothionein-I gene 
(MT-I) in response to metals and oxidative stress.  Studies by Andrews [2000] 
have suggested that the DNA-binding activity of Mtf-1 could be rapidly and 
reversibly activated by zinc-finger domains. 
hZac and Zac1 hZac and Zac1 are tumor suppressors that could inhibit uncontrolled cell 
proliferation [Spengler et al., 1997; Varrault et al., 1998]. 
 
2.3.1.3 Cytoprotection 
Zinc has numerous chemical properties that could be advantageous for cytoprotection.  
Zinc has been well documented as an antioxidant that inhibits and neutralizes free radicals 
[Tate et al, 1999, and references therein].  It helps to shield DNA from the deleterious effects 
of oxygen damage by acting as scavengers, absorbing unstable oxygen molecules.  The 






and thus stabilizes the structure of cell membranes [Zago and Oteiza, 2001].  Furthermore, zinc 
protects macromolecules (e.g., proteins and DNA) from proteolysis, and stabilizes 
macromolecular complexes (e.g., microtubules) and subcellular organelles (e.g., membranes) 
[Vallee and Falchuk, 1993].  Therefore the maintenance of optimal zinc concentrations within 
cells is critical for their functional and structural integrity.   
The affinity of zinc for sulfydryl groups, coupled with lack of redox activity, enables it 
to reversibly suppress cysteine-dependent enzymes (including caspases) without irreversible 
damage or inactivation [Truong-Tran et al., 2000].  Zinc also induces an increase of 
intracellular metallothionein (MT) content, which is a potent hydroxyl radical scavenger 
[Chubatsu and Meneghini, 1993]. 
2.3.1.4 Suppression of Apoptosis 
Numerous studies have shown that zinc-depletion stimulates apoptosis in cells.  
Apoptosis was induced in various types of cells when cultured in a zinc-free medium [Martin et 
al. 1991], and when zinc was depleted by membrane-permeant zinc chelators {e.g. N,N,N',N'-
tetrakis-(2-pyridylmethyl)-ethylenediamine (TPEN), and phenanthroline} [Treves et al., 1994; 
Zalewski et al., 1991,1993].  Zinc deficiency–induced apoptosis has all the major features of 
classic apoptosis (DNA fragmentation, caspase activation, nuclear fragmentation, chromatin 
condensation and apoptotic body formation).  Martin et al. [1991] has found that zinc-
deprivation also causes necrosis in some cells (e.g. T-cell leukemic Molt-3 cells). 
(a) Inhibition of caspases.  Zinc has been found to selectively inhibit caspase-3 and 
caspase-6 activities (e.g., complete inhibition of caspase-3 at millimolar concentrations of zinc 
in Molt4 leukemia cells [Perry et al., 1997], selective inhibition of caspase-6 at submicromolar 
ranges of zinc [Stennicke and Salvesen, 1997], and complete inhibition of caspase-6 at 10 
µmol/L zinc in human cells [Takahashi et al. 1996]).  There is currently no physiochemical 






sensitive apoptosis-related molecular target of zinc, although it remains to be determined 
whether this enzyme is directly influenced by intracellular zinc concentrations.  Because 
caspase-6 is responsible for the cleavage of lamins for nuclear membrane dissolution 
[Srinivasula et al. 1996; Takahashi et al. 1996], zinc-supplementation could retard these events.  
In addition, caspase-6 is known to cleave and activate the proenzyme form of caspase-3 
[Srinivasula et al., 1996]. This could be an explanation for the apparent retardation of caspase-
3 activity by zinc [Perry et al., 1997]. 
(b) Increased Bcl-2 levels.  Fukamachi et al. [1998] has demonstrated that zinc increases 
intracellular Bcl-2/Bax ratio of human premonocytic U937 cells, thereby increasing their 
resistance to apoptosis.  In another study, Ishido et al. [1999] has shown that zinc increased the 
level of Bcl-2 in porcine kidney LLC-PK1 cells, without activating Pi3k nor Akt [Ishido and 
Kunimoto, 2001].   
(c)  DNA synthesis.  Ishido and Kunimoto [2001] have suggested that the ability of zinc 
(5µmol/L) to facilitate DNA synthesis might contribute to its anti-apoptosis properties.  
According to them, the inhibition of programmed cell death by zinc could occur via the 
promotion of the entry of cells into the S phase (for DNA synthesis) of the cell cycle. 
(d) Potential subcellular targets.   There are many potential targets for the participation 
of subcellular zinc pools in the suppression of apoptosis [Truong-Tran et al., 2000, and 
references therein].  These targets could be located in the nucleus (e.g. Ca/Mg endonuclease, 
various gene promoters), cytosol (e.g. caspase-6, metallothionein, oxyradicals, Ca ions), 
cytoskeleton (e.g. microtubules) and the mitochondria (e.g. Bcl-2, Bax).  Truong-Tran et al. 
[2000] has shown that the most likely targets for zinc in apoptosis-suppression are primarily 
cytoplasmic (e.g. caspases).  Other potential targets are the microtubular cytoskeleton (which is 
disrupted in zinc deficiency [Nickolson and Veldstra, 1972]) and oxidative stress-related 






zinc [Vallee and Falchuk 1993]).  Zinc could also temporarily suppress glucocorticoid-induced 
apoptosis by inhibiting the binding of glucocorticoid to cytoplasmic receptors [Fraker and 
Telford 1997]. 
(e) A further note.  A valid reservation of zinc-mediated apoptosis-suppression is the 
eventual divergence of the cells into necrosis [Fraker and Telford, 1997].  This is because 
necrosis will lead to a greater inflammatory response than apoptosis.  Fraker and Telford 
[1997] concluded their appraisal of zinc-mediated apoptosis-suppression with the comment, 
"…the more important question may be whether so-called inhibitors of apoptosis actually 
provide cells with long term protection, or only a very temporal blockage that is subsequently 
overridden with greater detriment.”.  
2.3.2 Cellular Zinc Sensors 
Metal-response element-binding transcription factor-1 (Mtf-1) functions as a cellular 
zinc sensor which coordinates the expression of genes involved in zinc homeostasis, metal 
toxicity protection and oxidative stress protection [Andrews, 2001].  In mice, these genes are 
known to include the metallothionein (MT), the zinc-transporter-1 (ZNT-1) and the gamma-
glutamylcysteine synthetase heavy chain (gammaGCShc) genes.  The cysteine-rich MTs 
function as intracellular metal-chelators that bind to zinc with high affinity, whereas the 
transmembrane protein ZnT-1 exports zinc from the cell [Andrews, 2001]. Gamma-
glutamylcysteine synthetase controls the rate-limiting step in glutathione (Gsh) biosynthesis. 
Gsh, which is present in millimolar concentrations in cells, effectively chelates large amounts 
of zinc in vitro. Both MT and Gsh also function as antioxidants [Langmade et al., 2000; 




 Table 2.3 Overview of key cellular zinc sensors 
Zinc sensors Description 
MT Metallothioneins (MTs) are small, cysteine rich heavy metal-binding proteins, 
which participate in an array of protective stress responses [Andrews, 2000, and 
references therein].  MT of higher eukaroytes has evolved as a mechanism to 
regulate zinc levels and distribution within cells and organisms.  These proteins 
can also protect the cell metal-toxicity and oxidative stress-inducing agents.  In 
mice, among the four known MT genes (isoforms1 of each other), MT-I and MT-II 
genes are most widely expressed [Liang et al., 1996].  In contrast, MT-III and 
MT-IV genes show restricted and specific patterns of expression.  The 
transcription of these genes is rapidly and dramatically up-regulated in response 
to zinc and cadmium, as well as in response to agents that cause oxidative stress 
and/or inflammation.  MTs could be isolated from tissues as zinc-MT complexes 
[Andrews, 1990; Kagi, 1991]. 
1 An isoform is a protein that has the same function and similar (or identical) 
sequence to another protein, but is the product of a different gene.  Different 
isoforms are usually tissue-specific.  The term has a stronger implication of 
functional similarity than the term `homologous'. 
Mre Metal response elements (Mre’s) are essential for the transcriptional induction of 
MT-I and MT-II genes by zinc [Giedroc et al., 2001].  These DNA motifs are 
present in multiple copies in the proximal promoters of MT genes.  Mre’s have 
also been shown to confer response to cadmium and oxidative stress [Giedroc et 
al., 2001].  Interestingly, Mre’s protect mouse hepatoma Hepa-1 cells against 
zinc-toxicity, but not cadmium-toxicity [Solis et al., 2002]. 
Mtf-1 The DNA-binding activity of Mre-binding transcription factor-1 (Mtf-1) is 
rapidly and reversibly activated by zinc (via the zinc-finger domain) [Andrews, 
2000].  Mtf-1 binds specifically to Mre’s and transactivates MT gene expression 
in response to zinc and cadmium. 
 
 
2.3.3 Effective Zinc Dosage and Zinc Toxicity in Cell Culture 
While there were no reports of zinc dosage studies on hybridoma cells, a number of 
studies have demonstrated that the optimal ranges of extracellular zinc concentration for 






of Zn2+) sufficed to inhibit Ca-induced DNA fragmentation in isolated mouse thymocytes 
nuclei [Cohen and Duke 1984].  Chvapil et al. [1976] showed that the inclusion of 10µmol/L 
of zinc (0.65mg/L of Zn2+) in the cell isolation medium of canine lymphocytes significantly 
increased their viability.  This effect was accompanied by increased cellular zinc uptake.  In 
another study, 5–25 µmol/L of zinc (i.e. 0.33-1.6mg/L of Zn2+) strongly suppressed inter-
nucleosomal DNA fragmentation and cell death in intact human lymphatic leukemia cells 
when administered in the presence of zinc ionophores such as pyrithione [Zalewski et al., 
1991].   
The zinc content in commercial media normally does not exceed 0.2mg/L [Table 2.4], 
while an extracellular concentration of above 10-15mg/L of zinc ions is cytotoxic for most cell 
lines [Borovanský and Riley, 1989; Telford et al., 1995; Fraker and Telford, 1997; Iguchi et 
al., 1998; Hamatake et al., 2000].   
Table 2.4 Zinc content of various commercial media (based on 
manufacturer’s specifications) [www.invitrogen.com]
Commercial Media Zinc content Zn2+ ion (mg/L) 
Ham’s F-12 0.86mg/L of ZnSO4·7H2O 0.195676 
DMEM/F12 (1:1) 0.432mg/L of ZnSO4·7H2O 0.098293 
Improved MEM Zinc Option 0.10mg/L of ZnSO4·H2O 0.036451 
F-12K (Kaighn’s Modification) 0.144mg/L of ZnSO4·7H2O 0.032764 
IPL-41 (For insect cells) 0.04mg/L of ZnCl2 0.019177 
Ham’s F-10 0.03mg/L of ZnSO4·7H2O 0.006826 
MCDB 131 0.0003mg/L of ZnSO4·H2O 0.000109 
William’s Media E 0.0002mg/L of ZnSO4·7H2O 0.000046 








However, some studies have shown that 200–5000µmol/L of zinc (i.e.13-327mg/L of 
Zn2+) retarded cell death (at least in the short term) in cultured rat cells of lymphoid, hepatic, 
and neoplastic origins [Sunderman, 1995; Zalewski and Forbes, 1993].  The requirement and 
tolerance of these cells for high levels of extracellular zinc concentration could be due to the 
relatively poor uptake of zinc across their cell membrane.   
Relatively moderate zinc concentrations (5-15mg/L of Zn2+) have been shown to be 
toxic for some cells, and zinc toxicity-induced cell deaths are not limited to necrosis.  Telford 
and colleagues have shown that 80-200 µmol/L of zinc (5.2-13mg/L of Zn2+) was toxic to 
mouse thymocytes [Telford et al., 1995; Fraker and Telford, 1997], and that the primary form 
of cell death was apoptosis, not necrosis.  However, an increase in intracellular zinc 
concentration could only temporarily suppress apoptosis, and the cells may still die via 
necrosis in the longer term.  For example, zinc fails to block glucocorticoid-induced apoptosis 
in mouse thymocytes in the long term [Fraker and Telford 1997].  In a study on 
lymphoblastoid leukemia Molt-4 cells conducted by Hamatake et al. [2000], cell viability 
decreased to near 0% when exposed to 300 µmol/L of zinc (19.6mg/L of Zn2+) for 48 hrs.  
With exposure to 100 and 200 µmol/L of zinc (6.5 and 13mg/L of Zn2+) for 48 hrs, the 







Figure 2.6 Viability of Molt-4 cells at different zinc dosages [Hamatake et al., 2000] 
 
According to Hamatake, zinc induced both necrosis and apoptosis in Molt-4 cells, in a manner 
independent of caspase activation.  Another study has shown that 200-500µmol/L of zinc (i.e. 
13-33mg/L of Zn2+) induced necrosis in human prostate carcinoma cells [Iguchi et al., 1998].   
2.4 Zinc – Insulin Interactions 
Due to the scarcity of cell culture literature addressing zinc-insulin interactions, both 
cell culture and whole animal studies are discussed in this section.    
2.4.1 Inclusion of Zinc in Insulin Preparations 
The majority of commercially available insulin preparations contain small amounts of 
zinc [Section 2.4.1.2; Table 2.5].  Zinc primarily acts as a ‘stabilizer’ in these preparations 
[Section 2.2.3], while it also serves as a trace-element cofactor in diabetes treatment [Kimura, 
1996, and references therein].  However the corresponding mechanisms and interactions of 
zinc in carbohydrate metabolism are not well understood [Kimura, 1996], and the probable 






More specifically, it is not known whether the trace amounts of zinc present in insulin 
preparations could contribute (synergistically or otherwise) to the known functions of insulin 
in cell culture.  On the other hand, moderate concentrations of extracellular zinc (15-60µmol/L, 
i.e. 1.0-4.0mgZn2+/L) have been reported to collaborate with insulin (and Igf-1) to stimulate 
DNA synthesis in various fibroblast cultures [She et al., 1999; Huang et al., 1999; Huang et 
al., 2000].  In both cases, the inclusion of zinc into insulin preparations is not expected to 
propagate any undesirable side effects in cell culture and whole animal therapy.  
2.4.1.1 Zinc Ions in Insulin Structure 
Insulin was first crystallized and made available for clinical use by Abel and co-
workers in 1925 [Abel, 1926], and Scott discovered in 1934 that the rhombohedral insulin 
crystals were actually zinc-insulin complexes [Scott, 1934].  More accurately, insulin exists in 
solution as monomers or dimers (depending on concentration and pH), and in rhombohedral 
crystals as hexamers [Section 2.2.3].   
The insulin hexamer, the basic unit that is utilized in preparations for cell culture and 
whole animal therapy, predominates in the presence of zinc ions [Milthorpe et al., 1977; 
Brange et al., 1986, Brange and Langkjoer, 1993].  Under a hexagonal arrangement, insulin 
exists naturally as a trimer of dimers.  There are two forms of insulin hexamers, in which either 








Figure 2.7 Insulin hexamer with 2 zinc ions [RasMol] 
 
Because both polar and non-polar residues are buried between the dimers, the packing 
of dimers into a hexamer is more difficult than the packing of monomers into a dimer.  In order 
for hexamerisation to take place, the electrostatic repulsion caused by the six B13 glutamic 
acid residues (which are to be packed close together in the core of the insulin hexamer) must 
be reduced.  The coordination of zinc in the core balances the charges, and is the driving force 
toward hexamer formation in insulin [Coffman and Dunn 1988].  Other divalent metal ions 
with similar coordinations (e.g. Ni2+, Co2+, Cd2+ and Cu2+) could also play similar roles in 
insulin hexamerisation [Schlichtkrull, 1958; Hill et al., 1991]. 
2.4.1.2 Survey of Zinc Content in Insulin Preparations 
Although the majority of commercially available insulin preparations contain small 
amounts of zinc [Table 2.5], the exact zinc content is seldom reported.  From Table 2.5, it 
could be seen that the amount of zinc in insulin preparations meant for cell culture applications 














~ 0.5% (w/w)** 




< 0.01% (w/w) 
Product description for 
Sigma I-2767 
Insulin, Zinc Crystallized 
(Bovine Pancreas) 
Contains ‘small’ (unknown 
levels) amounts of heavy metals, 
such as zinc or cobalt. 











Contains ‘zinc suspension’  
(Unknown zinc content) 
Human Ultratard® (Novo 
Nordisk); Humulin Zn® 
(Lilly) 
PZI (protamine zinc insulin) a 
slow-acting form of insulin For 
increased cellular efficiency 
Unknown zinc content [Huggins, 1977] 
Isophane insulin suspension 
(NPH), zinc-insulin crystals 
modified by protamine. 
For diabetics 
Unknown zinc content Novo Nordisk 
Lente insulin (Ultralente, Lente 
and Semilente) 
For diabetics 
Contains ‘zinc suspension’ 
(Unknown zinc content) 
Novo Nordisk 
 
* ‘Insulin from Bovine Pancreas’, Sigma I-1882, was used in the studies described in Chapters 4 and 
5.  The corresponding product information sheet states that purified insulin was first crystallized 
without zinc, followed by recrystallization with zinc.   
 
** This works out to be around 0.05mg/L of zinc in 10mg/L insulin.  If the possibility of lowered zinc 
requirement in the presence of insulin could be eliminated, this amount of zinc alone could not have 






2.4.2 Insulin-Mimetic Properties of Zinc 
Zinc has been reported to be highly insulin-mimetic in some cell culture studies.  In 
one of these studies, 5µmol/L of ZnSO4, i.e. 0.33mgZn2+/L, (together with 5µmol/L FeCl4) was 
sufficient to induce and support the proliferation of B16 melanoma cells in serum-free EMEM 
(Eagles modified essential medium) in the absence of insulin and transferrin [Korohoda et al., 
1993].  May and Contoreggi [1982] have also observed insulin-like effects of zinc in rat 
adipocytes when their experiments indicated that 250-1000µmol/L of zinc (16.4-
65.5mgZn2+/L) mimicked several actions of insulin, including the stimulation of 3-O-
methylglucose transport and total glucose metabolism.  They then suggested that a major 
portion of these effects could be due to H2O2 generation via thiol auto-oxidation.  On the other 
hand, rat hepatocytes cells grown in a medium supplemented with 50µmol/L of zinc 
(3.3mgZn2+/L) for 24 hrs showed decreased expression of insulin-like growth factor-1 gene 
(IGF-1) [Lefebvre et al., 1998].  
While zinc sulfate (especially zinc sulfate-7-water) is most commonly used, other zinc 
salts (e.g. zinc chloride, zinc nitrate, and zinc bromide) were also effective as insulin-
substitutes in embryonic stem cell culture [Price et al., 1998].  It should be mentioned that 
some other trace elements (e.g. vanadium and selenium) were also observed to exhibit insulin-
like physiological effects, via a post-insulin receptor kinase mechanism [Kimura, 1996]. 
 
2.5 Microarray 
Until recent years, serum- and protein-free media have been developed via trial-and-
error type experimentations with varying levels of success [Barnes and Sato, 1980; Stoll, 1996 
and references therein].  The advent of new technologies enabling routine high capacity 
computation (e.g. supercomputer) and high throughput analysis (e.g. microarray) could allow a 






could be used to understand the effects of serum-free media supplements on gene regulation.  
This knowledge could subsequently help in the design of culture media that caters more 
closely to the requirements of various cell lines.  
2.5.1 Introduction to Microarray Technology 
Since its beginnings in the mid-1990s [Schena et al., 1995; Shalon et al., 1996], 
microarray technology has been one of the most popular tools for high-throughput genome-
scale profiling.  Microarrays are prepared by high-speed robotic printing of complementary 
DNAs on glass slides, and are used for quantitative expression measurements of the 
corresponding genes.  Because of the miniaturized platform and high density of the arrays, the 
expression of more than 20,000 genes could be monitored in parallel, on a single 3”x1” array.  
This high-capacity system could potentially detect rare transcripts in probe mixtures derived 
from as low as 2µg of total cellular messenger RNA [Schena et al., 1995]. 
Microarrays experiments are especially useful in the detection of differential gene 
expression (determination of relative expression levels or abundance of genes) and gene 
mapping (identification of gene sequence).   
In differential gene expression studies, "probes" - either cDNA (500-5,000 bases long) 
or oligonucleotide (20-80-mer oligos) - are arrayed onto microscope slides. "Targets" are 
cDNAs that are made from RNA transcripts through reverse transcription (RT).  During the 
reverse transcription process, a fluorescent dye is incorporated into the cDNA.  This results in 
a mixture of fluorescence-labeled cDNAs that corresponds to the transcriptional profile of the 
cell during the test condition.  If the experiment calls for a comparison of gene expression 
patterns between two populations (i.e. ‘test’ vs. ‘control’), two dyes with non-overlapping 
spectra are used to separately label each population of targets.  A mixture of the two 
fluorescent target populations is then hybridized with the probes on the array.  Gene expression 






The process is summarized in Figure 2.8, while a more detailed flow chart is presented in 
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Figure 2.8 The major steps of a microarray-based 
comparative gene expression study
 
For gene mapping applications, microarrays are used to locate DNA sequence 
polymorphisms, single-nucleotide polymorphisms (SNPs), or small deletions/insertions in a 
specific chromosome.  "Probes" comprising ordered clones of DNA from chromosomes of 
interest are arrayed onto the slide, and allowed to hybridize with labeled DNA targets from two 
different tissues (e.g. ‘test’ and ‘control’ tissues, or two different genotypes). Differences in 







Contemporary microarrays are mainly used for disease diagnosis, disease 
characterization, drug discovery and screening (Pharmacogenomics), and bioprocessing-
related applications.   
2.5.2 Current Microarray Applications in Bioprocessing 
In bioprocessing, microarray technology has been widely adopted to characterize gene 
expression profiles of various types of cells cultured in different culture conditions.  After 
statistical screening for reproducibility, the interpreted array data will typically highlight a 
relatively small percentage of spots representing differentially-expressed genes that will be 
further investigated.  Alternatively, the overall pattern of expression can be used as a 
"fingerprint" to characterize specific cell types and culture conditions, even when not all of the 
differentially-expressed genes on an array have been identified.   
Specific examples of how DNA microarray could be used in bioprocessing include 1) 
elucidation of the regulatory structures in the cell – through the establishment of cause-effect 
relationship between certain genes and culture conditions, 2) identification of metabolic flux 
patterns to aid metabolic engineering efforts – since microarray allows the simultaneous 
monitoring of expression levels of thousands of genes, and 3) improvement of production 
strains for biomanufacturing and downstream processing – by monitoring the expression of 
genes during growth and harvest, and by identifying genes for effective intervention 
[Nakanishi et al., 2001; Panda et al., 2003; Fadiel and Naftolin, 2003].  
However, interpreting the large amounts of data from microarray experiments can be 
challenging.  In fact, one of the defining characteristics of genome-scale expression profiling 
experiments is that the examination of so many diverse genes in parallel simply opens a 
window on all the (inherently integrated) processes that actually occur, and not merely the 






years before microarray analyses could make any significant contribution to the field of culture 





3. MATERIALS AND METHODS 
            
3.1 Cell Culture 
Section 3.1 details the materials and methods used in the cell culture studies described 
in Chapter 4.  The corresponding inventory list can be found in Appendix A. 
3.1.1 Cell Line and Culturing Conditions 
The murine hybridoma cell line, ATCC CRL-1606, produces and secretes an 
immunoglubulin IgG against human fibronectin.  The cell line was originally grown in serum-
supplemented media [Xie and Wang, 1996] and serum-free media [Balcarcel, 1999; Section 
3.1.2]. 
The cells were cultured at 37oC, under a humidified atmosphere of 8% CO2 for T-
flasks (Corning), and 5% CO2 for shake flasks (Corning).  Batch culturing was used in all the 
studies described in Chapter 4 and 5.  For maintenance and expansion, the cells were passaged 
every 2 days, with an inoculum cell concentration of 3 x 105 cells/mL for both T- and shake 
flask cultures.  All the inoculums (for both maintenance and experiments) were obtained by 
spinning down the cells in a centrifuge (Beckman Coulter) at 950 rpm for 5 mins.  The 
supernatant was discarded, and the cell pellet was resuspended with fresh maintenance or test 
media before inoculation.   
3.1.2 Experimental Setup and Culture Media 
Iscove’s Modified Dulbecco’s Medium, IMDM, (Gibco) was used as the basal 
medium.  CRL1606 has been previously adapted to serum-free conditions by supplementing 
IMDM with 7.5mg/L BSA, 3.5µL/L ß-mecaptanol, 10mg/L insulin, 10mg/L transferrin, and 
2.44µL/L ethanolamine (all supplied by Sigma).  1%(w/v) of Pluronic F68 (Gibco) was also 
added into shake flask cultures to protect the cells from shear-induced damage.  The cells were 





basal medium was prepared by dissolving powdered IMDM (Gibco) in MilliQ water 
(Millipore, Bedford).  Penicillin – streptomycin, supplied as a sterile 10,000x stock solution 
(Gibco), was added during basal media preparation.  Stock solutions of the various 
supplements were made by dissolving the respective chemicals in basal IMDM solution. 
Both the basal medium and stock solutions were sterile filtered in a laminar hood with 
0.22µm bottletop filters (Nalgene) and then stored at 40C.  They were warmed to 37°C in a 
water bath (B.Braun, Melsungen) before use.  The final culture medium was obtained by 
mixing appropriate volumes of the basal medium and stock supplement solutions in sterile 
conditions (in the laminar hood).  The stock and culture concentrations of the supplements 
used are listed in Table 3.1, while the various test media are listed in Table 3.2.  The same final 
culture medium, supplemented with 10 vol-% DMSO (Sigma), was used to cyropreserve the 
cells in liquid nitrogen at a concentration 9 x 106 cells/mL. 
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 Table 3.1 List of supplements used in serum-and albumin-free IMDM media 
Supplement# 
Concentration 




ß-mecaptanol 3.5µl/L 10x Mr = 78.13, ρ = 1.11g/mL 
Insulin### 10mg/L 10x Mr = 5733.5, Bovine, Sigma I-1882 contains 0.5% (w/w) Zn2+ [Table 2.5]. 
Transferrin 10mg/L 100x Fe = 300-600µg/g 
Ethanolamine 2.44µl/L 100x Mr = 61.08, ρ = 1.02g/mL 
Penicillin 1 U/mL 10,000x 
Streptomycin 1µg/mL 10,000x 
Commercially available as a 10,000x 
‘penicillin – streptomycin’ stock 
(Gibco)**. 
 
# Sigma Chemical Co supplied all the supplements, except penicillin-streptomycin. 
 
## All are prepared in by dissolving in basal IMDM solution except penicillin – streptomycin. 
 
### Due to potential degradation of reconstituted insulin [Section 2.2.1.2], insulin stock solutions were 
freshly reconstituted from lyophilized insulin (Sigma) (within 24 hours) before all experiments.  
However such efforts were not carried out during routine maintenance and expansion of the cell line. 
Table 3.2 Experimental setup for cell culture studies 
Experiment Experimental Setup/ Test Media Used* Culture Flasks Used 
Insulin Dosage Response 
[Section 4.1] 
Insulin dosages tested: 0.25x, 
0.5x 0.75x, 1x (control) and 1.5x, 
where 1x = 10mg-insulin/L 
20mL T-flasks (Corning) 
Effects of Insulin Starvation 
[Section 4.2] Insulin-free (IF**) and BITTE 
20mL T-flasks and 50mL shake-
flasks (Corning) *** 
Zinc Dosage Response 
[Section 4.3] 
Zinc dosages tested: 0.0, 0.1, 1.5 
and 5.0mg-ZnSO4·7H2O/L  
50mL shake-flasks (Corning) 
 
* Refer to Nomenclature ‘In-House Media Formulations’.  In all experiments, a BITTE culture (1x 
insulin) is used as the control. 
 
** Since CRL1606 cells proliferate much slower in the IF medium, IF cultures were passaged every 4 
days (during prolonged maintenance) instead of every 2 days for BITTE cultures. 
 
*** The metabolite profiles, integrated viable cell densities (IVCD = ~4e6 cells-day/mL), and final Mab 
titers of the shake- and T-flask cultures were comparable with each other, and thus only the results from 
shake-flask experiment is presented in Section 4.2.  The shake-flask cultures achieved higher peak cell 
densities (20-30% increase), but had shorter viable culture period than the T-flask cultures.  This could 
be attributed to more efficient oxygen transfer in the shake-flasks, despite a larger working volume 





In all the experiments, samples were drawn for analysis [Section 3.1.3] every 24 hours 
from inoculation until the test cultures reached zero viability.  To minimize the effects of 
insulin-simulation carried over from the pre-adaptation medium and thus affecting 
experimental accuracy, all insulin-free and zinc-supplemented test cultures had been 
maintained in the same (insulin-free) test medium for at least 2 passages prior to the 
experiment.  This is in spite of the observation that optimal cell viability could be maintained 
in the zinc-supplemented medium without prior adaptation. 
3.1.3 Analytical Methods 
Approximately 2mL of each test culture was sampled in sterile conditions and sterile-
pipetted into sterile 1.5mL eppendoff vials.  ~200µL of this was set aside for determination of 
cell concentration and viability [Section 3.1.3.1].  The rest of the sample was centrifuged 
(B.Braun, Melsungen) at 14,000 rpm for 8 minutes.  ~300µL of the supernatant was then 
carefully extracted into each new sterile 1.5ml eppendoff vials and stored at –20oC for further 
analysis detailed in Sections 3.1.3.2 and 3.1.3.4.  The cell pellets were discarded. 
3.1.3.1 Cell Counts and Viability 
Cell number and viability were determined using cell counts on a hemocytometer with 
trypan blue (Sigma) dye suitably diluted with PBS.  A minimum of two counts was done for 
each sample and the average result recorded. 
3.1.3.2 Nutrient and Metabolite Concentrations 
D-Glucose, L-Lactate, L-Glutamine and L-Glutamate concentrations were determined 
using an immobilized enzyme biochemical analyzer (Yellow Spring Instruments, Ohio).   
Ammonia concentration was quantified using an ammonia analytical kit (Sigma) based 
on reductive amination of 2-oxoglutarate.  This is done using glutamate dehydrogenase 






NADPGlutamateNADPHNHteOxoglutara GLDH + →++− 32  
(3.1) 
 
The decrease in absorbance at 340 nm (A340), due to oxidation of NADPH, is proportional to 
the ammonia concentration [Neeley and Phillipson, 1968; van Anken and Schiphorst, 1974]. 
The concentrations of various amino acids were obtained by quantitative amino acid 
analysis (AAA). The samples were first deproteinated by centrifugation using a molecular 
weight cut off (Centra free-MC, Millipore, MA), and then derivitized using 6-aminoquinolyl-
N-hydroxy-succinimidyl carbonate (AccQFluor Reagent, Waters, Milford).  Analysis was 
done via reversed phase HPLC (Shimadzu, Kyoto) with a C18 amide reversed phase column 
(Shim-pack VP-ODS, Shimadzu, Kyoto). 
3.1.3.3 Zinc Ion Concentration 
An inductively coupled plasma-optical emission spectrometer (Thermo Jarrell Ash, 
Australia) was used to measure the zinc ion content in the supernatant of fresh and spent zinc- 
and insulin-supplemented cultures.  This analysis is performed by the Chemical and Molecular 
Analysis Centre (CAMC), located in the National University of Singapore (NUS). 
3.1.3.4 Monoclonal Antibody Concentration 
The Mab concentration was determined using the following ELISA protocol.  First, the 
capture antibody (Anti-Mouse IgG1, 1.1mg/mL, Sigma) was diluted to 5µg/mL in a capture 
antibody solution (Sigma, C3401) containing 0.1% (w/v) sodium azide.  100µL of the diluted 
capture antibody mix was then added to each well on a 96-well plate (Nunc InterMed, 
Polylabo, Paris) and incubated overnight at 4oC.  After incubation, 200µL of a blocking 
solution (SuperblockTM, Pierce) was added and removed from each well three times in 
succession.  Next, 100µL of either pre-diluted  (1:200) samples or standards (IgG1 Kappa from 





1:400 to 1:1600 times.  All dilutions were done with sample buffer, made up of 1 part blocking 
solution and 9 parts washing buffer (1x PBS with 0.05% Tween 20).  For Day-1 samples, in 
which the Mab level was expected to be low, a lower dilution of 1:200 to 1:800 times was 
used.  After the dilutions, the 96-well plate was incubated for 1 hour at room temperature.   
After incubation, 100µL of a 1:10,000 diluted detection antibody solution (Goat Anti-
Mouse IgG conjugated to peroxidase, Sigma) was added and incubated for 1 hour at room 
temperature.  After each of the previous two incubating steps, the plates were washed three 
times with the washing buffer.  Finally, 200µL of the substrate solution (OPD Peroxidase 
Substrate, Sigma) was added and incubated for 30 minutes in the dark.  The reaction was 
stopped with 3M HCl and the absorbance was read at 492 nm on a microplate reader (HTIII, 
Anthos Labtec Instruments, Salzburg), with the reference filter set at 620nm.  The Mab 




This section details the materials and methods used in the microarray studies described 
in Chapter 4.  The corresponding inventory list can be found in Appendix B.  Most of the 
microarray protocols used were adapted from those published in the web page of Dr. Patrick 
Brown’s laboratory in Stanford University [http://cmgm.stanford.edu/pbrown].  In keeping 
with the convention mentioned in Section 2.5.1, the DNA tethered to the microscope slide are 
referred to as the "probes", and labeled DNA sequences from the experimental and control 
populations are referred to as the "targets". An overview of the microarray workflow used in 











Figure 3.1 An overview of the microarray workflow 
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3.2.1 Initial Preparation 
3.2.1.1 Slide Coating 
Poly-L-lysine and 3-aminopropyltriethoxysilane (APS) coatings techniques are 
typically used to coat microarray slides before probe attachment via robotic printing [Section 
3.2.2.3].  Both Silane and poly-L-lysine coated slides comprise positively-charged surfaces to 
which nucleic acid probes adhere electrostatically.  Fixation of the probes could then be done 
through UV crosslinking [Section 3.2.2.4].  Poly-L-lysine coating (whose protocol was the 
simpler of the two) was used in this thesis.  3”x1” microscope slides (Gold Seal, Portsmouth) 
were first cleaned in a cleaning solution (2.5M NaOH – 57% ethanol) to remove trace nuclease 
contamination.  Further cleaning of the slides was done by gently shaking the slides in fresh 
cleaning solution (6 racks of 30 slides per rack were immersed in a plastic basin containing 3 
liters of cleaning solution) for 2 hours.  The slides were then rinsed in double-distilled (MilliQ, 
Millipore) water at least 4 times (each time in fresh double distilled water for 1 minute) using 
repeated plunging actions.   
Coating of the slides was done by gently dipping them in polylysine solution (to make 
up 700mL polylysine solution: 70mL poly-L-lysine + 70mL tissue culture PBS + 560mL 
MilliQ water) for 1 hour.  The slides were then rinsed by plunging 10 times into fresh MilliQ 
(Millipore) water.  After rinsing, the coated slides were quickly spun-dry in a centrifuge 
(B.Braun, Melsungen, Germany) at 500rpm.  To minimize exposure of the slides to dust, each 
rack was separately wrapped in fresh aluminum foil immediately after spin-dry.  The slides 
were subsequently left in a 42oC vacuum oven for 10-15 minutes to dry.   
The coated slides needed to be aged for a minimum of 2 weeks before they could be 
used for printing.  At 2-4 weeks after coating, 6 slides randomly selected from each coating 
batch (i.e. those that were coated in the same basin of poly-L-lysine solution) were scanned to 





3.2.1.2 Preparation of Probe DNA   
The probe DNAs originated from a ‘basic’ mouse oligolibrary (MOULIB96) supplied 
by Compugen (Jamesburg, USA).  The oligolibrary consisted of 7,524 oligos, representing 
7,445 unique genes (LEADSTM cluster).  While this accounted for around a third of the entire 
mouse genome, the oligolibrary contained most of the functionally characterized mouse genes.  
Selection was based on clustering and assembly of GenBank EST and mRNA sequences using 
Compugen's proprietary LEADSTM technology for transcriptome prediction.  1 nmole of each 
oligo was supplied, while oligo length / modification was at 65bp/5'-C6 amino modifier.   
The oligolibrary was delivered, lyophilized, in 79 separate 96-well plates.  After re-
suspension in filtered 0.1M NaPO4 buffer (pH7.5) to 50µM, it was transferred via manual 
pipetting to clean 96-well plates, and diluted to 20µM (in 1x printing buffer = 50% DMSO, 2x 
SSC) for use as working plates.  The oligos were then manually pipetted to 384-well plates, 
and further diluted to 10µM (in 1x printing buffer) for use as the printing plates.  384-well 
printing plates were preferred over 96-well printing plates to reduce the number of printing 
cycles (each cycle refers to the transferring of oligos from a printing plate onto the slides) and 
thus shorten the overall printing period for a single batch of microarrays.  The printing plates 
were covered with aluminum microplate seal (Axygen, California), spun-down briefly, and 
stored at -20oC.   
3.2.1.3 Array Design 
The area on each slide that probe DNA could be printed on is referred to as the 
‘printing area’.  After allowing for a minimum of 1 mm margin around the edges, between the 
printing area and label, the available printing area on each slide was approximately 22x60mm.  
The printing area consisted of regularly arranged rectangular grids of probe DNA called 
‘subarrays’.  All the probes in each subarray were printed by one printing pin (in a multi-pin 





in subarray arrangements, but sped up the printing process.  The printhead that was used 
(SPH48 Stealth Printhead, ArrayItTM, TeleChem, Sunnyvale) could hold a maximum 48 pins in 
12x4 configuration.  A 48-pin configuration (together with a 384-well printing plate set-up) 
was used to minimize the printing time and to prevent excessive evaporation of the 
reconstituted probes.  The 48-pin configuration produced a complete array that comprised of 




Figure 3.2 Arrangement of subarrays printed with a 48-pin configuration.  Each subarray 
has 16x21 spots, constituting a 16,128-element array with 7,524 unique elements 
 
In this arrangement, each pin was spaced 4.5mm apart to match the center-to-center 
distance between the wells in standard 384-well plates.  The microarrays were produced by 
offsetting the pins between individual printing actions, with 2 horizontal spotting actions per 
oligo per slide, creating duplicates for each oligo that were horizontal to each other.   
Compugen’s basic oligolibrary, delivered in a total of 79 96-well plates, would 
ordinarily be transferred into 20 384-well printing plates.  However, extra positive controls 
(‘landing lights’) were added to the microarray design, printed at the diagonal corners of each 






Figure 3.3 Arrangement of clones (Yellow) and additional controls (Green: Cy 3 
‘landing lights’, Red: Cy5 ‘landing lights’, Blue: positive controls, White: negative 
controls) in each 16x21-spot subarray
 
The additional controls (which increased the final number of printing plates to 21) 
helped in the identification of the subarrays during post-scan spot-alignment [Section 3.2.6.2].  
An element spacing of 200µm was used on the slide.  This microarray design allowed all 
16,128-elements (inclusive of control and duplicate elements) to be printed onto a single slide.  
The microarray was designed with the help of an array-visualization software (Clonetracker, 
BioDiscovery, California).  Clonetracker was subsequently used to track the position of each 
probe on the microarray. 
3.2.2  Printing Probe DNA 
The printing process involved the sequential printing of oligo samples as an ordered 
array of small spots on the glass slide, based on the array design detailed in the previous 
section.  This was done robotically, using a Cartesian robot commonly referred to as the 
‘microarrayer’ [Section 3.2.2.1].   
3.2.2.1  Microarray Printer  
A Semi-automatic DNA Dispensing Cell (SDDC-3) microarrayer from Virtek (Bio-





style Cartesian robot microarrayer that employed split-type printing pins [Figures 3.3 and 3.4].  
The printhead can accommodate up to 48 pins in a 12x4 configuration [Figure 3.4]. 
 
 
Figure 3.4 A SDDC-3 microarrayer printing using a Stealth Printhead 
(SPH48) loaded with 48 SMP3 pins (bottom-left) [http://arrayit.com] 
 
Sample cross-contamination between printing cycles was prevented by a combination 
of pin sonication, repeated dip-washing and suction-drying.  The entire microarrayer workbed 
was also enclosed in a de-humidified chamber (50-60% humidity) to reduce spot-smudging 
and dust contamination.  Printing was carried out at a temperature range of 21-23oC. 
3.2.2.2 Printing Pins 
Stealth micro spotting pins (SMP3, ArrayItTM, TeleChem, Sunnyvale) were used for 
probe deposition.  These pins have a split quill design that draws up a DNA sample volume of 
~250nL by capillary action, and deposits a spot volume of ~0.6nL on split-second contact with 





Figure 3.5 Close-up views of SMP3 pins [http://arrayit.com] 
  
All the printed spots should ideally have a diameter ranging from 90-100µm, but the 
actual sizes depended on a variety of factors.  The printing pins created between 5 and 10 
‘preprints’, which were low-quality microarray slides that were eventually discarded.  This is 
because the spot size and quality of the ‘preprints’ were typically larger (thus increasing the 
risk of smudging and cross-contamination between spots) and more variable (making the post-
scanning spot-alignment procedure more difficult [Section 3.2.6.2]) than subsequent slides.  
This problem could be addressed by fine-tuning the number of pin ‘blotting’ steps on the 
blotting plate.  Other factors that could affect the size and quality of the printed spots included 
the volume of solution applied (which can be adjusted with time and depth of pin immersed 
within the sample solution, the time of pin-to-slide contact, and the force applied by the pin to 
the slides) and surface tension (which can be affected by the salt concentration of the 
suspension medium and room humidity).  
A pin cleaning kit (Micro Cleaning Kit, ArrayItTM, TeleChem, Sunnyvale) was used to 
clean and maintain the pins and printhead between printing runs. 
3.2.2.3 Printing Procedure 
The printing plates were spun-down briefly, and thawed at 4oC just before printing.  
Although each SMP3 pin requires only ~250nL for printing 126 slides (maximum number of 





well of the source printing plates was required for reliable printing.  Evaporation resulted in 
the loss of about 1µl of probe oligo every 1 hour (at 50-60% humidity, 21-23oC), which was 
the time the microarrayer required to process one printing cycle (defined here as transferring 
all oligos from one 384-well printing plate onto 126 slides, using a 48-pin configuration, with 
2 replicate spots per oligo).  Thus, topping up with 1x printing buffer was necessary after every 
4-5 printing batches.   
Prior to printing, each well was visually checked to ensure that there was sufficient 
volume.  Previous batch printing records of the printing plates were also used to determine the 
expected liquid volume left in the wells.  The wells were then topped up with appropriate 
volumes of 1x printing buffer (if significant evaporation has occurred) or with the same oligos 
drawn from the working plates (after ~5-10 batch printing runs) where necessary.  Printing 
buffer was made by mixing equal volumes of DMSO (Sigma) and 4x SSC, to form a final 
composition of 50% DMSO, 2x SSC. 
Printing proceeded in a left-right-top-down fashion.  The spots were visible to the 
naked eye after printing, prior to further processing.  If missing spots were observed during 
printing, the printing process would be stopped at the end of the ongoing cycle (between post-
print sonication and loading of fresh probe oligo), and the non-functioning pins would be 
removed for cleaning using a pin cleaning kit (Micro Cleaning Kit, ArrayItTM, TeleChem, 
Sunnyvale).  The respective bores in the printhead would also be cleaned using a printhead 
cleaning kit (ArrayItTM, TeleChem, Sunnyvale).   
After printing, each microarray was manually checked for smudging, ‘donuts’, missing 
spots and other artifacts.  A microscope (Olympus, UK) was used where necessary and all 
imperfections would be recorded into a logbook and the corresponding Reference Files 
[Section 3.2.6.2].  The slides with >1% printing imperfections were discarded.  The bottom 





ID, print date, and a unique slide ID), and stored in a lightproof slide box.  The slides were 
then desiccated at room temperature prior to immobilization, which typically took place the 
day after printing.    
3.2.2.4  DNA Immobilization on Slides 
After desiccation of the printed slides, the oligo elements must be immobilized on the 
glass surface. The immobilization process started with a very brief period (< 10 secs) of spot 
rehydration in a warm, humidified chamber to ensure that the spots were well-rounded.  The 
rehydrated spots were then immobilized via covalent bond induction, with UV crosslinking at 
650 (x100µJ).   
Following immobilization, the slides were dipped into a blocking solution (made up of 
2g succinic anhydride dissolved in 400mL anhydrous 1,2-dichloroethane, and 5mL of 
acylating catalyst N-methylimdazole), and left for 1 hour on an orbital shaker.  The blocking 
solution was washed off the slides by repeated plunging into 70% ethanol for 2 minutes.  The 
slides were then fixed in 95% ethanol and spun-dried.   
At this point the slides could be used immediately for hybridization, or stored in a 
slide box desiccated at room temperature.  The slides could be stored and used for up to 6 
months, although there was a slight deterioration in slide quality (increased background signal 
and emergence of ‘cracks’ in the Poly-lysine coat) towards the end of the shelf life.  
3.2.3 Experimental Setup and RNA Extraction 




 Table 3.3 Experimental setup for microarray studies 
 
Experiment # Experimental Setup/ Test Media Used ## Culture Flasks Used 
Comparative Analysis of 
‘Zinc’ vs. ‘Insulin’         
[Section 4.4] 
 
‘Zinc’ (IF+Z), an insulin-free culture 
which contained 1.5mg-ZnSO4·7H2O/L, 
i.e. 0.34mgZn2+/L. 
Sampled on: Day-1, Day-2 and Day-3 
      
‘Insulin’ (BITTE), which contained 10mg-
insulin/L. 




Comparative Analysis of 
‘Low-Zinc’ vs. ‘Optimal-Zinc’ 
[Section 4.5] 
 
‘Low-Zinc’ (Day 2), an insulin-free culture 
which contained 0.2mg-ZnSO4·7H2O/L’ 
(i.e. 0.045mgZn2+/L). 
Sampled on: Day-2 only 
 
‘Optimal-Zinc’ is equvilant to ‘IF+Z’.  





# The log-transformed differential expression ratios shown in this thesis were based on ‘Cy-5 tagged 
sample’ vs. ‘Cy-3 tagged sample’ comparative study.  I.e. if the expression of a particular gene (e.g. 
gene i) in the ‘Cy-5 tagged sample’ exceeded the expression of the same gene in the ‘Cy-3 tagged 
sample’, then (Log Ratio)i > 0; if the expression that gene in the ‘Cy-3 tagged sample’ was greater than 
in the ‘Cy-5 tagged sample’, then (Log Ratio)i < 0. 
 
## Refer to Nomenclature ‘In-House Media Formulations’. 
 
Note: All test cultures were grown in IMDM (Gibco) supplemented with 3.5µL/L β-mercaptoethanol, 
2.44µL/L ethanolamine and 10mg/L transferrin [Table 3.1], and have been adapted to their respective 
test media for at least 3 passages.  This was to reduce the possibility of any carry-over effects caused by 
the pre-adaptation media, which could be carried over to the test cultures.   
 
3.2.3.1 Sample Collection 
As the working volume for shake-flask (Corning) cultures was limited to 200mL, separate 
flasks of each test culture had to be grown, with each flask to be dedicated for a single 
sample/harvest.  (For example, one flask each for BITTE Day-1, BITTE Day-2, IF+Z Day-1, 
IF+Z Day-2, etc.)  Cell counts [Section 3.1.3.1] were performed for each cell-pellet sample 
(results not shown in this thesis). The culture volume was then split into appropriate volumes 
and spun down to yield pellets of 4e7 viable cells each.  A portion of the supernatant was 
stored at –20oC for future analysis and the rest discarded.  All the cell pellets were stored at -





results (not shown in this thesis) were compared with those in Sections 4.1 and 4.3, to check 
for abnormalities and to ensure consistency when comparing microarray data from separate 
comparative studies. 
Note:  The concentrations of key metabolites (e.g. glucose and glutamine) could be used to characterize 
and verify the stage of the batch culture sample, and thus serve as an extra dimension in future 
comparison and verification with microarray data.  The rate of accumulation/depletion of the key 
metabolites in the supernatant could also be used to verify the regulation of related genes.   
 
3.2.3.2 RNA Extraction 
The cells were first lysed, by adding 1mL of Trizol (Invitrogen) for every 10 million 
cells.  The supernatant was then removed and ~200mL of chloroform (EM Science) was added 
to remove total RNA via phase extraction.  Another round of phase extraction was applied by 
adding ‘phenol: chloroform: isoamyl alcohol (125:24:1)’ (Sigma).  The RNA was then 
precipitated by cold iso-propanol (-20oC) and subsequently washed with 75 % ethanol.  
Finally, the RNA pellet was air dried and dissolved in an appropriate volume of diethyl 
pyrocarbonate- (DEPC) treated water (usually 50-100µL for every 40 million starting cells) to 
yield 2-3µgRNA/µL.  The mix was heated at 60oC for 10 minutes to promote dissolution.   
The quantity (concentration) and quality (purity) of the final total RNA solution was 
determined with a spectrophotometer (Amersham Biosciences, GeneQuant Pro).  If the 
A260/A280 ratio was < 1.8, further RNA clean-up with Zymo kit (Zymo Research) would be 
carried out.  50µg of purified total RNA from each sample (control or test) would be used for 
hybridization on each microarray chip [Section 3.2.4]. 
3.2.4 Preparation of Target DNA 
The target cDNA was produced through reverse transcription (RT) of poly-A mRNA, 
such that amino-allyl modified nucleotides for the esterification of the Cyanine (Cy) dyes 
(Amersham Pharmacia FluoroLinkTM) could be incorporated.  Two populations of 





labeled with Cy5) could then be hybridized with the complementary probe oligo DNA attached 
to the surface of the slide. 
Poly-A attachment to mRNA was done by incubating 25µL (of 2µg/µL) total RNA 
with 0.5µL of 4µg/µL anchored oligo dT28 (Genset Oligos) at 75oC for 10 mins.  For first 
strand cDNA synthesis, a master RT mix consisting of 1µL of 40U/µL Rnasin (Promega), 
10µL of 5x first strand buffer (Invitrogen), 1µL of 40x aminoallyl-dNTP mix (Invitrogen), 4µL 
of 0.1M DTT (Invitrogen), 1µL of 200U/µL SuperscriptTM II RT (Invitrogen) was prepared, 
and reverse transcription was done by incubating the master RT mix with poly-A mRNA at 
42oC for 2 hrs.  The reaction was subsequently quenched by adding 4µL of 50mM EDTA, then 
2µL of 10M NaOH, and incubated at 65oC for 20 mins.  The quenched reaction mix was then 
neutralized with 4µL of 5M acetic acid (Merck).  Before coupling of the Cy dyes, the cDNA 
(‘first strand’) was cleaned by ethanol precipitation.  2 volumes (~120µL) of absolute ethanol 
was added to the cDNA and precipitated overnight at –20oC.  The precipitated content was 
then spun down at 14rpm for 15 mins, the supernatant discarded, and the pellet was washed 
with 750µL of 75% ethanol.  The mix was spun down again at 14rpm for 15 mins, the 
supernatant discarded, and the cDNA pellet was air-dried. 
Cy3 and Cy5 have distinctly different excitation and emission wavelengths 
(excitation/emission Cy3: 550/570 nm and Cy5 649/670).  The fluorescent signal was 
produced by illuminating the slide with filtered light of the appropriate excitation wavelengths.  
The signal could then be detected via measurement of the emitted fluorescence.  The Cy dyes 
were supplied in lyophilized form, suspended in DMSO, aliquoted and vacuum-dried in 
separate eppendoffs.  As the Cy dyes were light sensitive, they were stored in the dark (in a 
desiccated chamber at 2-8oC).  For coupling, the dried Cy dye was resuspended in 10µL of 
0.1M NaHCO3 (which was prepared fresh), the cDNA pellet was then added, and the reaction 





subsequently terminated with the addition of 5µL of 4M hydroxylamine and incubation in the 
dark at room temperature for 15mins.  The samples designated for each slide (test experiment-
Cy5 and control-Cy3) were then pooled together at this point.  Finally, the labeled target 
cDNAs were cleaned using cold (-20oC) absolute ethanol precipitation (with the addition of 
7.5M ammonium acetate), then washed with 75% ethanol, spun down, and air-dried before 
proceeding to hybridization.  
3.2.5 Hybridization 
Hybridization is the process of incubating fluorescent-labeled target DNA with probe 
DNA tethered to the microarray substrate. The target DNA will hybridize to the 
complementary probe oligo on the slide, and the amount of immobilized fluorescence (which 
represents the relative abundance of individual target cDNAs) can then be determined by 
scanning.  
Pre-hybridization could reduce unspecific binding of target cDNA to the microarray, 
and thus lower the background signal intensity.  The pre-hybridization mix (consisting of 5x 
SSC, 0.1% SDS and 1% BSA) was applied onto the slide, and allowed to spread slowly under 
a Liferslip (Erie Scientific Company) as it was gently lowered.  The slides were encased in 
watertight hybridization chambers, which were put into a 42oC water bath for 1 hour.  The 
hybridization chambers were kept moist during incubation by wetting the bottom surfaces with 
~60µL 20x SSC.  After incubation, the slides were washed by immersion in ultrapure water 
(Millipore).  The slides were then spun dry and could be used immediately for hybridization. 
For each slide, a master hybridization mix (without hybridization buffer) was prepared 
by mixing 1µL of 10µg/µL poly-A, 1µL of 10µg/µL mouse Cot-1 DNA, 1µL of 10µg/µL yeast 
tDNA [Table 3.4], landing lights (1µL of 1µM of Cy5-labeled Accession M24537 and 1µL of 





DEPC-treated or nuclease free water to 40µL per slide, and combined with the cleaned labeled 
target cDNA to constitute the target DNA mix.  
 
Table 3.4 List of blockers used during microarray hybridization 
Blocker Description 
Mouse Cot-1 DNA Blocks mouse repetitive sequences.  The term "Cot" refers to the DNA 
concentration (Co) multiplied by incubation time (t). This use of this 
blocker is optional* in oligo-based arrays since they were designed with a 
high degree of specificity. 
Poly-A DNA Blocks hybridization to eukaryotic poly-A tails.  Since the probe 
oligonucleotides were oligo-dT primed, the use of Poly-A was optional*. 
Yeast tRNA General bulk blocker that acts against non-specific hybridization caused by 
cross hybridization of the oligo elements. 
 
* These blockers were used in our microarray experiments as an added measure of precaution. 
 
 
The next step involved the denaturation of the target DNA mix at 95oC for 3 mins, to 
prevent unwanted complementary binding.  After denaturation, the target DNA mix was 
topped up with 40µL (per slide) of 2x hybridization buffer (60% formamide, 10x SSC, 0.2% 
SDS, 5% dextran T500) to a total of 80µL per slide.  The final target DNA mix was then 
centrifuged at 14rpm for 5mins to spin down undissolved residues (to avoid unspecific bright 
‘specks’ from appearing in the scanned image), and the top 75µL (carefully drawn to exclude 
the undissolved residues at the bottom of the vial) of the final target DNA mix was used for 
hybridization.   
The final target DNA mix was then spread over the slide under a Liferslip (Erie 
Scientific Company), and encased in a watertight hybridization chamber, which was put into a 





during incubation by wetting the bottom surfaces with ~60µL 20x SSC.  The dark and 
moistened condition was found to promote optimal hybridization, and minimize 
photobleaching.  The majority of the hybridization takes place in the first few minutes to the 
first few hours, up to an optimum of 8 hours.  However there was no apparent signal saturation 
when longer hybridization periods were used.  Therefore, 12-16 hours of hybridization was 
used as a convenient overnight step, and to compensate for not rocking the hybridization 
chambers (which could increase artifacts, e.g. scratches).  The target cDNA was allowed to 
mix via natural Brownian motion.   
Following hybridization, the Lifterslips were removed by gently immersing the slide 
in 1x SSC, 0.2% SDS at room temperature in the dark.  The slides were then washed by 
repeated plunging in the dark, in a series of solutions with progressively lower concentrations 
of SSC and SDS (2xSSC, then 0.1xSSC/0.1%SDS, then 0.1xSSC; 3 minutes in each wash 
solution), and spun dry.  Finally, the washed slides were transported in the dark and scanned as 
soon as practical. 
3.2.6 Signal Detection and Analysis 
After hybridization, any target that was bound to a complementary DNA probe would 
produce a fluorescent signal upon excitation with light of the appropriate wavelength.  The 
intensities of the fluorescent signals were measured, analyzed and the data was then related 
back to the probe sequences in the array.  
3.2.6.1 Signal Detection 
A CCD-based scanning system ArrayWoRxTM (Applied Precision, Seattle) was used 
for fluorescence detection.  The ArrayWoRx system consisted of several hardware 
(illumination module, detection optics) and software components (probe identification, data 





The illumination module consisted of a broadband light source, and a filter wheel containing 
four pairs of excitation and emission filters sets (including Cy3/Cy3TM and Cy5/Cy5TM filter 
sets).  A motorized shutter controlled exposure time, while the condenser lens focused light 
emitted from the selected excitation filter onto the filter optic bundle.  The filter optic bundle 
then delivered filtered light to the microarray slide. 
The delivery optics module (homogenizer) allowed both the focus and capture of light 
from the source.  Oblique illumination prevented direct entry of excitation energy into the 
detection optics, yielding a lower background and allowed the use of a more intense excitation 
source.  The detection optics consisted of objective lens (a single lens slot designed to 
accommodate par-focal objectives), focus mechanism, tube lens (lens that focuses the image 
collected by the objective onto the camera), a CCD camera, as well as a filter wheel that was 
shared with the illumination module. 
The CCD camera was made up of an array of photosensitive elements upon which the 
array image was projected.  The value of each pixel represents the light intensity for the 
corresponding area of the array.  Most of the slides were scanned at an exposure time of 0.5 
seconds for Cy3 and 1.0 sec for Cy5.  The scanned images were then saved as Tiff files 
[Figure 3.6] and exported for analysis by ArrayWoRxTM Analysis software. 
 
Figure 3.6 A typical Tiff image of hybridized microarray slides 





3.2.6.2 Image Analysis 
ArrayWoRxTM Analysis software (ver 1.50) was used for image analysis.  The 
software was provided along with the ArrayWoRx scanning system.  After scanning the image, 
the ArrayWoRx Analysis software provided a ‘working window’ for viewing multi-
wavelength and multi-panel image data in grayscale or colour.  Two monochrome images were 
produced - one for each wavelength scanned. The images were composed of pixels, and each 
pixel represented a discrete signal from the array.  To link the extracted data from the 
fluorescence-detected spots on the scanned slide to the identities of the oligos, an ArrayWoRx 
reference file using ‘Reference File Generator’ was created.  Each spot in the array was 
assigned a reference number, starting from the lower-left corner and proceeded from left to 
right.  Once the end of a row had been reached, numbering continued at the leftmost spot one 
row up.  The completed reference file contained information on the content of microtiter plates 
(gene name, unique ID, microtiter plate and spot location, etc), and the printing process.   
To standardize the conversion of microtiter plate data to the reference file format, an 
intermediate file format, called the ‘ArrayWoRx Microtiter Plate (AMP)’ was developed.  
AMP files were then converted to reference files using information pertaining to the printing 
process (array design, pin-configuration, printing pattern, spot spacing etc).  Finally, the 
‘Reference File Editor’ was used to verify the reference files, by opening the reference file in 
conjunction with a corresponding microarray image and determining whether the spot 
information was correct.  ‘Reference File Generator’, ‘Reference File Editor’, and AMP-
compatibility was provided in the ArrayWoRx system package. 
Once the spot information was verfied, the designated ‘regions of interest’ (ROIs, i.e. 
‘areas for florescence quantification’) was manually adjusted to align with the actual spot 
areas.  The ROIs that corresponded to unprinted or damaged spots were ‘flagged-off’.  The 





and AMP Files.  The ROIs of the ‘flagged-off’ spots and controls would appear red in the 
‘working window’, as compared to white for normal experimental spots.  The fluorescence 
signals of these ‘flagged-off’ spots would still be quantified, but they would be identifiable by 
‘nil’ process control codes in the exported database, and could thus be easily isolated/deleted.  
The sizes of individual ROIs were also adjusted accordingly to offset experimental variables 
such as spot shape and size irregularity.  
Finally, the respective spot intensities were quantified by determining the average 
pixel value in that spot, which was proportional to the extent of probe hybridization.  The 
extent of probe hybridization was in turn considered to be proportional to the amount of 
corresponding DNA in the target sample (assuming no loss of data-sensitivity via saturation in 
the previous steps [Appendix C]).  ‘Local background subtraction’ was used to determine the 
signal levels, as it was apparent that the background florescence varied slightly across the slide 
(caused by ‘halos’ of neighboring bright spots, and other artifacts).  The average pixel value of 
a hybridized spot at each wavelength was used to compute the ratio of the 2 fluorescence 
signals (i.e. Cy5/Cy3).  This ratio was then used to produce a false-color overlay which 
depicted spots as: 1) green, if more of the ‘control’ population hybridizes, 2) red, if more of the 
‘test’ population hybridizes, 3) or yellow if equal amounts of each population hybridize. 
The data output (clone and spot information with its corresponding spot and 
background signal intensities at each wavelength) could be exported as tab-delimited files, and 
converted to Excel spreadsheets for further analysis.  The measured fluorescence ratio values 
were then log transformed to treat inductions or repressions of identical magnitude as being 
numerically equal but with opposite sign (i.e. symmetrical to each other).  Log transformation 
base 2 was used for simplicity, since a 2-fold change was applied as the ‘cut off’ for 





as the minimum criteria for a gene to be classified as being differentially-expressed [Nadon 
and Shoemaker, 2002; Geoffrey, 2003, and references therein]. 
3.2.6.3 Data Normalization 
Due to differences in labeling efficiency, intensity and hybridization properties 
between Cy3 and Cy5 [Appendix D], the measured fluorescence intensities were normalized 
before analysis. A normalization method detailed by Quackenbush [2002, and references 
therein] was adopted for this purpose.  The underlying principle of this method was to assume 
that the mean comparative-expression ratio of all genes in each sample was 1.0.  Using this 
‘total intensity normalization’ approach, a normalization factor (Ntotal) was calculated by 


















where Ri and Gi were defined as the measured signal intensity minus background signal 
intensity of Cy5 and Cy3 channels respectively for the ith element, and Narray represents the 
total number of unique elements in the array (including controls and excluding duplicates).  In 
this thesis, Narray = 7524.  One set of the fluorescence intensities was re-scaled using Ntotal: 
itotali RNR ='  
(3.3) 

























This process was equivalent to subtracting a constant from the logarithm of Ri: 
)(N)(R)(R' totalii 222 logloglog −= , 
(3.5) 
to result in a mean log2(ratio) of 0.  Figure 3.7 illustrates the effect of total intensity 
normalization on dye-biased data.   
 
 
Figure 3.7 Intensity distribution plots illustrating total intensity 
normalization of dye biased data  
 
On top of total intensity normalization, lowess (locally weighted linear regression) 
normalization was employed to remove the systematic dependence of expression ratio values 
on signal intensity.  The easiest way to visualize intensity-dependant effects, and the starting 
point for lowess analysis, was to plot Mi [= log2(R’i/Gi)] as a function of log2 intensity, Ai 
[=0.5{log2(Gi)+log2(R’i)}].  Ai is a measure of total signal intensity or hybridization strength 
for the ith element.  The ‘M-A’ plot could also be used to review intensity-specific artifacts in 
the data set.  A quadratic trendline was inserted into the M-A plot [Figure 3.8], and the lowess-







Figure 3.8 Intensity distribution plots illustrating lowess normalization 
of intensity-dependent dye biased data  
 
The above-mentioned steps were necessary if one intended to screen the differential 
expression data with Student’s t-test, because using replicates from separate experiments with 
unnormalised data would skew the final results.  Sample calculations for the normalization of 
microarray data are presented in Appendix J. 
3.2.7 Data Screening 
A portion of the data was not reproducible among replicates of the same comparative 
study [Appendix E].  This is consistent with what has been reported in literature [Lee et al., 
2000; Kamb and Ramaswami, 2001; Tseng et al., 2001; Yang et al., 2002], and could either be 
due to natural transcriptional variations of individual culture samples, or differences in 
experimental conditions.  This phenomenon is further described in Appendix E (Section 
A.E.1).   
The first filtration step was to isolate and delete the data that had been ‘flagged off’ 
[Section 3.2.6.2].    The Student’s t-test was then used to sort out and ‘filter’ the expression 
data that showed statistically consistent fold-changes, while making an inherent assumption of 





from a review paper published by Chen and colleagues [Chen et al., 1997].  The hypothesis 
test was set up as the following:  
0: ,0 =inormMH  
(3.10) 
0: ,1 ≠inormMH  
(3.11) 
The null hypothesis was tested with a 2-tailed distribution, paired type t-test Microsoft Excel 
function ‘TTEST(array1, array2,2,1)’.  ‘array1’ contains n log2 expression ratios (replicates) of 
the genes, while ‘array2’ contains n zeros.  The TTEST function would compute the p-values 
for each gene in the array.  The p-value of each gene represented the probability that the 
certain gene was seen being differentially expressed (log ratio )0≠  when in reality it was not 
(log ratio = 0).  These p-values were used as the basis to filter the microarray data at stipulated 
confidence levels and ‘cut offs’ [Table 3.5].  As only very small portions of the differential 
expression data met the various screening criteria shown in Table 3.5, pre-screened data was 




 Table 3.5 Overview of differential expression data screened with 
Student’s t-test at different confidence levels and cut-offs 
Confidence level (%) 99 99 99 95 95 95 90 90 90 
p-value (n = 3) 0.01 0.01 0.01 0.05 0.05 0.05 0.10 0.10 0.10 
Cut off * 3x 2x 1.6x 3x 2x 1.6x 3x 2x 1.6x 
No. of genes with 
pi < p-value 
76 76 76 394 394 394 719 719 719 
• Up-regulated 0 1 6 2 18 23 3 18 41 
• Not regulated 73 69 61 371 335 298 689 618 532 
• Down-regulated 3 6 9 21 41 73 27 83 146 
• % Regulated 3.9 9.2 19.7 5.8 15.0 24.4 4.2 14.0 26.0 
 
Note: The data shown above are based on the average ratios obtained from a triplicate set up (n = 3) of 
‘zinc’ vs. ‘insulin’ comparative microarray study. 
 
* Fold-change of differential expression, that the gene would be considered as being differentially 
expressed. 
 
Table 3.5 shows that significantly more genes could be considered as being 
differentially expressed when less stringent screening criteria (lower confidence level and 
lower ‘cut off’) are applied.  The minimum threshold of 95% confidence (n = 3, pi < 0.05) and 
2-fold change for statistical significance was subsequently chosen.  This criterion was used, as 
it was the standard in many microarray studies [Geoffrey, 2003, and references therein].   
While a total of 59 genes (pi < 0.05: 18 up-regulated, 41-down-regulated) had been 
differentially regulated (> 2x fold change) with 95% confidence [highlighted column in Table 
3.5], there were another 235 differentially expressed genes (> 2x fold change, 53 up-regulated, 
182-down-regulated), whose data fell outside the 95% confidence interval (pi > 0.05).  To 
prioritize subsequent analyses, the differential expression data that fell within the 95% 
confidence interval was analyzed in greater detail [Sections 4.4 and 4.5].  Appendix G lists out 





regulated) in all replicate experiments, but whose individual expression fold-changes were not 
highly reproducible (< 95% confidence).  Two examples of such genes were the caspase 
homolog (CASH) [(log2 ratio)1 = 0.08, (log2 ratio)2 =  1.53, (log2 ratio)3 = 1.76, average log2 
ratio = 1.13] and delta-like 3 homolog (Dll3) [(log2 ratio)1 = 2.19, (log2 ratio)2 =  1.05, (log2 
ratio)3 = 4.02, average log2 ratio = 2.42].    
There were also a group of genes whose average fold-change revealed differential 
expression in one direction, but the fold-change in at least one of the replicate experiments 
showed differential expression in the opposing direction.  An example of such a gene was 
CD53 antigen (CD53) [(log2 ratio)1 = 5.20, (log2 ratio)2 = -0.26, (log2 ratio)3 = -0.25, average 
log2 ratio = 1.56].  These genes are not listed in Appendix G, but nonetheless included in the 
overview of differential expression profiles [Appendix F] as only a very small fraction of the 
differential expression data met the screening criteria.  An alternative approach that was used 
to verify the computed p-values is presented in Appendix J.  The major steps in the statistical 





Raw Intensiti s and Ratios e
Normalization 
• Dye Bias Correction 
• Lowess 
• Intensities Across Replicates 
t-test 
• Various cut-offs and 
confidence intervals 
• A final criteria of “> 2-fold 
change in expression, 95% 
confidence (p<0.05)” was used
 
Figure 3.9 Flow chart summarising the major steps 
in statistical analysis of microarray data
 
3.2.8 Data Mining 
Although various levels of total RNA were used, only data from experiments done 
with 50µg (triplicate experiments) and 75µg (duplicate experiments) of total RNA (per sample 
per slide) [Section 3.2.3] were used for subsequent data mining.  This is because the data from 
these experiment sets were of higher quality (high signal-to-back ground ratio with minimal 
data saturation) than the others [Appendixes C and D].  As these data were also found to be 
highly reproducible among each other [Table A.E.1 in Appendix E], only the mean data from 
the experiments done with 50µg starting total RNA are presented in Chapter 4.   
The use of the Student’s t-test [Section 3.2.7] was found to filter off a very large 
portion of the original expression data.  This was because the magnitudes of differential 





‘Insulin’ experiments showed less than 16-fold change (log2 ratio < 4.0) - the average log2 
ratios for the differentially expressed genes (>2-fold) were 1.4 (~2.7-fold) for up-regulation, 
and 1.6 (~3-fold) for down-regulation.  Therefore while only the statistically significant 
differential expression data are listed in Chapter 4, no statistical screening was applied for a 
broader overview of the global expression profiles based on cellular functions [Section 3.2.8.1, 
Appendix F] and for pathway visualization [Section 3.2.8.2].  The differential expression data 
that did not meet the screening criteria (<95% confidence) are listed in Appendix G to 
facilitate future analysis.   
3.2.8.1 Functional Classification 
Genes in the microarray oligolibrary (Basic Mouse Oligolibrary, Compugen, 
Jamesburg, USA) was classified under 7 major cellular functions [Table 3.6].   
Table 3.6 Functions used for initial gene classification 
Function Remarks 
Apoptosis  Includes ‘cell death’ and ‘necrosis’. 
Cell cycle  Includes ‘DNA replication’, ‘meiosis’ and ‘mitosis’. 
Cytoskeleton  Includes ‘cell adhesion’, ‘cell motility’, ‘microtubule-based process’. 
Growth and/or maintenance  
Includes ‘biogenesis’, ‘biosynthesis’, ‘homeostasis’, ‘repair’, 
‘response’, and ‘salvage’ genes. 
Protein processes  
RNA- and protein-related genes including ‘translation’, ‘protein 
folding’, ‘protein traffic’, amino acid-related, ‘protein complex 
assembly’ and ubiquitin-related genes. 
Transcription Includes ‘transcription co-repressor’ genes.  
Other functions * 
Non-bioprocess related genes.  Includes genes involved in tissue-
specific, organ-specific, and organism-level processes. 
Unknown function Includes all ESTs. 
 
* These functions are not relevant in the bioprocessing context, and the respective genes are referred to 






The classification was based on specific ontologies supplied by Compugen for each gene.  
3.2.8.2 Pathway Analysis 
The GenMAPP software (Gladstone Institutes, California) was used to visualize 
microarray expression data in the context of known (or suggested) biological pathways and 
gene families.  ‘GenMAPP’ is the common abbreviation of ‘Gene Microarray Pathway 
Profiler’ and the software was available as a freeware (downloaded from 
http://www.genmapp.org/).   
Pathways based on genes that had been reportedly regulated by zinc and insulin were 
assembled on a visualization platform (.MAPP file), using drafting tools provided in the 
GenMAPP software package.  The platform was then used to visualize the relevant expression 
data (converted into .gex file) using simple Boolean-based selection criteria (e.g. IF ‘Average 
log2 ratio’ > 1, SHOW ‘red’).  Such visualization could be used to study specific pathways that 
were mediated by zinc and insulin in CRL1606 cultures, and to help identify candidate genes 
for further analysis.  The genes that showed more than 2-fold changes in expression were 
depicted in red (up-regulated in zinc) and green (down-regulated in zinc).  In addition, the 
genes that showed 1.5 to 2.0-fold changes in expression were depicted in pink (slightly up-
regulated in zinc) and light blue (slightly down-regulated in zinc).  The genes that showed less 
than 1.5 fold changes were depicted in grey (not regulated/no criteria met).   
To facilitate analysis, logarithm base 2 was applied to transform the raw ratios to log-
scale (i.e. to a continuous linear spectrum of values), and thus compare up- and down-




Table 3.7 Reference table for raw ratios and their 


















The same .gex files were also applied to readily available MAPP files (download from 
the Internet) to browse through processes that were less well known, and determine if there 









4.   RESULTS AND DISCUSSION 
              
4.1 Insulin Dosage Response 
Prior to this project, insulin has been added into CRL1606 cultures as an essential 
serum-free supplement.  However, the removal of insulin was necessary for the development 
of a protein free medium.  The experiment shown in this section was part of an early effort to 
gradually wean CRL1606 cells out of insulin dependence.  The objective was to characterise 
the effect of different insulin dosages in the range of 0.25 to 1.5x (where ‘1x’ = 10mg-
insulin/L) on CRL1606 culture.  Refer to Table 3.2 in Section 3.1.2 for the experimental setup. 
From Figure 4.1, we could observe that increased insulin-supplementation accelerated 
cell growth.  The doubling time during exponential phase was approximately 20hrs, and the 
peak cell density was around ~1.6E6cells/mL.  The viable cell densities of the cultures that 
were supplemented with 0.75 to 1.5x insulin peaked on Day-3, while those that were 
supplemented with 0.25 to 0.5x insulin-supplementation peaked later on Day-4.  All test 
cultures exhibited similar cell viability profiles from Day 1 to 4.  
 
 
Figure 4.1  Cell growth and viability profiles of CRL1606 cultures supplemented with 







Expectedly, increased insulin-supplementation also accelerated glucose and glutamine 
depletion, as well as lactate accumulation [Figure 4.2].  The extents of glutamate and ammonia 
accumulation (in volumetric terms) were largely independent of insulin dosage.    
 
 
Figure 4.2 Supernatant metabolite profiles of CRL1606 cultures supplemented 







Mab production profiles among the test cultures were similar up to Day-4.  The ‘0.5x insulin’ 
culture yielded a marginally higher Day-5 Mab titer (0.13mg/L) than the other test cultures 
[Figure 4.3].   
 
Figure 4.3 Mab production profiles of CRL1606 cultures supplemented with 
various levels of insulin (BITTE = ‘1x insulin’ = 10mg-insulin/L)
 
To summarise, increase in insulin-supplementation (in the range of 2.5-15mg/L) 
accelerated cell growth, lactate accumulation, glucose and glutamine depletion, while having 
little impact on Mab production, cell viability, glutamate and ammonia accumulation profiles.  
 
4.2 Effect of Insulin Withdrawal 
This experiment characterised the effect of insulin withdrawal (without any substitute 
supplement) on CRL1606 culture.  It aimed to establish whether substitute-supplements were 
needed for a viable insulin-free (and serum-free) culture.  Refer to Table 3.2 in Section 3.1.2 







As shown in Figure 4.4, the peak cell density and viability of CRL1606 culture were 
significantly lowered by the withdrawal of insulin.  This is consistent with a study (also on 
CRL1606 culture) by Chung et al. [1998].  We could therefore conclude that the use of 
suitable non-proteinaceous substitute-additive(s) is necessary for a viable insulin-free (and 
serum-free) CRL1606 culture.   
 
Figure 4.4 Growth and viability profiles of 1x insulin-supplemented 
(BITTE) and insulin-free (IF) CRL1606 cultures 
The reduced cell viability in insulin-free (IF) culture could be due to apoptosis from 







surviving cells could proliferate slowly and not entirely arrested in quiescent (Go) phase in the 
absence of insulin.  This observation in CRL1606 culture does not correspond to a study that 
showed insulin addition was essential to drive CHO cells from G0 into cycle [Sanfeliu et al., 
2000].  
To investigate the long-term cell proliferation and viability characteristics of IF 
culture, prolonged maintenance (50 passages) was carried out.  Figure 4.5 illustrates that the 
cell growth rate and viability varied significantly from passage to passage.  The cell viability 
started to drop sharply from Day-96 (Passage #48) onwards, and reached 0% at Day-101 
(Passage #50).  The observation is in contrast to insulin-supplemented cultures, which could be 
passaged indefinitely with little variation in cell growth and viability between passages.   
 
 
Figure 4.5 Cell growth and viability profiles of CRL1606 cells maintained 
under prolonged insulin-withdrawal conditions 
 
The unstable proliferation and viability profiles in IF culture is suggestive of inherent 







could not be effective in developing a feasible insulin-free culture, as the selection and 
adaptation process (even if successful) is likely to be time-consuming and unpredictable. 
The longer batch cultivation period of IF culture [Figure 4.4] matched the expectation 
that batch cultures with lower peak cell densities could remain viable for a relatively longer 
period due to slower depletion of macronutrients (e.g. glucose), and slower accumulation of 
waste products (e.g. lactate) [Figure 4.6].   
 
 
Figure 4.6 Supernatant metabolite profiles of 1x insulin-supplemented (BITTE) 









While the slower-growing IF culture exhibited consistently higher specific 
productivity, the final volumetric Mab production titers in the presence and absence of insulin 
were generally comparable (~0.15mg/mL) [Figure 4.7].   
 
Figure 4.7 Mab production and specific productivity of CRL1606 grown in 
1x insulin (BITTE) and insulin-free (IF) media 
 
The phenomenon outlined in Figures 4.6 and 4.7 is generally consistent with a study 
by Zhou and Hu [1995], which showed that the presence of insulin in serum-free hybridoma 
cultures increased glucose consumption with no beneficial effect on final Mab titer.  However, 







that study.  According to Zhou and Hu [1995], insulin had little effect on cell growth in their 
serum hybridoma cultures, which was grown in DMEM/F12 (ratio 1:1) (a medium formulation 
which contains 0.432mg-ZnSO4·7H2O/L [Table 2.4]).   Incidentally, the IMDM-based medium 
used in our experiments up to this point did not contain zinc [Table 2.4].  Therefore the 
relatively high zinc content in DMEM/F12 (ratio 1:1) could be pivotal in restoring cell growth 
under insulin-free condition in Zhou and Hu’s experiments [Zhou and Hu, 1995].  The effect 
of zinc on insulin-free CRL1606 culture would be investigated in the following section 
[Section 4.3]. 
To conclude, the deprivation of insulin retarded cell proliferation and reduced cell 
viability (in the absence of zinc).  Consequently, the insulin-deprived cultures displayed lower 
glucose consumption and lactate accumulation.  The cells also exhibited unstable proliferation 
and viability under prolonged maintenance in insulin-deprived conditions.  The final Mab 
production titers in the presence and absence of insulin were comparable.   
 
4.3 Zinc Dosage Response 
It was demonstrated in the previous section, that the addition of suitable non-
proteinaceous supplement(s) in place of insulin was necessary to achieve a viable insulin-free 
CRL1606 culture.  Comparison with Zhou and Hu’s experiments [1995] revealed that zinc 
could restore hybridoma cell growth under insulin-free conditions.  In addition, zinc has also 
been reported to exhibit insulin-mimetic properties in the cultures of certain cell types [Section 
2.4.2].  Therefore the effect of zinc in insulin-free CRL1606 culture should be studied.  Refer 








Together with results from a preliminary study*, Figure 4.8 illustrates that the addition 
of zinc in the range of 0.5-5.0mg-ZnSO4·7H2O/L (0.11-1.14mgZn2+/L) restored growth in 
insulin-free CRL1606 cultures without any adverse effect on culture viability.  No adaptation 
into the zinc-supplemented medium was necessary. 
 
Figure 4.8 Growth and viability profiles in 1x insulin-supplemented 
(BITTE) and various zinc-supplemented insulin-free (IF) CRL1606 cultures 
* In a preliminary zinc dosage study (data not shown here; the choice of zinc dosages was based on 
related literature reports [Section 2.3.3]), the cell growth, viability, metabolite and Mab production 
profiles of IF cultures supplemented with zinc in the range of 0.5-2.0mgZn/L (0.11-0.45mgZn2+/L) were 
highly comparable among each other.  Therefore the ‘IF + 1.5mgZn/L’ test culture in this section could 
represent the effect of zinc in the range of 0.5-2.0mg-ZnSO4·7H2O/L.  Together with the results 
demonstrated in this section, the ‘IF + 1.5mgZn/L’ and ‘IF + 5.0mgZn/L’ test cultures could collectively 
represent the effect of zinc in the range of 0.5-5.0mg-ZnSO4·7H2O/L.  The latter zinc dosage range is 







The relatively low cell growth rate and viability of the IF+0.1mgZn/L culture 
resembled that of the IF culture, although the IVCD of the former culture was significantly 
higher.  From this observation, the lower limit for optimal zinc-supplementation to insulin-free 
CRL1606 culture could be in the range of 0.1 - 0.5mg-ZnSO4·7H2O/L (0.02 - 0.11mgZn2+/L). 
Optimal zinc-supplementation resulted in faster depletion of glucose and glutamine, 
and quicker build-up of lactate when compared insulin-supplementation (BITTE) [Figure 4.9].  
However, the final lactate levels in the zinc-supplemented cultures were substantially higher 









Figure 4.9 Supernatant metabolite profiles in 1x insulin-supplemented (BITTE) 








Profiles of most amino acids in the BITTE culture lagged behind optimal zinc-
supplemented cultures (IF+1.5mgZn/L and IF+5.0mgZn/L) by one day [Figure 4.10].  This 
observation is consistent with the corresponding growth profiles [Figure 4.8].  Both the 
insulin- and optimal zinc-supplemented cultures utilized glutamine and methionine to 
depletion.  A previous experiment on additional amino acid-supplementation (1x increase of 
glutamine, methionine and asparagine dosage; results not shown here) in BITTE culture 
resulted in higher cell density but decreased specific productivity of the cells, such that there 








Figure 4.10 Supernatant amino acid profiles in 1x insulin-supplemented 
(BITTE) and various zinc-supplemented insulin-free (IF) CRL1606 cultures 










Figure 4.10 Supernatant amino acid profiles in 1x insulin-supplemented 
(BITTE) and various zinc-supplemented insulin-free (IF) CRL1606 







ICP-OE measurements revealed that the supernatant zinc ion content in zinc-
supplemented culture dropped by 35% from Day-0 to Day-3 [Table 4.1].  This result suggested 
significant cellular uptake and/or biosorption of zinc under insulin-free conditions. 
Table 4.1 Supernatant zinc ion content in zinc- and insulin-
supplemented CRL1606 cultures 
Zinc Ion Content (ppm) 
Sample ID # 
Expected 






IF+Z (Day-0) 0.34 * 0.20 0.34 
IF+Z (Day-3) - 0.13 0.22 
BITTE (Day-0) ~0.05 ** <0.01 *** <0.017 
BITTE (Day-3) - <0.01 *** <0.017 
 
# ‘Day-0’: Sterile fresh-medium; ‘Day-3’: Sterile-filtered Day-3 supernatant of various 
CRL1606 cultures; ‘IF+Z’ is supplemented with 1.5mg-ZnSO4·7H2O/L*; ‘BITTE’ is 
supplemented with 10mg-insulin/L. 
 
## The measured (raw) ICP-OE results were significantly lower than expected.  This 
could be due to significant matrix interference caused by the high sodium content in the 
culture medium (~3000ppm).  Operationally, matrix interference is an enhancement or 
suppression of the emission signal from a chosen element, caused by concomitant 
specieses that are present in the sample.  In other words, the saturation emission signal 
from the sodium ions could have suppressed the emission signal from the zinc ions.  
Assuming that the level of matrix interference was proportional to the actual zinc ion 
content in the samples, the normalised ICP-OE results were obtained by multiplying the 
measured ICP-OE by a factor of 1.7 (= 0.34/0.20), i.e. the ratio of the expected and 
measured zinc ion content in fresh IF+Z medium.  
 
* 1.5mg-ZnSO4·7H2O/L is equivalent to 0.34mg-Zn2+/L. 
 
** BITTE insulin preparation (Sigma I-1882) contained ~0.05 ppm of zinc [Table 2.5 in 
Section 2.4.1].   
 









The ICP-OE measurements have also verified that there was, at most, a trace amount 
of zinc in BITTE culture medium (< 0.017 ppm).  This amount of zinc alone could not be 
sufficient for optimal cell growth in insulin-free CRL1606 culture [Figure 4.8], and could not 
account for any insulin-mimetic effects in other cell cultures [Section 2.4.2].  However, these 
observations did not rule out the possibility that the zinc requirement for optimal proliferation 
of CRL1606 cells could be lowered in the presence of insulin.  This issue could be addressed 
through experiments using zinc-free insulin preparations or insulin-like growth factor (Igf) 
[Section 5.2]. 
The final Mab titers of all the test cultures were generally comparable (0.10 + 
0.02mg/mL) with each other [Figure 4.11], although Mab production in the slower growing IF 
and IF+0.1mgZnL cultures initially lagged behind the other cultures.  The final Mab titer in 
IF+0.1mgZn/L culture (~0.12mg/mL) was ~20% higher than that of IF culture, a result which 
is in line with higher IVCD in the former culture [Figure 4.8].   
 
Figure 4.11  Mab production profiles in 1x insulin-supplemented (BITTE) 







While there have been no other reports on the effect of zinc on insulin-free hybridoma 
cells, the zinc dosage response of insulin-free CRL1606 culture is similar to some other cell 
cultures.  For example, Chvapil et al. [1976] has demonstrated that the inclusion of 10 µmol/L 
(0.65mgZn2+/L) zinc in the cell isolation medium of canine lymphocytes significantly 
increased their viability.  Korohoda et al. [1993] has also shown that 5µmol/L ZnSO4 
(0.325mgZn2+/L), together with 5µmol/L FeCl4, was sufficient to induce and support the 
proliferation of B16 melanoma cells in serum-free EMEM in the absence of insulin and 
transferrin.  Other studies have reported substantially higher zinc requirements for optimal 
growth and apoptosis-suppression.  For example, an extracellular zinc ion concentration of 
200–5000 µmol/L  (13-327mgZn2+/L) was needed to suppresses apoptosis-related events and, 
at least in the short term, cell death in cultured rat cells of lymphoid, hepatic, or neoplastic 
origin [Zalewski and Forbes 1993; Sunderman, 1995].  The requirement for high extracellular 
zinc levels to inhibit apoptosis in these studies could be due to poor uptake of zinc across the 
cell membrane of those cells [Finley et al., 1995; De Stasio et al., 1996].   
To summarise, the addition of zinc (0.5-5.0mg-ZnSO4·7H2O/L, i.e. 0.11-
1.14mgZn2+/L) restored growth to insulin-free CRL1606 cultures with a high cell viability of  
~97%.  No adaptation into the new medium is necessary.  Profiles of amino acid, ammonia and 
metabolite, as well as Mab production in the optimal zinc- and insulin-supplemented cultures 
were found to be highly comparable.  ICP-OE measurement indicated significant cellular 
uptake and/or biosorption of zinc under insulin-free conditions.  
 
 
Note: A zinc dosage of 1.5mg-ZnSO4·7H2O/L (0.34mgZn2+/L, 3x the lowest optimal zinc dosage tested 
in this section) was used in subsequent maintenance and experimentation of insulin-free CRL1606 
culture to develop a protein-free hybridoma medium (results not shown in this thesis), as well as in 
microarray studies [Sections 4.4 and 4.5].  The formulation, termed in this thesis as ‘IF+Z’, contains at 




4.4 Comparative Analysis of ‘Zinc’ vs. ‘Insulin’ 
Section 4.3 has demonstrated that 0.5-5.0mg-ZnSO4·7H2O/L of zinc could replace 
insulin in CRL1606 culture without adversely affecting cell growth, viability and Mab 
production.  This section compares the transcriptional effects of zinc and insulin in CRL1606 
cultures through microarray experimentation.  Refer to Table 3.3 in Section 3.2.3 for the 
experimental setup.  The statistically significant differential expression data are shown in 
Figure 4.12, Table 4.2 and Table 4.3.  The differential expression data that did not meet the 
screening criteria (< 95% confidence) are listed in Appendix G to facilitate future analysis.   
Figure 4.12 shows that signal transduction, transcription and growth/maintenance-
related functions were prominently featured among the regulated genes.  This is consistent 
with a study on rat intestine cells, which showed that genes with transcription, signal 
transduction and growth-related functions were significantly regulated by zinc [Blanchard et 
al., 2001].  Moore et al. [2003] have also found that zinc regulated transcription-related genes 
in mouse cells.  However, it should be mentioned that the studies by Blanchard et al. [2001] 
and Moore et al. [2003] were conducted on (dietary) zinc-deficient whole animals, and not on 













Figure 4.12 Profiles of differentially expressed genes (n = 3, 95% confidence) 





Table 4.2 Genes up-regulated (>2-fold, n = 3, 95% confidence) 
by zinc when compared to insulin (18 genes) 
 
Name Abbreviation Log2 Ratio Description GenBank ID 
Cytoskeleton-related 








AF251078 2.6 thymus-expressed gene AF251078, 
NM_021532 
apoptotic cell clearance 
receptor 
PtdSerR 1.2 apoptotic cell clearance 
receptor 
AF304118 




Signal transduction     
peptidyl arginine 
deiminase, type II 
Pdi2 1.7 GPCR that catalyses the 








Hcph 1.2 protein-tyrosine 
phosphatase playing a key 






Cry1 1.0 photolyase receptor AB000777, 
NM_007771 
Transcription regulation    
apoptosis-linked gene 4, 
deltaC form 
Alg-4 2.7 transcription regulation AF055668 
nuclear factor of activated 
T-cells 5 
Nfat5 1.2 transcription factor 
NFAT5 isoform b. 
AF200687, 
NM_018823 
purine binding factor-1 Pur-1 1.1 transcriptional activator 
found in promoter of 
insulin I and II genes 
L04649 
bromodomain adjacent to 
zinc finger domain,1B 
Baz1b 1.1 DNA packaging AF084480, 
NM_011714 
Transport-related     
chloride channel calcium 
activated 1 
Clca1 2.2 chloride channel AF052746, 
NM_009899 
synaptotagmin 4 Syt4 1.1 calcium binding protein  U10355, 
NM_009308 
Other     
vesicle-associated 
membrane protein 1 




Unknown function     
brain clone MNCb-4134 MNCb-4134 1.3 - AB041600 
unknown protein clone 301A6 1.2 - Z78150 






Table 4.3 Genes down-regulated (>2-fold, n = 3, 95% confidence) by 
zinc when compared to insulin (41 genes).  Table is shown over 2 pages.  
Name Abbreviation Log2 Ratio* Description 
GenBank 
ID 
 Apoptosis      
Fas-associating protein with 
death domain 
Fadd -1.6 Apoptotic adaptor U43184, 
NM_010175 
 deoxyribonuclease II Dnase2 -1.4 hydrolyzes DNA AF045741, 
NM_010062 
 Cytoskeleton-related     
 procollagen, type V, alpha 1 Col5a1 -1.7 cell adhesion AB009993, 
NM_015734 
 Metabolism-related     
 proliferin-related protein Plfr -1.3 lactation X02594, 
NM_011120 
 kinesin-related protein Kifc5C -1.1 ATP binding AF221104 
 Protease/inhibitor     




 Calpain large subunit nCL-4 -1.3 proteolysis and peptidolysis U89513 
 Cysteine proteinase inhibitor MS2 -1.2 intracellular thiol 
proteinase inhibitor 
M92418 
 Signal transduction     
 Burkitt lymphoma receptor 1 Blr1 -2.2 cytokine receptor that binds 








 dickkopf homolog 1 (Xenopus 
laevis) 




 glutamate receptor, ionotropic, 
delta 1 
Grid1 -1.3 excitatory neurotransmitter 
at many synapses 
D10171, 
NM_008166 
 angiopoietin 4 Agpt4 -1.3 antagonist to tyrosine 




 Ras-like GTP-binding protein 
(diabetes associated) 




 neuropeptide Y receptor Y2 Npy2r -1.1 receptor for neuropeptide Y 
and peptide YY 
D86238, 
NM_008731 




 transforming growth factor 
(TGF) ß-activated kinase 1 
Tak1 -1.1 regulator of MAP kinase 
signaling induced by TGF-
ß 
 Transcription regulation     
 cyclin C Ccnc -2.3 transcription regulation U49050, 
NM_016746 
 Runt related transcription 
factor 1 




 Transmembrane protein     
 Transmembrane receptor 
frizzled 5 
Fzd5 -1.5 receptor for Wnt proteins, 
Wnt-mediated inhibition of 






Table 4.3 Genes down-regulated (>2-fold, n = 3, 95% confidence) by 
zinc when compared to insulin (41 genes).  Table is shown over 2 pages.  
Name Abbreviation Log2 Ratio* Description 
GenBank 
ID 
Transmembrane protein     
 protein tyrosine phosphatase, 
non-receptor type 8 






 Transport-related     
 organic cation transporter 1 Octn1 -2.2 solute carrier BC010590, 
NM_019687 
 Inositol 1,4,5-triphosphate 
receptor 2 
Itpr2 -1.3 second messenger that 




 cytochrome c oxidase, 
 subunit VIIa 1 
  Cox7a1/ 
  Coxk 









 Other     
 hairy/enhancer-of-split related 
with YRPW motif 1 
Hey1 -1.7 neurogenesis-related gene AF151521, 
NM_010423 
 claudin-12 mRNA claudin-12 -1.4 nerve ensheathment AF247664 
 myelin oligodendrocyte 
glycoprotein 
Mog -1.1 myelin sheath component, 
cell cell communication 
U64572, 
NM_010814 
 Unknown function     
 U5 small nuclear RNA,  
clone 11 
 U5, clone 11 -3.3 - M29246 
 TSIP1 p53-induced apoptosis  TSIP1 -2.8 - U50962 
 muscarinic acetylcholine 
receptor protein 
m1 -2.8 - AJ006521 
 hypothetical protein 
(LOC57391) 




 myotonic dystrophy region M82903 -2.3 - M82903 
 stretch regulated skeletal 
muscle protein 
Usmg1 -1.9 - AJ290943 
 hypertrophy-associated L33255 -1.8 - L33255 
 def-2 def-2 -1.8 - X96700 
 olfactory receptor 17 Olfr17 -1.8 - AF247657, 
NM_020598 
 B2 repetitive sequence B2 -1.7 - M35838 
 Trinucleotide repeat mRNA CAG -1.6 - U80892 
 decay accelerating factor Daf -1.5 - AF143539 
 olfactory receptor 37a Olfr37a -1.4 - AJ251154, 
NM_019473 
 
Note: In Tables 4.2 and 4.3, genes with defined threshold of more than two-fold differential expression 
are listed in terms of their known functions.  Each gene is represented with a common abbreviated name, 
and the log (base 2) ratio of differential expression.  Brief descriptions also added for most genes. 
 





Table 4.2 shows that a number of insulin-related genes were up-regulated in zinc-
supplemented culture.  Among them was a signal-transduction gene CDC42 (cell division 
cycle 42). Cdc42 activates E2F-mediated transcription in NIH3T3 fibroblasts [Gjoerup et al., 
1998], a process that is essential for the progression of the cell cycle (through G1 progression 
and DNA synthesis).  Gjoerup et al. [1998] have found that activated cdc42 (together with 
Rac) induced cyclin D1 accumulation and pRB hyperphosphorylation in serum-deprived cells, 
outlining one route leading to enhanced E2F-mediated transcription.  The inhibitory effect of 
the cyclin-dependent kinase inhibitors, p16, p21, and p27 on Rac/cdc42-mediated E2F 
transcription corroborates a role for pRB family members and their functional inactivation by 
cyclin-dependent kinases in generating E2F activity [Gjoerup et al., 1998].  In another study, 
cdc42 was found to activate Pi3k (phosphatidylinositol 3-kinase) in mammary epithelial cells 
[Keely et al., 1997].  Pi3k binds to tyrosyl-phosphorylated Irs1 (insulin receptor substrate-1) in 
insulin-treated adipocytes.  This step plays a central role in the regulated movement of the 
glucose transporter, Glut4, from intracellular vesicles to the cell surface [Backer et al., 1992; 
Stephens and Pilch, 1995; Antonetti et al., 1996; Clark et al., 1998].  Usui et al. [2003] has 
also reported that siRNA of cdc42 reduced glucose uptake, while constitutively active cdc42 
stimulated glucose uptake in a Pi3k-dependent manner in 3T3-L1 adipocytes.  All these 
suggest that the cdc42 – Pi3k relationship could be an important contributory factor toward the 
insulin-mimetic properties of zinc in CRL1606 culture, although further studies are necessary 
to confirm this phenomenon. 
Among the transcription regulation genes up-regulated by zinc was PUR-1 (Purine 
binding Factor-1), a transcription factor that binds to the GA box (GGGAGGG) at the ME1a1 
site within the first exon of the c-myc gene [Kennedy and Rutter, 1992].  Purine-rich stretches 
of nucleotides (GAGA boxes) are usually present upstream of transcription-start sites in many 




1992].  Kennedy and Rutter [1992] has found that the GC-richness of the PUR-1 promoter and 
the absence of a TATA sequence were characteristic of promoters of genes that were thought 
to have housekeeping functions with respect to cell proliferation.  Interestingly, the human 
homologue of PUR-1 is a zinc finger protein named MAZ (myc-associated zinc finger protein) 
[Song et al., 2000] (Pur-1 also requires zinc in order to bind to DNA [Kennedy and Rutter, 
1993]).  Both Pur-1 and Maz regulate a number of target genes, including the c-myc gene, and 
rat genes for insulin I and insulin II, and have roles in both the initiation and termination of 
transcription [Kennedy and Rutter, 1992].  The expression of c-myc, a proto-oncogene, has 
been reported to be essential to drive quiescent lymphocyte and fibroblast cells into cell cycle 
[Kelly et al., 1983].  Pur-1 was also found to be a potent transactivator in both pancreatic and 
nonpancreatic cells, and was able to activate an intact insulin promoter in HeLa cells, where it 
was normally inactive [Kennedy and Rutter, 1992].  The up-regulation of PUR-1 in zinc-
supplemented CRL1606 culture coupled with reported effects of Pur-1 on rat insulin I and II 
genes [Song et al., 2000] and insulin promoter [Kennedy and Rutter, 1992] suggests that Pur-1 
could play a role in helping the cells to overcome insulin dependence.   
CD19 was also found to be up-regulated in zinc-supplemented culture.  Cd19 is 
rapidly phosphorylated upon B-cell antigen receptor (Bcr) cross-linking, leading to the 
recruitment of downstream signalling intermediates [Otero et al., 2001].  A prominent feature 
of Cd19 signalling was the binding and activation of phosphoinositide 3-kinase (Pi3k), which 
accounts for the majority of Pi3k activity induced by Bcr ligation [Otero et al., 2001].  In the 
report, Otero suggested that the activation of the serine/threonine kinase Akt imparts survival 
signals in a Pi3k-dependent fashion in A20 B-lymphoma cells.  The common downstream 
targets of Pi3k-Akt in Cd19- [Otero et al., 2001] and insulin- [Bevan, 2001] mediated 




The up-regulation of CLCA1 (chloride channel calcium activated 1) in zinc-
supplemented cultures is also noted, as insulin had been found to inhibit calcium-dependent 
chloride secretion through a Pi3k-dependent pathway in T84 colonic epithelial cells grown in 
serum-supplemented media [Chang et al., 2001].  Other than in T84 cells, insulin also 
stimulates the activation of Pi3k in other cell types [Xu and Wu, 2000; Bevan, 2001], although 
it is not known if these actions are calcium-dependent.  Insulin has also been found to inhibit 
chloride secretion even in the presence of elevated levels of intracellular calcium [Chang et al., 
2001].  
In essence, the over-expression of the above-mentioned genes, and their relationship 
with Pi3k indicates the importance of Pi3k in integrating zinc-induced signalling with the 
insulin-mimetic effects observed in zinc-supplemented CRL1606 culture. 
Table 4.3 shows that very few of the known insulin-responsive genes were amongst 
the genes down-regulated in zinc-supplemented culture.  Among them was FADD (Fas-
associating protein with death domain), an apoptotic adaptor gene.  Fadd recruits caspase-8 or 
caspase-10 to activate Fas or Tnfr-1 (tumour necrosis factor receptor-1) receptors [Cohen, 
1997].  The resulting aggregate is commonly referred to as the ‘death-inducing signalling 
complex’ (DISC).  DISC performs the proteolytic activation of caspase-8 [Chinnaiyan et al., 
1995].  The active caspase-8 then triggers a cascade of caspase-mediated apoptosis [Cohen, 
1997].  On the other hand, Zhang and his colleagues reported that FADD/DISC was not 
essential for apoptosis in (FADD-deficient) mice cells [Zhang et al., 1998]. 
TAK1, transforming growth factor (Tgf) ß-activated kinase 1, was also down-regulated 
by zinc.  Tak1 is a signal transduction-related protein which controls downstream events linked 
to cell activation and programmed cell death [Lee et al., 2000].  Tak1 is also an important 
component in the signalling pathways activated via pro-inflammatory stimuli, and Tak1-




et al., 2000].  However, the exact mechanism of Tak1-mediated intracellular signalling 
transduction is unknown.  Relevant to the context of this thesis, Lee has shown that both Tak1 
and Pi3k mediate PkB/Akt-dependent survival of murine pre-B cells.  This Pi3k-PkB/Akt 
relationship could also be found in insulin-mediated signalling pathways [Bevan, 2001]. 
RAD (Ras-like GTP-binding protein) was another signal transduction-related gene that 
was down-regulated in zinc-supplemented culture.  Rad is a Ras-like GTPase that exhibited 
increased expression in some human subjects with Type II diabetes [Reynet and Kahn, 1993], 
and thus could be involved in insulin-mediated signalling.  In particular, Moyers et al. [1996] 
have shown that the over-expression of RAD in myocyte and adipocyte cell lines resulted in a 
50-90% reduction in insulin-stimulated 2-deoxyglucose uptake, while Laville et al. [1996] 
have observed that insulin infusion into human muscle induced a significant increase in the 
mRNA levels of Glut4 and Rad.  Interestingly, Todaka et al. [1996] have demonstrated that the 
over-expression of RAD in Chinese Hamster Ovary (CHO) cells did not affect insulin-
triggered Glut4 translocation.  Taken together, the above studies suggest that Rad could be a 
negative regulator of glucose uptake by inhibiting the activity of the transporter molecules, 
rather than influencing the translocation of Glut4 [Moyers et al, 1996].  Thus, one could 
hypothesize that the down-regulation of RAD in zinc-supplemented CRL1606 cultures 
promotes glucose uptake. 
Figure 4.13 illustrates the pathway visualization of the expression data in the context 






Figure 4.13 Pathway visualization of ‘zinc’ vs. ‘insulin’ microarray data [GenMapp].  The value 
shown on the right of each gene label is the mean log2 ratio (n = 3, before screening) for that gene. 
Note: Pre-screened data was used in Figure 4.13 as the process of screening filtered off most of the 




Figure 4.13 indicates that the following zinc-induced mechanisms could contribute to 
the insulin-mimetic effects observed in insulin-free CRL1606 cultures: 
• Increased expression of PUR-1 (Purine binding Factor-1), a transcription factor regulating 
a number of target genes that were reported to be insulin-related: insulin-like peptides and 
insulin precursors gene for insulin I and insulin II.  This could have a stimulatory effect on 
the insulin receptor substrate (Irs) via the insulin receptor (IR), which in turn up-regulates 
other insulin-related genes further downstream (e.g. Pi3k) to trigger insulin-mimetic 




• Increased expression of CD19, which binds to and activates phosphoinositide 3-kinase 
(Pi3k).  The activated Pi3k could then activate Akt, which in turn imparts survival signals 
via the 14-3-3 complex to sequester the pro-apoptotic Bad.   
• Decreased expression of the apoptotic adaptor FADD, which results in the inhibition of 
caspase-8 proteolytic activation, and thus prevents apoptosis via the caspase-8 cascade. 
• Decreased expression of RAD, which is a negative regulator of glucose uptake. 
Further analysis using MAPPs (Microarray Pathway Profiler platform files for 
GenMAPP analyses) based on other known zinc and insulin functions like cell cycle [Sections 
2.2.2 and 2.3.1], as well as publicly available MAPPs (to browse through processes which 
were less well-known) revealed minimal differential expression profiles (results not shown 
here).  This was expected, as our results showed that the transcriptional profiles in the zinc- 
and insulin-supplemented cultures were highly similar (0.7% {n = 3, 95% confidence} of the 
examined genes were differentially-expressed).  On the other hand, some of the transcriptional 
changes could be too subtle to be detected via microarray experimentation.  Furthermore, some 
of the insulin-mimetic mechanisms (e.g. phosphorylation-activated processes) could be post-




4.5 Comparative Analysis of ‘Low Zinc’ vs. ‘Optimal Zinc’ 
To further characterize the transcriptional effect of zinc on insulin-free CRL1606 
culture, a microarray comparative study of ‘low-zinc’ and ‘optimal-zinc’ cultures was 
performed.  Refer to Table 3.3 in Section 3.2.3 for the experimental setup.  The statistically 
significant differential expression data are shown in Figure 4.14, Table 4.4 and Table 4.5.  
Regulation data that did not meet the screening criteria (< 95% confidence) are listed in 
Appendix G to facilitate future analysis.  Pathway visualization of the expression data using 
the same GenMapp platform shown in Figure 4.13 (Section 4.4) is presented in Appendix I. 
49 genes were found to be differentially expressed, and similar numbers of genes were 
up- (24 genes) and down-regulated (25 genes) in low-zinc culture.  Figure 4.13 shows that a 
large portion of the up-regulated genes was signal transduction-related.  As this function was 
also prominent in the regulation data shown in Section 4.4, signal transduction is likely to play 
a key role in mediating insulin-mimetic effects in zinc-supplemented culture.  The down-
regulation of cell cycle, growth and maintenance genes in low-zinc culture was consistent with 
the lower growth rate and cell viability.  The results were also in line with reports that DNA 
synthesis was particularly sensitive to zinc-deficiency [William and Chesters, 1970; Chesters, 








Figure 4.14 Profiles of differentially expressed genes (n = 3, 95% 
confidence) in low-zinc and zinc-supplemented CRL1606 cultures 
 
Table 4.4 Genes up-regulated (>2-fold, n = 3, 95% confidence) by 





Name Symbol Log2 Ratio * Description 
GenBank 
ID 
Apoptosis     
phosphodiesterase 1A, calmodulin-
dependent 
Pde1a 1.15 has high affinity for cGMP U56649 
Growth and/or maintenance       
Ngfi-A binding protein 2 Nab2 1.08 cell proliferation U47543 
Metabolism-related       
mRNA fragment, clone D90 D90 1.81 leucine metabolism M94311 
ornithine decarboxylase  
antizyme 3 
Oaz3 1.19 polyamine metabolism AF175297 
Protein processes       
thioredoxin-like (32kD) Txn1 1.59 protein-disulfide reduction AF052660 
membrane-type-3 matrix 
metalloproteinase 
Mt3mmp 1.05 proteolysis and peptidolysis AB021228 
Signal transduction       
U5 small nuclear RNA, clone 3 U5, clone 3 1.04 signal transduction M29243 
src homology 2 domain-containing 
transforming protein D 
Shd 1.05 signal transduction AB018423 
putative protein kinase YSK4 1.09 signal transduction U49951 
protein tyrosine phosphatase, non-
receptor type 12 
Ptpn12 1.24 transmembrane receptor protein 
tyrosine phosphatase signaling 
X86781 
cholecystokinin, 3' end CCK 1.16 peptide hormone for release of 
pancreatic enzymes 
X59520 
Transport       
5-hydroxytryptamine (serotonin) 
receptor 3A 
Htr3a 1.34 non-selective ligand-gated ion 
channel 
X72395 
Other     
lymphotoxin B receptor Ltbr 1.24 lymph gland development U29173 
serum amyloid A 2 Saa2 1.12 acute-phase response M17791 
Unknown function       
formyl peptide receptor, related 
sequence 3 
Fpr-rs3 2.21 - AF071181 
Mouse mRNA - 2.02 - L26397 
B2 repetitive sequence, 5' end B2 1.89 - M35838 
28S large subunit rRNA, 5' end 28S 1.88 - M19226 
U5 small nuclear RNA, clone 7 U5, clone 7 1.75 - M29244 
epidymal sperm gene LOC57359 1.56 - X99300 
U5 small nuclear RNA, clone 11 U5, clone 
11 
1.55 - M29246 
mRNA expressed in islet cells (clone 
41) 
- 1.26 - Z47779 
def-2 def-2 1.25 - X96700 





 Table 4.5 Genes down-regulated (>2-fold, n = 3, 95% confidence) by ‘limited-zinc’ when 
compared to ‘optimal-zinc’ (25 genes).  Footnotes are shown on the following page.  
Name Symbol Log2 Ratio * Description 
GenBank 
ID 
Apoptosis     
stromal cell derived factor 5 Sdf5/sFRP2 -1.29 secreted frizzled related protein U88567 
Cytoskeleton-related       
alpha-1 type-III collagen - -1.61 soft connective tissues X57983 
activated leukocyte cell adhesion 
molecule CD166 
Alcam -1.13 binding of T and B cells to 
activated leukocytes 
U95030 
mRNA for high-glycine tyrosine 
keratin type II.3 
- -1.08 intermediate filament D89901 
Cell cycle       
MAP kinase-interacting 
serine/threonine kinase 1 
Mknk1 -1.17 cell cycle Y11091 
Growth and/or maintenance       
stearoyl-Coenzyme A  
desaturase 2 
Scd2 -1.57 fatty acid biosynthesis M26270 
Rad51 homolog Rad51 -1.51 DNA recombination D13803 
protein tyrosine phosphatase 4a1 Ptp4a1 -1.30 DNA replication U84411 
malonyl-CoA decarboxylase Mlycd -1.23 fatty acid biosynthesis AJ131522 
lysine oxoglutarate reductase, 
saccharopine dehydrogenase 
Lorsdh -1.03 lysine metabolism AJ224761 
Protein processes       
ubc-like protein MMS2 Mms2 -1.19 proteolysis and peptidolysis  AF303828 
zinc finger protein 318 Zfp318 -1.17 protein modification AF159455 
Signal transduction       
muskelin 1, intracellular mediator 
containing kelch motifs 
Mkln1 -1.61 signal transduction U72194 
WSB-2 protein Wsb-2 -1.26 signal transduction AF033188 
growth factor receptor bound protein 
10 
Grb10 -1.05 insulin and Igf1 signaling U18996 
Transcription regulation       
paired box gene 6 Pax6 -1.28 bind to insulin promoter S74393 
eukaryotic translation initiation 
factor 4E binding protein 1 
Eif4ebp1 
/Phas1 
-1.05 insulin-stimulated mediator of 
protein synthesis 
U28656 
Transport       
prenylated Rab acceptor Pra -2.89 non-selective vesicle transport AF252856 
Other       
huntingtin interacting protein 1 
related 
- -1.86 receptor mediated endocytosis AF221713 
heat shock protein hsp40-3 Hsp40-3 -1.83 heat shock response AF088983 
calcium binding protein P22 Chp -1.43 developmental processes U39875 
actin-like Actl -1.22 muscle development AF195094 
numb gene homolog Numb -1.11 neurogenesis U70674 
claudin-15 mRNA - -1.02 nerve ensheathment AF124427 
Unknown function       
M.domesticus mRNA for P 
lysozyme gene 
- -1.03 - X53630 
 






Note: In Tables 4.4 and 4.5, genes with defined threshold of more than two-fold differential expression 
are listed in terms of their known functions.  Each gene is represented with a common abbreviated name, 
and the log (base 2) ratio of differential expression.  Brief descriptions also added for most genes. 
 
* Differential expression ratio based on ‘Low-Zinc’ vs. ‘High-Zinc’, i.e., if ‘Low-Zinc’ > ‘High-Zinc', 
“+”; if ‘Low-Zinc’ < ‘High-Zinc', “-”.  
 
 
Table 4.4 shows that 3 clones of the U5 gene were up-regulated in low-zinc culture.  A 
U5 clone (clone 11) was also found to be down-regulated (average log2 ratio = -3.3) in zinc-
supplemented culture, as compared to insulin-supplemented culture [Section 4.4].  One of the 
U5 clone (clone 3) is signal transduction-related, while the other two (clones 7 and 11) are 
unclassified.  Literature reports of U5 are not in the context of this thesis.  For example, 
Hamada et al. [1999] has suggested that U5 is capable of driving normal rabbit reticulocyte 
lysate cells into tumorigenic cells when expressed with a poly(A) tail.  Therefore, further 
investigation (e.g. through gene knock-out experiments) would be necessary to decipher the 
implication of U5 regulation in CRL1606 cultures. 
Among those down-regulated in low-zinc culture [Table 4.5] were three insulin-related 
genes: GRB10 (which regulates insulin and Igf1 signalling [Wick et al. 2003]), PAX6 (which 
binds to the insulin promoter [Sander et al., 1997]) and EIF4EBP1/PHAS1 (an insulin-
stimulated mediator of protein synthesis [Lin et al., 1994; Lin et al., 1995]). 
Grb10 (growth factor receptor bound protein 10, also called Grb-IR) is an insulin 
receptor (IR)-interacting protein [Wick et al. 2003].  It could influence intracellular signal 
transduction through the insulin receptor substrate (Irs)/Pi3k pathway, and moderate the 
actions of downstream effectors such as Akt [Wick et al. 2003].  The major Grb10 proteins 
appear to be present in at least 3 isoforms, varying in the presence of a pleckstrin homology 
domain and in the sequence of its amino terminus [Liu and Roth, 1998].  The specific 
functional role of Grb10 is currently unclear, and there are contradictory reports of the effect of 






promoted insulin-induced mitogenesis in mouse fibroblast cells [Wang et al., 1999].  But Liu 
and Roth have found that the expression of GRB10 in CHO cells reduced insulin-dependent 
phosphorylation of insulin receptor substrate-1 (Irs-1) [Liu and Roth, 1995].  They have also 
suggested that the direct binding of Grb10 protein to IR could inhibit signalling via the IR-
mediated signalling pathway. 
Pax6 (paired box gene 6), together with Pdx1 and Nkx6, is known to be a pancreatic 
transcription factor for insulin, and is a key regulator of pancreatic islet hormone gene 
transcription [Sander et al., 1997].  Sander and colleagues have identified the Pax6 protein as a 
transcription factor that binds to a common element in the glucagon, insulin, and somatostatin 
promoters.  They have also shown that Pax6 transactivates the glucagon and insulin promoters 
[Sander et al., 1997].  At the organism-level, over-expression of PAX6 has been observed 
during the early stages of pancreatic development in mice and in mature endocrine cell.  Since 
mice lacking in Pax6 failed to develop any mature endocrine cells, Pax6 could also be essential 
for endocrine development in the pancreas [St-Onge et al., 1997]. 
Phas1 (also known as eukaryotic translation initiation factor 4E binding protein 1, 
Eif4ebp1) is a heat-stable protein found in many tissues [Blackshear et al., 1983].  It is rapidly 
phosphorylated in rat adipocytes incubated with insulin or other growth factors [Blackshear et 
al., 1983].  Non-phosphorylated Phas1 binds specifically to eukaryotic initiation factor 4E 
(Eif4e, a mRNA 5'-cap binding protein) and inhibits protein synthesis.  Hyper-phosphorylation 
of Phas1 causes it to dissociate from Eif4e, thereby relieving the translational inhibition.  Thus, 
Phas1 is an insulin-activated stimulator of protein synthesis [Lin et al., 1994; Lin et al., 1995], 
and acts to stimulate the overall rate of translation and promote cell growth [Pause et al., 
1994].   
To summarise, the microarray comparative analyses in Sections 4.4 and 4.5 revealed 






exhibited greater than 2-fold differential expression (n = 3, 95% confidence).  Signal 
transduction-related functions were prominently featured among the genes that were 
differentially expressed.  This could point to the importance of signal transduction-related 
processes in mediating the effects of zinc in insulin-free CRL1606 culture.  The co-regulation 
of several insulin/Pi3k-related genes identified in Sections 4.4 and 4.5 also suggests that Pi3k 
(downstream of insulin-receptor IR) may be instrumental in integrating zinc-induced signalling 
with the insulin-mimetic effects observed in zinc-supplemented culture [Figure 4.15].  Table 
4.6 provides an overview of the microarray results highlighted in Sections 4.4 and 4.5. 
 
 
Figure 4.15 Proposed mechanism of zinc-mediated insulin-mimetic effects in insulin-free 
CRL1606 culture [GenMapp].  Values shown on the right of the gene labels are the mean 
log2 ratios (n = 3, before screening) for that gene in ‘Zinc’ vs. ‘Insulin’ experiment. 
 
Note: Pre-screened data was used in Figure 4.15 as the process of screening filtered off most of 
the regulation data.  The data visualised in this GenMapp could be used for preliminary 






 Table 4.6 Summary of microarray results  
(Section 4.4) 
Up-regulated by                 
‘Zinc’ (1.5mg-ZnSO4·7H2O/L) 
compared to ‘Insulin’ (10mg/L) 
Down-regulated by               
‘Zinc’ (1.5mg-ZnSO4·7H2O/L) 
compared to ‘Insulin’ (10mg/L) 
% Differentially expressed*  0.24% (18 genes) 0.55% (41 genes) 
Functions prominently 
featured amongst the genes 
that were differentially-
expressed ** 
• Transcription (~22%) 
• Signal transduction (~21%) 
• Growth and/or maintenance 
(~17%)  
• Signal transduction (~27%) 
• Transport (~10%) 
Candidate genes identified 
for further studies 
• PUR-1 (activate insulin 
promoter transcription) 
• CD19 (activate PI3K-
dependent cell survival) 
• CDC42 (activate E2F-
mediated transcription, for cell 
cycle progression) 
• FADD (apoptotic adaptor) 
• TAK1 (up-regulates Akt) 
• RAD (negative regulator of 
glucose uptake) 
• U5, Clone 11 (unknown 
function) 
(Section 4.5) 
Up-regulated by ‘Low-Zinc’    
(0.2mg-ZnSO4·7H2O/L)        
compared to ‘Optimal-Zinc’       
(1.5mg-ZnSO4·7H2O/L) 
Down-regulated by ‘Low-Zinc’ 
(0.2mg-ZnSO4·7H2O/L)        
compared to ‘Optimal-Zinc’       
(1.5mg-ZnSO4·7H2O/L) 
% Differentially expressed*  0.32% (24 genes) 0.33% (25 genes) 
Functions prominently 
featured amongst the genes 
that were differentially-
expressed ** 
• Signal transduction (~21%) 
• Metabolism (20%) 
• Signal transduction (12%) 
• Cytoskeleton (12%) 
Candidate genes identified 
for further studies 
• U5, Clone 3 (signal-
transduction related) 
• U5, Clone 7 and 11 (unknown 
function)  
• GRB10 (regulates insulin and 
Igf1 signalling) 
• PAX6 (which binds to insulin 
promoter) 
• EIF4EBP1/PHAS1 (insulin-
mediated of protein synthesis) 
 
Note: All data shown in the table have been statistically screened via Student’s t-test (n = 3, 95% 
confidence). 
 
* Out of 7524 genes examined. 
 







            
5.1 Conclusions 
The addition of zinc in the range of 0.5-5.0mg-ZnSO4·7H2O/L (0.11-1.14mgZn2+/L) 
restored cell growth and viability in insulin-free CRL1606 culture without the need for 
adaptation.  The amino acid, ammonia, metabolite and Mab production profiles of these zinc-
supplemented cultures were similar to its insulin-supplemented counterpart.  The results 
indicate that zinc is an effective insulin-replacement for CRL1606 culture.   
Microarray comparative analyses of various zinc- and insulin-supplemented cultures 
have revealed limited differential expression profiles.  These results have indicated that signal 
transduction-related functions could be instrumental in mediating the effects of zinc in insulin-
free CRL1606 culture.  The importance of Pi3k in integrating zinc-induced signalling with the 
insulin-mimetic effects observed in zinc-supplemented culture has also been suggested. 
To sum up, the cell culture results presented in this thesis have essentially met the 
objectives set out in Section 1.2.1.  Although the microarray results generated some positive 
hypothesis, further verification work is necessary before they could be used for the purposes 
outlined in Section 1.2.2 [Section 5.2].   
 
 
5.2 Recommendations for Future Work 
The identification of genes for further studies was based on statistically significant 
differential expression data (n = 3, 95% confidence).  Taking into account the inherent 
variability of the microarray results [Yue et al., 2001], and the possibility that some of the 
zinc-mediated insulin-mimetic effects could be post-translational, it is necessary to 






quantitative real-time PCR).  The combined results could then be used to better identify 
potential targets for genetic manipulation, and also to improve understanding of zinc-induced 
insulin-mimetic mechanisms in CRL1606 cells. 
Pending further verification studies outlined above, genetic manipulation using targets 
identified in this thesis could help to overcome the dependence of industrially important cell 
lines on protein-based media supplements.  An example of such manipulation is Super-CHO, a 
cell line that has been genetically engineered to produce Igf-I and transferrin, and is capable of 
autocrine growth in a fully defined protein-free medium [Pak et al., 1996].  The results could 
also be used to metabolically engineer a cell line that can be rapidly adapted to protein-free 
media through growth-stimulation.  This is exemplified by CHO-K1:CycE, a cyclin E 
overexpressing cell line that is capable of optimal proliferation under protein-free conditions 
[Renner et al, 1995].   
It could also be interesting to compare the CRL1606 microarray data with those of a 
hybridoma that does not respond positively to zinc-supplementation, but grows well in insulin-
supplementation.  This knowledge could be useful for the design of a balanced and generic 
hybridoma media formulation that caters more closely to the cells’ requirements and thus 
improve cell growth, product formation and productivity.   
The insulin preparations used in the studies described Chapter 4 contained 0.5%(w/w) 
zinc.  Even though it has been established that this trace-amount of zinc alone is not sufficient 
for optimal growth in insulin-free CRL1606 culture [Section 4.3], there is a possibility that the 
zinc requirement could be lowered in the presence of insulin.  Therefore, it is desirable to 
confirm the insulin-dependence of the cells using zinc-free insulin preparations or insulin-like 
growth factor (Igf).  Igf could be used because it has been shown to be highly insulin-mimetic 
[Cheatham and Kahn, 1995; Chang et al., 2001], and is available in zinc-free preparations (e.g. 






to investigate whether insulin facilitates zinc transport, with the testing of at least two 
hypotheses: (i) Insulin alone may or may not be essential for cell growth, while zinc (at a low 
concentration) helps to propagate insulin-mediated signal transduction pathways.  (ii) Zinc is 
required for cell growth at a high concentration under insulin-free conditions, because the zinc 
transporter (ZnT) requires such a concentration to have a sufficiently high transport rate, and 
insulin facilitates zinc transport by its association with zinc.  The association of insulin with 
zinc in the medium needs to be verified in the latter hypothesis.  Both hypotheses could be 
tested via the blocking of ZnT and insulin receptor (IR). 
A portion of the cells could survive prolonged maintenance in insulin-free medium 
without any substitute additives [Section 4.2].  There could be component(s) in the medium 
that have promoted survival (albeit at reduced cell viability) in the absence of both insulin and 
zinc.  They could be identified via factorial experimentation with media lacking various test 
components.  Increasing the presence of these component(s) could then result in alternative 
insulin-free media.  However, the adaptation process can be time-consuming and unpredictable 
[Renner et al, 1995; Zang et al., 1995]. 
A wide range of workable zinc dosage in insulin-free cultures was demonstrated in 
Chapter 4. This could imply that the cells have a rigorous homeostatic mechanism (for uptake, 
retention and exportation of intracellular-zinc) that worked well, even under extreme 
extracellular zinc concentrations.  To better understand the zinc requirement/uptake of the cells 
under insulin-free conditions, zinc ion ICP-OE measurements could be conducted in the 
cultures supplemented with various levels of zinc.  To complement the ICP-OE results, 
Zinquin [(2-methyl-8-p-toluenesulphonamido-6-quinolyloxy)-acetic acid], a membrane-
permeant fluorophore specific for zinc (II) ion, could be used with spectrofluorimetry and 






The microarray experimental set up described in this thesis did not provide enough 
samples to allow the effective clustering of the expression data using Eisen’s Cluster and 
Treeview software.  For better clustering, fed-batch experimentation based on deprivation and 
stimulation (step-feeding) of zinc/insulin, coupled with tighter sampling intervals could be 
undertaken [Appendix C]. 
Signal transduction genes were prominent among the list of differentially expressed 
genes shown in Sections 4.4 and 4.5.  On the other hand, the functional classification of the 
genes could be refined in due course.  For example, ‘metabolism’ and ‘growth and 
maintenance’-related genes could be classified under the same functional group for ‘growth 
and housekeeping’.  If so, this new functional grouping would be prominent in the differential 
expression data as well.   
Around a third of all differentially expressed data shown in Chapter 4 were classified 
under ‘other (non-biotech related)’ and ‘unknown’ functions.  These data could not be 
meaningfully analysed in this thesis.  However, some of these genes may be instrumental in 
the insulin-mimetic properties of zinc in insulin-free CRL1606 cultures.  Therefore ‘data-
mining’ of these results might be useful.  For example, the DNA sequences of the unknown 
genes could be screened for common motifs/promoters using Multiple EM for Motif 
Elicitation (MEME) software [Bailey and Elkan, 1994], from which homology to previously 
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APPENDIX A: Cell Culture Inventory List  
            
Reagents 
• Albumin, Bovine (Sigma, A-8806) 
• Ammonia kit (Sigma, LD-L 10, Procedure: 171-UV) 
• Anti-FN standard, 1mg/mL (Sigma, M9269) 
• Blocking solution (SuperblockTM, Pierce 37515) 
• Capture antibody solution (Sigma, C3401) 
• Capture antibody, anti-Mouse IgG1, 1.1mg/mL (Sigma, M8770) 
• CO2 gas for incubator (Singapore Oxygen Air Liquid Pte Ltd, SOXAL) 
• Detection antibody (Sigma, A2304), Substrate solution (Sigma, P9187) 
• DMSO, liquid (Sigma, D2650) 
• eRDF modified (Hyclone, SH40015-8) 
• Ethanolamine, ~98% (Sigma, E-0135) 
• Insulin ELISA kit, Bovine (Mercodia, 10-1131-01) 
• Insulin, from Bovine Pancreas, lyophilized (Sigma, I-1882) 
• Iscove’s Modified Dulbecco’s Medium (IMDM: Gibco, 12200) 
• OPD (o-Phenylenediamine dihydrochloride) Peroxidase Substrate tablets (Sigma, P9187) 
• PBS (Sigma, P-4417) 
• Penicillin – Streptomycin (Gibco, 15140-122) 
• Pluronic F68 (Gibco, 24040-032) 
• Sample buffer (1 part Blocking solution and 9 parts Washing buffer) 
• Serum, fetal bovine, triple 0.1µm sterile filtered (FBS: Hyclone, SH30071.03) 






• ß-mecaptoethanol, 98+% (Sigma, M-3148) 
• Transferrin, human, Siderophilin; partially iron-loaded, ~98% (Sigma, T-8158) 
• Trypan blue (Sigma, T6146) 
• Tween 20, detergent (Calbiochem, 655205) 
• Washing buffer (1x PBS with 0.05% Tween 20) 
• Zinc Chloride (Sigma, Z-0173) 
• Zinc Sulfate (Sigma, Z-0251) 
 
Specialist Computer Softwares  
• RasMol Ver 2.6 (RasWin Molecular Graphics) 
 
Equipment and Consumables 
• 96-well plate for ELISA (Nunc, InterMed 469914) 
• Bioprocess analyzers (YSI, 2700 Select) 
• Bottletop filter (Nalgene, Bottle Top) 
• Centrifuge, large (Beckman, GS-6) 
• Centrifuge, small (B.Braun, 5145) 
• CO2 incubator (Jouan, EG 115 IR; Sanyo, MCO 17AI/AIC) 
• Coulter Counter (Coulter, Z2) 
• Double distilled water (Millipore) 
• Flasks, horizontal (T-flask: Corning) 
• Flasks, shake (Erlenmeyer: Corning) 
• Hemocytometer (Marienfeld, Neubauer improved bright line 0.0025mm2) 






• Laminar Hood (Gelman, BH Class II Series; Nuaire, Class II Type A/B3) 
• Liquid N2 storage tank monitor (MVE Cryogenics, TEC 1000 system monitor) 
• Microcentrifuge (Millipore, Centra free-MC) 
• Microplate seal, aluminum (Axygen, 5/0038) 
• Microscope (Olympus, BX40/IX70) 
• Microwell plate reader (Anthos, HTIII) 
• Microwell plate washer (Tecan, 96 PW) 
• Osmometer, vapour pressure (Wescor, VaproTM 5520) 
• pH meter (Beckman, Ф34) 
• Pipette tips, disposable (Falcon) 
• Pipette, serological (Falcon, 35721/2) 
• Pipettor, large (Drummond, Pipet-Aid XP) 
• Pipettor, small (BIOH-T, Proline; Gilson, Pipetman) 
• Reversed-phase column, C18 amide (Shimadzu, Shim-pack VP-ODS) 
• Tubes, sterile (Greiner bio-one) 
• Votex (IKA® MS1 Minishaker) 
• Water bath (B.Braun, Certomat® WR) 







APPENDIX B: Microarray Inventory List 
            
Reagents  
• 1,2-dichloroethane, anhydrous  (Aldrich, 15,478-4) 
• 1-Methylimdazole (Sigma, M8878) 
• 1-Methyl-Imidazole (Sigma, M8878) 
• 3-aminopropyltriethoxysilane (Sigma, A3648) 
• Acetic acid (Merck, UN2789) 
• Acetone (Sigma, A4206) 
• Aminoallyl-dUTP (Invitrogen) 
• Betaine, Anhydrous (Sigma, B2629) 
• Centrifugal Filter Devices (Amicon Millipore, Microcon YM-30, 42410 331) 
• Chloroform (EM Science, CX1055-44) 
• CyTM3, monofunctional dye (Amersham Pharmacia FluoroLinkTM, PA23001) 
• CyTM5, monofunctional dye (Amersham Pharmacia FluoroLinkTM, PA25001) 
• Dimethyl sulfoxide (DMSO: Sigma D8148) 
• dNTP set, 100mM (Invitrogen, 10297-018) 
• DTT, 0.1M (Invitrogen, Part no. Y00147)  
• Ethanol (Merck, UN1170) 
• First Strand Buffer, 5x (Invitrogen, Part no. Y00146)  
• Hydroxylamine (Sigma, H2391) 
• Isopropanol (Sigma, I-9516) 
• Mouse COT-1 DNA (Invitrogen, 18440-016) 






• Oligo dT, primer MW=6637, TM=46, 220 OD/umol, 260uM (4µg/µl) (Genset Oligos, 
158948-S)  
• PBS, 1x (8g/L NaCl, 0.2g/L KCl, 1.44g/L Na2HPO4, 0.24g/L KH2PO4) 
• Phenol: chloroform: isoamyl alcohol 125:24:1, pH 4.7 (Sigma, P1944) 
• Pin cleaning solution (ArrayItTM, Micro Cleaning Solution, MCS) 
• Poly-L-lysine solution, 0.1% w/v (Sigma P8920) 
• Print head cleaning reagent (ArrayItTM, Micro Cleaning Solution, PHCR80) 
• RnaseZap (Ambion, 9780/2) 
• RNasin® RNase Inhibitor, 2,500U (400U/µl) (Promega, N211A) 
• Salmon sperm DNA (Invitrogen, 15632-011) 
• SDS, 10% (Numi) 
• SSC, 20x (3M NaCl, 0.3M NaCitrate, pH 7.0) 
• Succinic anhydride, 99+% (Aldrich, 23,969-0 [180-30-5]) 
• SuperscriptTM II RT, 10000U (200U/µl) RNase H- Reverse Transcriptase (Invitrogen Cat 
no.18064-014) 
• TRIzol® Reagent (Invitrogen, Cat no. 15596-018) 
• Yeast tRNA (Roche, 109495) 
 
Specialist Computer Softwares  
• Analysis (Applied Precision, ArrayWoRx, ver 1.50) 
• Array design (BioDiscovery, Clonetracker ver 1.4)  
• Pathway visualization (GenMAPP, ver 1.0) 






Equipment and Consumables 
• 384 wells microarray plate, “V” well (Abgene, AB-1056/W) 
• Centrifuge (B Braun) 
• Dehumidifier (Cecilia, Super Dehumidifier) 
• Gel electrophoresis, power supply (Bio-Rad, Power Pac 300) 
• Hybridization cover slips (Erie Scientific Company, LifterSlip) 
• Hybridization station  (Genomic Solutions Inc, GeneTACTM) 
• Incubator, digital temperature controller (memmert; Polyscience) 
• Liquid handler (Tecan, Genesis) 
• Microscope  (Olympus) 
• Microscope slides, 75x25x1.05mm (Goldseal Products, Cat no. 3010) 
• Multipipetter (BIOHIT) 
• Pipette tips, disposable (Axygen) 
• Printer (Bio-Rad Laboratories Inc; Virtek Vision International Inc., Virtek ChipWriter™ 
semi-automatic DNA dispensing cell, SDDC-3 ver 1.0) 
• Scanner, CCD based (Applied Precision, ArrayWoRxTM ver 4.0) – prototype 
• Slides, APS coated (Sigma SigmaScreenTM, S9936) 
• Spectrophotometer (Amersham Biosciences, GeneQuant Pro) 
• Spotting pins, stealth micro spotting pins (ArrayItTM, SMP3)  
• Unix system (Sgi, Silicon graphics 02) 
• UV crosslinker (Stratagene, Stratalinker 1800) 
• Vaccum drying (Savant, Speed Vac® SPD121P) 







APPENDIX C: Saturation of Microarray Data 
            
Figures A.C.1 and A.C.2 compares data from microarray experiments using different 
amounts of starting total RNA (ranging from 50 to 100µg per sample per slide) for 
reproducibility.  Results of perfect reproducibility would form a diagonal line from the lower-
left quadrant of the chart, across the origin to the upper-right quadrant.  The data was only 
moderately reproducible across the replicates, as 20-40% of all collected data fell into the 
upper-left and lower right quadrants (i.e. up-regulated in one replicate, down-regulated in the 
other).  Data saturation (i.e. loss of data sensitivity w.r.t. fold change) was less apparent when 
comparing data originating from 75µg to 50µg starting total RNA [Figure A.C.1].  However, 
there were signs of saturation when comparison of data originating from 100µg starting total 
RNA to 50µg starting total RNA [Figure A.C.2] was carried out.   
 
 
Figure A.C.1 Distribution plots comparing Z2vsB2 data (before statistical screening) 







Figure A.C.2 Distribution plots comparing Z2vsB2 data (before statistical screening) 
originating from 100µg starting total RNA to 50µg starting total RNA 
 
In particular, the range of expression fold-changes exhibited by data originating from 
100µg starting total RNA was limited as compared to data originating from 50µg starting total 
RNA.   
The results shown in Table A.C.1 suggest that 50-75µg of starting total RNA could be 
considered optimal in terms of minimal data saturation, and high signal-to-background ratio.  
A lower threshold for differential expression (e.g. 1.5 fold-change) needs to be applied to the 
data originating from 100µg starting total RNA to compensate for the reduced data sensitivity 







Table A.C.1 Differentially expressed genes (before statistical screening) when a cut-off of 2.0 
fold change is applied in experiments with various levels of starting total RNA 
 
Sample Z2 vs. B2 B2 vs. Z2 (Dye Swap) 
Starting total RNA 
(µg) 50 75 100* 50 75 100* 
No. of up – 
regulated** genes 1201 727 523 901 881 603 
No. of down –
regulated*** genes 1950 1485 433 1331 1855 694 
Total no. of 
differentially 
expressed genes 
3151 2212 956 2232 2736 1297 
% Change in no. of 
differentially 
expressed genes 
compared to 50µg 
starting total RNA 
- -29.8% -69.7% - +22.6% -41.9% 
 
* Average of Triplicate 
 
** Log2 Ratio > 1.00 
 






Note1: ‘Z2’ and ‘B2’ refers to zinc-supplemented (1.5mg-ZnSO4·7H2O/L or 0.34mgZn2+/L, Day-2) and 
insulin supplemented (10mg-insulin/L, Day-2) CRL1606 cultures respectively.  Some of these 
experiments are not mentioned in the main text of this thesis. 
 
Note2: ‘Dye-swap experiments’ refers to reverse-labelled experiments in which each of the two samples 
to be compared was divided into two aliquots and labelled with the two different Cy dyes (i.e. Cy3 and 
Cy5) in separate steps.  Two hybridisation experiments (dye-swap of each other) were then performed.  
In the ideal case, the differential expression data in these two experiments should be symmetrical (in the 






APPENDIX D: Variance of Microarray Data  
            
It was found that the signal-to-background intensity ratios (S/B) were highly similar 
among each batch of slides, but differed greatly between different batches of slides [Tables 
A.D.1 and A.D.2].   
 
 
Table A.D.1 Signal intensity levels (including controls) observed 
in various microarray experiments 
 
Experiment 
Code / Level 
of starting 
total RNA 
BG SG SG/BG 
G = 
SG-BG 
BR SR SR/BR 
R =  
SR-BR 
R/G 
Z2(Cy5) vs. B2(Cy3) 
2A (50µg) * 145.2 181.5 1.3 36.3 262.4 307.8 1.2 45.4 1.3 
2B (75µg) ** 125.0 168.8 1.3 43.7 260.6 322.3 1.2 61.7 1.4 
2C (100µg) ** 622.3 838.2 1.3 215.9 440.0 534.1 1.2 94.1 0.4 
1A (50µg)  *** 106.4 227.9 2.1 121.5 106.1 225.4 2.1 119.3 1.0 
1B (50µg) *** 107.1 251.6 2.3 144.4 105.9 224.4 2.1 118.5 0.8 
Reverse labelling experiments: B2(Cy5) vs. Z2(Cy3) 
2Ads (50µg) * 127.5 173.5 1.4 45.9 266.2 321.9 1.2 55.7 1.2 
2Bds (75µg) ** 115.5 153.8 1.3 38.3 259.6 326.2 1.3 66.6 1.7 
2Cds (100µg) ** 299.9 461.5 1.5 161.6 428.4 575.3 1.3 146.8 0.9 
 
Note1: ‘B’ means ‘Background Signal’; ‘S’ means ‘Spot Signal’; ‘G’ means ‘Green (Cy3) channel’; ‘R’ 
means ‘Red (Cy5) channel’. 
 
Note2: The mean intensity pixel values shown in this table includes those of all controls, landing lights, 
and flagged-off elements. 
 
* Triplicate experiments done using a batch of slides printed in Nov 02. 
 
** Duplicate experiments done using a batch of slides printed in Nov 02. 









Table A.D.2 Signal intensity levels (excluding controls) 
observed in various microarray experiments 
Experiment 
Code / Level 
of starting 
total RNA 
BG SG SG/BG 
G = 
SG-BG 
BR SR SR/BR 
R =  
SR-BR 
R/G 
Z2(Cy5) vs. B2(Cy3) 
2A (50µg) * 141.9 169.2 1.2 27.3 262.4 298.8 1.1 36.5 1.3 
2B (75µg) ** 124.9 158.6 1.3 33.6 260.5 311.6 1.2 51.1 1.5 
2C (100µg) ** 626.1 845.9 1.4 219.9 440.9 529.3 1.2 88.4 0.4 
1A (50µg)  *** 104.7 167.3 1.6 62.6 106.3 211.9 2.0 105.6 1.7 
1B (50µg) *** 104.9 178.7 1.7 73.8 105.8 202.6 1.9 96.8 1.3 
Reverse labelling experiments: B2(Cy5) vs. Z2(Cy3) 
2Ads (50µg) * 127.0 160.9 1.3 33.9 266.0 309.1 1.2 43.1 1.3 
2Bds (75µg) ** 115.3 143.6 1.2 28.3 259.5 314.4 1.2 54.9 1.9 
2Cds (100µg) ** 299.2 462.0 1.5 162.7 427.9 572.5 1.3 144.6 0.9 
 
Note3: ‘B’ means ‘Background Signal’; ‘S’ means ‘Spot Signal’; ‘G’ means ‘Green (Cy3) channel’; ‘R’ 
means ‘Red (Cy5) channel’. 
 
Note4: The mean intensity pixel values shown in this table excludes those of all controls, landing lights, 
and flagged-off elements. 
 
* Triplicate experiments done using a batch of slides printed in Nov 02. 
 
** Duplicate experiments done using a batch of slides printed in Nov 02. 
 
*** Experiment done using a batch of slides printed in Aug 02. 
 
 
The S/B ratios were independent of the level of starting total RNA (from 50 - 100µg), while 
the total intensity measured in each experiment (S + B) generally increased with the level of 
starting total RNA.  The corresponding level of exposure (0.5-3.0 seconds) for both channels 
could have played a key role in the latter phenomena.  It is noted that the positive control array 
spots, while slightly increasing the intensities measured in both channels, lowered the mean 







Note5: ‘A batch of slides’ refers to a group of slides that were coated, printed and post-processed 
together. 
 
Note6: ‘Z2’ and ‘B2’ refers to zinc-supplemented (1.5mg-ZnSO4·7H2O/L or 0.34mgZn2+/L, Day-2) and 
insulin supplemented (10mg-insulin/L, Day-2) CRL1606 cultures respectively.  Only experiments 2A 






APPENDIX E: Reproducibility of Microarray Data 
            
A.E.1. Inconsistencies in Microarray Data 
Factors that could contribute to inconsistencies in microarray data included 
inconsistent sequence fidelity of the spotted microarrays, variability of differential expression, 
low specificity of cDNA microarray probes, discrepancy in fold-change calculation and lack of 
probe specificity for different isoforms of a gene [Olshen and Jain, 2002].  In view of these 
pitfalls, data from microarray analysis needs to be interpreted cautiously.   
Random errors can be overcome by increasing the number of replicate spots printed on 
each slide, and by increasing the number of replicate hybridisations.  Lee et al. [2000] 
recommended that at least three replicates be performed for each comparative study.  
Systematic errors are much harder to detect and solve.  Outliers (defined here are extreme 
values in a distribution of replicates) has been reported to number as high as 15% in typical 
microarray studies [Lee et al., 2000], and are normally revealed only by the extreme deviance 
of their expression values relative to other replicates.  Undetected outliers bias the estimation 
of both the expression value and its associated random error, reducing both specificity and 
sensitivity [Nadon and Shoemaker, 2002].  Even though it is possible to eliminate nearly 15% 
of the data as obvious outliers, there would be up to another 25% of undetected outliers that 
would compromise the integrity of proceeding analytical efforts [Nadon and Shoemaker, 
2002].  On top of this, Lee et al. [2000] has found that it is not a certainly that an expressed 
gene will be classified as “expressed” on the slide, and “ghost” indications of genes (i.e. false 
positives) can occur with a frequency as large as 10% in a single experiment.  These studies 
show that replication do not ensure duplication of results in microarray experiments.  For 






are unusable because one or more of the replicates have non-positive values (after deducting 
background signal). 
In the application of standard deviation as an index of reproducibility, Shedden and 
Cooper, [2002] has reported that log-transformed data are generally preferred to ratios of raw 
signal values.  Transforming expression data to a log scale (any base) removes much of the 
proportional relationship between random error and signal intensity (with the exception of low 
signals).  Geller et al. [2002] has considered that genes with standard deviations (amongst 4 
replicates) more than 3x the overall average standard deviation to be unusable outliers (which 
eliminated 655 out of 15625 genes).  After doing duplicate of each experiment, Rashmi et al. 
[2002] classified genes with a fold-change higher than 1.6 and standard deviation lower than 
0.4 as being “differentially expressed”.  In all the genes were classified into absent, variable 
(standard deviation>0.4), unchanged and changed.   Rather than using absolute levels of 
standard deviation as cut offs for filtration, Richmond [2001] ignores the bottom 5.0% and the 
top 5.0% of the data points, based on a trimmed standard deviation calculated for each channel 
from each slide.   
It is interesting to note that standard deviation had also been used to isolate genes that 
shown differential expression across different time points.  This method has been named 
Significance Analysis of Microarrays (SAM), and works by assigning a score to each gene on 
the basis of change in gene expression relative to the standard deviation of repeated 
measurements (of the same genes across different time-points) [Tusher et al., 2001].  Shedden 
and Cooper [2002] chose 1000 genes (out of a total of approximately 6000 genes) with the 
highest standard deviation in experimental values (using the raw data) for further analysis.   
A.E.2. Dye Swap 
In a dye-swap design (reverse-labelled experiments), each of the two samples to be 






and Cy5) in separate steps.  Two hybridisation experiments (dye-swap of each other) were then 
performed.   The ratio data originating from these two experiments should thus rightly be the 
exact reverse of each other.   
Figure A.E.1 illustrates the comparison of data from Z2vsB2 against its dye swap (DS) 
of B2vsZ2 for different levels of starting total RNA.  Analogous to the analysis in for 
replicates [Appendix C], perfectly reproducible dye swap data should ideally form a diagonal 
line, this time from the upper-left quadrant of the chart, across the origin to the lower-right 
quadrant.  The dye-swap reproducibility of the data across all levels of starting total RNA (50, 
75, 100µg) was poor - around 50% of the data fall either on the upper-right or lower-left 
quadrants which signify that the fold change of the original experiment and the dye-swap 









Figure A.E.1 Distribution plots comparing data from Z2vsB2 against its dye swap (DS) of 
B2vsZ2 for different levels of starting total RNA (50, 75, 100µg).  Muted fold-change is 
observed for data originating from 100µg of starting total RNA, confirming the effects of 







A.E.3. Pearson Product Moment Correlation 
Pearson Product Moment Correlation (called Pearson's correlation for short) was used 
to counter-check the reproducibility among the replicates (of the same comparative study) and 
dye-swaps (reverse-labelled experiments).  Pearson's correlation is a type of distance matrix 
that determines whether a linear relationship exists between 2 arrays of variables.  The 
computation of the following formula returns a dimensionless index (the Pearson’s correlation 
coefficient, r) that ranges from –1.0 to 1.0:   
 
( ) ( )( )








r = Pearson’s correlation coefficient 
Narray = number of paired observations  
X = variable in an array of independent values  
Y = corresponding variable in an allegedly dependent array 
 
A positive Pearson's correlation coefficient indicates that the values of variable X vary 
in the same direction as variable Y. A negative Pearson's correlation coefficient indicates that 
the values of variable X and variable Y vary in opposite directions.  Pearson’s correlation is 
sensitive to extreme values in the data and can be used to quantify the similarities between two 
expression profiles.  Pearson's correlation coefficients are expected to be near 1.0 for replicates 
of the same experiment, and near –1.0 for corresponding dye-swaps.  The computed Pearson's 
correlation coefficients for some of the microarray studies mentioned in Chapter 4 are shown 






J. From Table A.E.1, it is apparent that the calculated Pearson’s coefficients are not within 
reasonable limits. 
Table A.E.1 Pearson’s coefficients of data from various ‘zinc vs. 























































50µg I - 0.011 0.043 0.048 0.018 0.079 0.007 0.089 -0.033 -0.016 
50µg II 0.011 - 0.274 0.067 0.138 0.066 0.231 0.036 -0.013 0.011 
50µg III 0.043 0.274 - 0.078 0.176 0.059 0.227 0.097 -0.005 -0.011 
(DS) 50µg I 0.048 0.067 0.078 - 0.048 0.073 0.035 0.123 -0.026 0.002 
(DS) 50µg II 0.018 0.138 0.176 0.048 - 0.081 0.165 0.035 0.059 -0.023 
75µg I 0.079 0.066 0.059 0.073 0.081 - 0.042 0.134 -0.013 -0.012 
75µg II 0.007 0.231 0.227 0.035 0.165 0.042 - 0.062 -0.008 -0.041 
(DS) 75µg 0.089 0.036 0.097 0.123 0.035 0.134 0.062 - -0.049 -0.056 
100µg -0.033 -0.013 -0.005 -0.026 0.059 -0.013 -0.008 -0.049 - 0.061 
(DS) 100µg -0.016 0.011 -0.011 0.002 -0.023 -0.012 -0.041 -0.056 0.061 - 
 




The dye swap reproducibility consistently ranges around 20-40%, and more than 50% 
of differentially expressed genes are not reproduced across replicates with different starting 






labelling experiments, few genes (~ 10% amongst all differential expression data) can be 














































Note: ‘Z2’ and ‘B2’ refers to zinc-supplemented (1.5mg-ZnSO4·7H2O/L or 0.34mgZn2+/L, Day-2) and 
insulin supplemented (10mg-insulin/L, Day-2) CRL1606 cultures respectively.  Some of these 






APPENDIX F: Overview of Regulation Profiles (Pre-screened) 
            
 
The data screening procedure shown in Section 3.2.7 was found to filter off a very 
large portion of the original differential expression data.  This was because the magnitudes of 
differential transcription were relatively small.  For example all the averaged Cy5/Cy3 ratios in 
‘Zinc’ vs. ‘Insulin’ experiments showed less than 16-fold change (log2 ratio < 4.0) - the 
average log2 ratios for the differentially expressed genes (>2-fold) were 1.4 (~2.7-fold) for up-
regulation, and 1.6 (~3-fold) for down-regulation.  Therefore while only the statistically 
significant differential expression data are listed in Sections 4.4 and 4.5, no statistical 
screening was applied for a broader overview of the global expression profiles based on 
cellular functions in Tables A.F.1 and A.F.2.  The aim of sure an overview is to help ascertain 
if there were specific cellular functions worth following up.  The overviews in Tables A.F.1 
and A.F.2 augment the finding in Sections 4.4 and 4.5, that signal transduction-related 




Table A.F.1 Overview of differential expression profiles (>2x, before screening) between zinc- 
and insulin-supplemented CRL1606 cultures (Results from 2 sets of experiments are shown 




Starting total RNA 50µg (n = 3) 75µg (n = 2) 
Function No. in library Number
% w/in 
same fn % overall Number
% w/in 
same fn % overall
Up-regulated (>2x) genes in zinc 
Apoptosis 129 4 3.10 0.05 5 3.88 0.07 
Cell cycle 271 10 3.69 0.13 13 4.80 0.17 
Cytoskeleton 633 22 3.48 0.29 29 4.58 0.39 
Growth and/or 
maintenance 647 26 4.02 0.35 39 6.03 0.52 
Metabolism 623 20 3.21 0.27 22 3.53 0.29 
Protein processes 1021 24 2.35 0.32 29 2.84 0.39 
Signal transduction 793 25 3.15 0.33 47 5.93 0.62 
Transcription 1127 32 2.84 0.43 42 3.73 0.56 
Transport 524 21 4.01 0.28 18 3.44 0.24 
Other functions 1151 42 3.65 0.56 51 4.43 0.68 
Unknown 605 21 3.47 0.28 31 5.12 0.41 
Total 7524 247 3.28 3.28 326 4.33 4.33 
Down-regulated (>2x) genes in zinc 
Apoptosis 129 6 4.65 0.08 7 5.43 0.09 
Cell cycle 271 10 3.69 0.13 13 4.80 0.17 
Cytoskeleton 633 30 4.74 0.40 53 8.37 0.70 
Growth and/or 
maintenance 647 20 3.09 0.27 31 4.79 0.41 
Metabolism 623 23 3.69 0.31 24 3.85 0.32 
Protein processes 1021 33 3.23 0.44 45 4.41 0.60 
Signal transduction 793 46 5.80 0.61 64 8.07 0.85 
Transcription 1127 44 3.90 0.58 63 5.59 0.84 
Transport 524 19 3.63 0.25 29 5.53 0.39 
Other functions 1151 66 5.73 0.88 96 8.34 1.28 
Unknown 605 64 10.58 0.85 86 14.21 1.14 
Total 7524 361 4.80 4.80 511 6.79 6.79 
Differentially-expressed (>2x) genes (Both up- and down-regulated) 
Apoptosis 129 10 7.75 0.13 12 9.30 0.16 
Cell cycle 271 20 7.38 0.27 26 9.59 0.35 
Cytoskeleton 633 52 8.21 0.69 82 12.95 1.09 
Growth and/or 
maintenance 647 46 7.11 0.61 70 10.82 0.93 
Metabolism 623 43 6.90 0.57 46 7.38 0.61 
Protein processes 1021 57 5.58 0.76 74 7.25 0.98 
Signal transduction 793 71 8.95 0.94 111 14.00 1.48 
Transcription 1127 76 6.74 1.01 105 9.32 1.40 
Transport 524 40 7.63 0.53 47 8.97 0.62 
Other functions 1151 108 9.38 1.44 147 12.77 1.95 
Unknown 605 85 14.05 1.13 117 19.34 1.56 
Total 7524 608 8.08 8.08 837 11.12 11.12 
Note: “% w/in same function” represents the percentage based on the number of genes classified under 
the same function (e.g. 129 genes for ‘Apoptosis’); “% overall” represents the percentage based on the 
total number of genes (i.e. 7524 genes). 
 
Table A.F.2 Functional classification of genes differentially expressed (>2x, before 




 Starting total RNA 50µg (n = 3) 
 Function No. in library Number
% w/in 
same fn % overall 
 Up-regulated in low-zinc over zinc-supplementation 
 Apoptosis 129 7 5.43 0.09 
 Cell cycle 271 10 3.69 0.13 
 Cytoskeleton 633 43 6.79 0.57 
 Growth and/or maintenance 647 26 4.02 0.35 
 Metabolism 623 26 4.17 0.35 
 Protein processes 1021 46 4.51 0.61 
 Signal transduction 793 52 6.56 0.69 
 Transcription 1127 48 4.26 0.64 
 Transport 524 48 9.16 0.64 
 Other functions 1151 91 7.91 1.21 
 Unknown 605 71 11.74 0.94 
 Total 7524 468 6.22 6.22 
 Down-regulated in low-zinc over zinc-supplementation 
 Apoptosis 129 9 6.98 0.12 
 Cell cycle 271 19 7.01 0.25 
 Cytoskeleton 633 45 7.11 0.60 
 Growth and/or maintenance 647 52 8.04 0.69 
 Metabolism 623 46 7.38 0.61 
 Protein processes 1021 71 6.95 0.94 
 Signal transduction 793 50 6.31 0.66 
 Transcription 1127 84 7.45 1.12 
 Transport 524 34 6.49 0.45 
 Other functions 1151 81 7.04 1.08 
 Unknown 605 36 5.95 0.48 
 Total 7524 527 7.00 7.00 
 Regulated genes (both up- and down-regulated) 
 Apoptosis 129 16 12.40 0.21 
 Cell cycle 271 29 10.70 0.39 
 Cytoskeleton 633 88 13.90 1.17 
 Growth and/or maintenance 647 78 12.06 1.04 
 Metabolism 623 72 11.56 0.96 
 Protein processes 1021 117 11.46 1.56 
 Signal transduction 793 102 12.86 1.36 
 Transcription 1127 132 11.71 
 Transport 524 82 15.65 1.09 
 Other functions 1151 172 14.94 2.29 
 Unknown 605 107 17.69 1.42 
 Total 7524 995 13.22 13.22 
1.75 
 
Note1: “% w/in same function” represents the percentage based on the number of genes classified 
under the same function (e.g. 129 genes for ‘Apoptosis’).  
 






APPENDIX G: Secondary Expression Data (<95% confidence) 
            
To prioritise subsequent analysis, the statistically significant differential expression 
data (n = 3, 95% confidence) were analysed in greater detail [Sections 4.4 and 4.5].  Some of 
the differentially expressed genes that did not meet the screening criteria (>2-fold change, n = 
3, <95% confidence, differentially expressed in the same direction in all the replicate 




Table A.G.1 List of genes regulated (n = 3, <95% confidence) in various comparative studies  
(Table is shown over 17 pages) 
Genes Up-regulated by ‘Zinc’ compared to ‘Insulin’ (93 genes) 





Description GenBank ID p-value 
Apoptosis      
caspase homolog (Cash) 1.69 induction of apoptosis  U97076 0.166 
Bcl2 homologous antagonist/killer (Bak) 1.44 apoptosis   Y13231 0.354 
baculoviral IAP repeat-containing 6 
(Birc6) 1.07 apoptosis    Y17267 0.262 
Cell-cycle     
nerve growth factor, beta (Ngfb) 1.49 cell cycle control   S62089 0.335 
proviral integration site 1 (Pim1) 1.19 cell cycle   M13945 0.106 
mitogen-activated protein kinase 11 
(Mapk11) 1.10 cell cycle    AF135185 0.065 
putative serine/threonine kinase (Fnk) 
mRNA, partial cds 1.03 cell cycle     U22434 0.215 
Cytoskeleton-related     
claudin 1 (Cldn1) 2.27 cell adhesion  BC002003 0.207 
haploid specific alanine rich acidic protein, 
chromosome X (Halapx-pending) 2.08 
cytoskeleton organization 
and biogenesis  AB032764 0.282 
claudin 4 (Cldn4) 1.48 cell adhesion     AB000713 0.305 
netrin 4 (Ntn4) 1.30 cell adhesion AF281278 0.174 
Murr2 mRNA, sequence 1.23 cytoskeleton organization and biogenesis  D85434 0.347 
mRNA for PA28 beta subunit, complete 
cds 1.19 cell adhesion      U60329 0.166 
ORF1 for hypothetical protein, clone 
424981 1.15 cell adhesion      AJ277114 0.359 
extracellular matrix protein 1 (Ecm1) 1.13 cytoskeleton organization and biogenesis   L33416 0.328 
alpha 2 delta calcium channel subunit 
mRNA, partial cds 1.05 cell adhesion        AF169633 0.144 
cytoplasmic linker 2 (Cyln2) 1.02 cytoskeleton organization and biogenesis   AJ228869 0.297 
Growth and/or maintenance     
mRNA for gastric mucin-like protein, 
partial 1.57 
cell growth and/or 
maintenance    AJ010752 0.098 
adipose differentiation related protein 
(Adfp) 1.41 
cell growth and/or 
maintenance    M93275 0.176 
bassoon (Bsn) 1.38 cell growth and/or maintenance     Y17035 0.058 
putative sperm protein sp18 mRNA, partial 
cds 1.29 
cell growth and/or 
maintenance    AF129872 0.066 
bone morphogenetic protein 6 (Bmp6) 1.22 cell growth and/or maintenance   U73517 0.121 
excision repair 1 (Ercc1) 1.21 DNA repair     X07414 0.113 
ligase I, DNA, ATP-dependent (Lig1) 1.18 DNA repair   U19604 0.335 
insulin-like growth factor binding protein 5 
protease (PRSS11) 1.17 
cell growth and/or 
maintenance      AF172994 0.088 
metallothionein 4 (Mt4) 1.13 cell growth and/or maintenance     U07808 0.166 
neuroblastoma, suppression of 
tumorigenicity 1 (Nbl1) 1.13 DNA binding        D50263 0.153 
B-cell receptor-associated protein 37 
(Bcap37) 1.12 
negative control of cell 
proliferation  X78683 0.345 




rheb mRNA for Ras homolog, complete 
cds 1.04 
cell growth and/or 
maintenance   AB039919 0.186 
Metabolism-related     
peptidylglycine alpha-amidating 
monooxygenase (Pam) 2.35 peptide metabolism    U79523 0.401 
glutamic acid decarboxylase 2 (Gad2) 2.31 glutamate decarboxylation    S67454 0.303 
intestine N-acetylglucosamine 6-O-
sulfotransferase (I-GlcNAc-6-ST) 1.62 methionine metabolism      AF176840 0.225 
prolactin-like protein F (Prlpf) 1.47 lactation AK005455 0.064 
epidermal 12(S)-lipoxygenase (Aloxe) 
mRNA, complete cds 1.30 leukotriene metabolism   U24181 0.094 
glyceraldehyde-3-phosphate 
dehydrogenase (Gapd) 1.15 glycolysis    M32599 0.168 
dihydropyrimidinase-like 4 (Dpysl4) 1.10 
nucleobase, nucleoside, 
nucleotide and nucleic 
acid metabolism  
Y09079 0.202 
for Ky protein (muscle-specific protein) 1.06 lipid metabolism     AJ293727 0.105 
partial cochlear mRNA (clone 32B12) 1.04 citrate metabolism    Z78147 0.285 
lipoprotein lipase (Lpl) 1.04 membrane lipid metabolism  M60842 0.352 
aldehyde reductase (Akr1A4) 1.03 lipid metabolism       AK011906 0.267 
phosphatidylinositol glycan, class B (Pigb) 1.01 GPI anchor metabolism    D84436 0.311 
Protein processes     
heterogeneous nuclear ribonucleoprotein C 
(Hnrnpc) 1.81 mRNA splicing   AF095257 0.342 
junctophilin 2 (Jp2-pending) 1.67 protein folding   AB024447 0.157 
puromycin-sensitive aminopeptidase (Psa) 1.37 proteolysis and peptidolysis      U35646 0.257 
folate receptor 3 (Folbp3) mRNA, 
complete cds 1.28 
post-translational 
membrane targeting    AF250145 0.348 
protein kinase C, alpha (Pkca) 1.13 protein phosphorylation       X52685 0.331 
rab19 mRNA 1.06 intracellular protein traffic    X80473 0.123 
adaptor protein complex AP-1, sigma 1 
(Ap1s1) 1.06 intracellular protein traffic M62418 0.400 
adaptor protein complex AP-1, mu 2 
subunit (Ap1m2) 1.06 intracellular protein traffic    AF139409 0.198 
carbonic anhydrase 5b (Car5b) 1.05 protein targeting AF192978 0.131 
LIM motif-containing protein kinase 2 
(Limk2) 1.00 protein phosphorylation    U88618 0.292 
Signal transduction     
integrin alpha8 mRNA, partial cds 2.06 integrin receptor signal signaling pathway  AF041409 0.336 
endothelial differentiation, sphingolipid G-
protein-coupled receptor, 3 (Edg3) 1.56 
G-protein coupled 
receptor protein signaling 
pathway  
AB028143 0.307 
transmembrane protein 2 (Tmem2) 
mRNA, partial cds 1.42 cell-cell signaling   AF137031 0.333 
interleukin 1 receptor-associated kinase 
(Il1rak) 1.36 signal transduction     U56773 0.277 
catenin beta (Catnb) 1.23 signal transduction    M90364 0.166 
transforming growth factor, beta receptor 
II (Tgfbr2) 1.22 
TGFbeta ligand binding to 
type II receptor   S69114 0.370 
G protein-coupled receptor 34 (Gpr34) 1.19 
G-protein coupled 
receptor protein signaling 
pathway   
AF081916 0.208 
tachykinin receptor 3 (Tacr3) 1.08 signal transduction    AF233341 0.361 
calcium binding protein Kip 2 
(LOC56506) 1.04 cell communication  AB016080 0.162 
neurotrophin-3 receptor non-catalytic 
isoform 1 (trkC) mRNA, complete cds 1.04 
transmembrane receptor 
protein tyrosine kinase 
signaling pathway 




Transcription regulation     
nuclear, factor, erythroid derived 2, like 2 
(Nfe2l2) 1.42 transcription regulation U20532 0.335 
protein inhibitor of activated STAT3 
(Pias3-pending) 1.36 transcription co-repressor    AF034080 0.241 
mRNA for mszf21, partial cds 1.30 transcription regulation      AB010334 0.279 
transcription factor AP-2, alpha (Tcfap2a) 1.23 transcription regulation     U17288 0.148 
caudal type homeo box 1 (Cdx1) 1.15 transcription regulation    M37163 0.196 
GTF2I repeat domain-containing 1 
(Gtf2ird1) 1.05 transcription regulation   AF260133 0.188 
liver receptor homologous protein (LRH-1) 
mRNA, complete cds 1.04 transcription regulation   M81385 0.341 
Transport-related     
calcium channel, voltage-dependent, L 
type, alpha 1C subunit (Cacna1c) 1.61 ion transport  U17869 0.277 
granuphilin (Gph-pending) 1.57 transport    AB025258 0.081 
25-hydroxyvitamin D3 1alpha-
hydroxylase, partial cds 1.26 electron transport    AB006034 0.380 
peripherial benzodiazepine receptor 
associated protein (Pap7) mRNA, 
complete cds 
1.23 non-selective vesicle transport     AF022770 0.192 
transferrin mRNA, partial cds, segment 4 1.12 iron transport      M23016 0.336 
Other     
delta-like 3 homolog (Drosophila) (Dll3) 2.42 skeletal development         Y11895 0.107 
p100 co-activator (LOC56463) 1.84 developmental processes    AB021491 0.172 
metabotropic glutamate receptor type 1 
(Glur1) mRNA, complete cds 1.79 olfaction      AF320126 0.263 
retinal cone arrestin 3 (Arr3) mRNA, 
complete cds 1.77 sensory perception        AF156979 0.188 
widely-interspaced zinc finger motifs 
(Wiz) 1.37 developmental processes    AB012266 0.232 
odorant receptor S41 mRNA, partial cds 1.29 olfaction       AF121978 0.135 
thymus chemokine 1 mRNA, complete cds 1.27 immune response    AF219112 0.194 
gene for cytokine-like protein (Zcyto7) 1.20 immune response   BC002271 0.342 
myelin-associated oligodendrocytic basic 
protein (Mobp) 1.14 neurogenesis     U81317 0.356 
exostoses (multiple)-like 1 (Extl1) 1.13 skeletal development  AF224461 0.128 
putative pheromone receptor (VR3) 
mRNA, partial cds 1.12 olfaction         AF011413 0.057 
annexin A4 (Anxa4) 1.08 immune response    U72941 0.196 
Unknown function     
Hira, exon 3A 2.62 biological process unknown     X99713 0.386 
hypothetical protein MNCb-2875 (MNCb-
2875) 1.65 
biological process 
unknown        AB041807 0.060 
clone S183 1.50 biological process unknown      M94295 0.058 
olfactory receptor 65 (Olfr65) 1.36 biological process unknown      AF071080 0.301 
ganglioside-induced differentiation 
associated protein 6 1.28 
biological process 
unknown       Y17855 0.352 
tex271 mRNA (3'region) 1.15 biological process unknown        X80431 0.398 
interferon alpha family, gene 8 (Ifna8), 
mRNA 1.05 
biological process 











Genes Down-regulated by ‘Zinc’ compared to ‘Insulin’ (112 genes) 





Description GenBank ID p-value 
Apoptosis      
CASP2 and RIPK1 domain containing 
adaptor with death domain (Cradd), 
mRNA 
-2.93 apoptosis   AJ224738 0.360 
small EDRK-rich factor 1 (Serf1), mRNA -1.32 apoptosis AF073517 0.196 
Cell-cycle     
c-mer proto-oncogene (Mer), mRNA -1.61 cell cycle regulator U21301 0.384 
syntrophin associated serine/threonine 
kinase (Sast-pending), mRNA -1.59 cell cycle AF077818 0.209 
meiosis expressed gene 1 (Meg1), mRNA -1.42 meiosis X64455 0.226 
MKP-5 mRNA for MAP kinase 
phosphatase-5, complete cds -1.05 DNA replication       AB037908 0.226 
sporulation protein, meiosis-specific, 
SPO11 homolog (S. cerevisiae) (Spo11), 
mRNA 
-1.04 meiosis AF173848 0.259 
RAD17 homolog (S. pombe) (Rad17), 
mRNA -1.04 mitotic checkpoint    AJ011923 0.069 
Cytoskeleton-related     
microtubule-associated protein 6 (Mtap6), 
mRNA -3.46 microtubule-based process Y16008 0.128 
fucosyltransferase 7 (Fut7), mRNA -1.32 cytoskeleton organization and biogenesis U45980 0.194 
chondroadherin (Chad), mRNA -1.01 cell adhesion    U96626 0.178 
repetin (Rptn), mRNA -1.00 cytoskeleton organization and biogenesis   X99251 0.241 
selectin, platelet (Selp), mRNA -1.00 cell adhesion M72332 0.333 
Growth and/or maintenance     
rat generating islet-derived, mouse 
homolog 3 alpha (Reg3a), mRNA -1.71 acute-phase response  D63356 0.222 
insulin-like growth factor binding protein 7 
(Igfbp7), mRNA -1.41 
negative control of cell 
proliferation  AB012886 0.216 
glycoprotein 38 (Gp38), mRNA -1.32 cell growth and/or maintenance    M96645 0.126 
growth arrest and DNA-damage-inducible, 
gamma (Gadd45g), mRNA -1.11 DNA repair        AK002237 0.080 
Metabolism-related     
methyltransferase (Cyt19), mRNA -1.88 vitamin metabolism AF166383 0.172 
solute carrier family 25 (mitochondrial 
carrier; adenine nucleotide translocator), 
member 10 (Slc25a10), mRNA 
-1.62 gluconeogenesis     AF188712 0.110 
cathelin-like protein (Cnlp), mRNA -1.60 nitrogen metabolism  U43409 0.116 
espin (Espn), mRNA -1.45 lipid metabolism       AF134858 0.136 
dihydropyrimidinase mRNA, complete cds -1.44 
nucleobase, nucleoside, 
nucleotide and nucleic 
acid metabolism  
 AF249296 0.087 
glucokinase mRNA, complete cds -1.34 glycolysis      M58755 0.112 
phospholipase A2, group IIC (Pla2g2c), 
mRNA -1.19 
membrane lipid 
metabolism    U18119 0.222 
solute carrier family 2 (facilitated glucose 
transporter), member 4 (Slc2a4), mRNA -1.08 carbohydrate metabolism    BC014282 0.134 
gp330 -1.04 vitamin metabolism       Y08566 0.108 
glutaryl-Coenzyme A dehydrogenase 
(Gcdh), mRNA -1.04 fatty acid metabolism    U18992 0.157 
Protein processes     
partial cds, clone:2-73 -1.61 intracellular protein traffic     AB030202 0.203 





type II, alpha (Pip5k2a), mRNA -1.40 protein folding         BC011097 0.160 
cathepsin J (Ctsj), mRNA -1.33 proteolysis and peptidolysis   AF158182 0.086 
cathepsin R (Ctsr), mRNA -1.16 proteolysis and peptidolysis      AK014432 0.294 
aryl hydrocarbon receptor nuclear 
translocator (Arnt), mRNA -1.03 
protein-nucleus import, 
translocation   U14333 0.195 
Signal transduction     
wingless related MMTV integration site 8b 
(Wnt8b), mRNA -2.10 signal transduction       AF130349 0.066 
receptor-type tyrosine phosphatase, 




pathway      
D45212 0.346 
glial cell line derived neurotrophic factor 
family receptor alpha 3 (Gfra3), mRNA -1.79 
TGFbeta receptor 
signaling pathway  AB008833 0.110 
Balb/C clone A2M2-22 adenosine receptor 
subtype mRNA, partial cds -1.56 
adenylate cyclase 
activation     U05672 0.247 
mRNA for ENH1, complete cds -1.44 signal transduction         AB016586 0.275 
interleukin 21 receptor (Il21r), mRNA -1.41 cell surface receptor linked signal transduction   AF269134 0.137 
kinesin-associated protein 3 (Kifap3), 
mRNA -1.41 
RHO protein signal 
transduction  D50366 0.050 
toll-like receptor 5 (Tlr5), mRNA -1.39 signal transduction      AF186107 0.227 
NKG2-D (Nkg2d) mRNA, complete cds -1.35 signal transduction          AF054819 0.155 
MAP kinase-activated protein kinase 5 
(Mapkapk5), mRNA signal transduction       
neuropeptide signaling 
pathway      
-1.17 
decay accelerating factor 
glycosylphoshatidylinositol-anchored form 
(DAF) mRNA, partial cds 
0.195 
0.167 
killer cell lectin-like receptor subfamily G, 
member 1 (Klrg1), mRNA 0.384 
-1.29 AF039840 0.191 
kallikrein 3, plasma (Klk3), mRNA -1.25 M58588 0.071 
RAS p21 protein activator 3 (Rasa3), 
mRNA -1.22 signal transduction         U20238 0.127 
fibroblast growth factor binding protein 1 
(Fgfbp1), mRNA -1.21 signal transduction         U49641 0.247 
Unc-51 like kinase 2 (C. elegans) (Ulk2), 
mRNA signal transduction         AF145922 0.328 
guanine nucleotide binding protein, alpha 
transducing 2 (Gnat2), mRNA -1.16 
G-protein coupled 
receptor protein signaling 
pathway  
L10666 0.392 
-1.16 complement activation, classical pathway        AF143541 
folate hydrolase (Folh1), mRNA -1.15 cell-cell signaling     AF026380 0.199 
angiotensin receptor-like 1 (Agtrl1), 
mRNA -1.14 
G-protein coupled 
receptor protein signaling 
pathway   
AJ007612 
-1.02 cell surface receptor linked signal transduction     AF097357 
thyrotropin releasing hormone receptor 
(Trhr), mRNA -1.02 signal transduction  M59811 0.293 
putative protein kinase YSK4 mRNA, 
partial cds -1.01 signal transduction       U49951 0.054 
Transcription regulation     
KRAB-zinc finger protein 76 (Zfp76) 
mRNA, partial cds -2.92 transcription regulation  U29510 0.390 
GLI-Kruppel family member GLI3 (Gli3), 
mRNA -2.26 transcription regulation       X95255 0.210 
Sjogren syndrome antigen A1 (Ssa1), 
mRNA -1.81 transcription regulation       L27990 0.102 
SRY-box containing gene 11 (Sox11), 




TSC22-related inducible leucine zipper 2 
(Tilz2) mRNA, complete cds -1.49 transcription regulation       AF201286 0.135 
RAR-beta mRNA for retinoic acid 
receptor-beta 2 isoform -1.31 transcription regulation       S56660 0.284 
peroxisome proliferator activated receptor 
binding protein (Pparbp), mRNA 
homeo box A7 (Hoxa7), mRNA 
transcription regulation       
zinc finger gonad protein 1 (Zfg1) mRNA, 
complete cds 0.359 
IAP promoted placental gene (Ipp), mRNA 
core promoter binding protein mRNA, 
partial cds 
 
putative chemokine receptor mRNA, 
complete cds 0.235 
0.234 
amino acid transport         
0.068 
-1.54 
tyrosine hydroxylase (Th), mRNA -1.24 
  
-1.29 transcription regulation       AF000294 0.132 
-1.26 transcription regulation       U15972 0.174 
paired mesoderm homeobox 2b (Pmx2b), 
mRNA -1.22 Y14493 0.148 
gli2 gene -1.10 transcription regulation        X99104 0.103 
gastrulation brain homeobox 2 (Gbx2), 
mRNA -1.09 transcription regulation      U74300 0.070 
-1.07 transcription regulation      AF204776 
-1.05 transcription regulation   X58524 0.219 
-1.04 transcription regulation     AF072403 0.188 
Transport-related    
-4.05 chemotaxis  AF305709 
Mouse voltage-gated sodium channel 
mRNA -1.88 sodium transport        L36179 
aquaporin 3 (Aqp3), mRNA -1.72 water transport         AF104417 0.098 
fructose transporter (Glut5), mRNA -1.37 transport         AF161071 0.165 
solute carrier family 7 (cationic amino 
acid, transporter, y+ system), member 11 
(Slc7a11), mRNA 
-1.15 AB037653 0.104 
Other     
TPCR09 protein -2.42 olfaction     X89681 0.061 
calcium channe, voltage-dependent, alpha 
1F subunit (Cacna1f), mRNA -2.23 synaptic transmission   AF192497 0.154 
Pendred syndrome homolog (human) 
(Pds), mRNA -1.70 
histogenesis and 
organogenesis    AF167411 0.080 
seminal vesicle protein 6 (Svp6), mRNA -1.69 copulation  S65753 0.101 
interleukin 2 (Il2), mRNA -1.55 immune response       AF065914 
t-complex protein-10 complex (Tcp10), 
mRNA spermatogenesis     X58170 0.335 
retinoid binding protein 7 (Rbp7) mRNA, 
complete cds -1.37 
ionic insulation of neurons 
by glial cells  AF260923 0.204 
TPCR52 protein -1.32 olfaction     X89690 0.053 
oligodendrocyte transcription factor 1 
(Olig1), mRNA -1.27 neurogenesis         AB038696 0.233 
serine protease inhibitor 7 (Spi7), mRNA -1.26 defense response  U54705 0.079 
erythrocyte protein band 4.2 (Epb4.2), 
mRNA -1.25 
histogenesis and 
organogenesis     U03487 0.126 
heart development     X53503 0.111 
heat shock protein (hsp68) mRNA, clone 
MHS243, partial cds -1.19 heat shock response       M12572 0.106 
reticulocalbin (Rcn), mRNA -1.17 developmental processes    D43952 0.286 
ceroid-lipofuscinosis, neuronal 8 (Cln8), 
mRNA -1.17 neurogenesis       AF125308 0.276 
sarcospan (Sspn), mRNA -1.16 muscle development      U02487 0.137 
hemochromatosis (Hfe), mRNA -1.14 immune response       U66849 0.159 
variable group of 2-cell-stage gene family 
(Lo1), mRNA -1.08 neurogenesis        AF067059 0.246 
M.musculus mRNA for TPCR18 protein -1.08 olfaction       X89684 0.211 
tubby like protein 1 (Tulp1) mRNA, 
complete cds -1.01 vision          AF085681 0.191 
Unknown function   
cDNA sequence AF104415 (AF104415-
pending), mRNA -2.40 
biological process 




NEDD-10 mRNA, partial sequence -2.35 biological process unknown D10920 0.051 
somatostatin receptor 1 (Smstr1), mRNA -2.01 biological process unknown M81831 0.171 
gene 154=olfactory receptor {5' region} 
[Mus musculus=mice, ssp. domesticus, 
C57BL/6, mRNA Partial, 291 nt] 
-1.85 biological process unknown S73844 0.137 




-1.48 biological process unknown 










unknown AB041550 0.052 
biological process 
unknown 
pyrimidinergic receptor P2Y, G-protein 
coupled, 4 (P2ry4), mRNA -1.62 
biological process 
unknown 
mRNA for S-1, complete cds -1.57  AB011019 0.081 
defensin related cryptdin, related sequence 
12 (Defcr-rs12), mRNA S77618 0.158 
-1.39 biological process unknown D50095 0.187 
clone pMG22 nonsatellite RNA sequence -1.27 U26224 0.144 
def-5 mRNA -1.24 biological process unknown X96704 
Mouse mRNA fragment, clone S334 -1.24 biological process unknown M94298 0.066 
-1.22 biological process unknown U26222 0.054 
strain C3H/HeN mRNA preferentially 
expressed in LPS-normoresponsive 
macrophages 
-1.10  AF032968 0.110 
E550 mRNA -1.10 biological process unknown Y10969 




hypothetical protein, MNCb-4779 
(LOC58229), mRNA -1.06 
cordon-bleu mRNA, partial cds -1.05 biological process unknown U26967 0.219 
Hox 2.7 protein (3'UTR, partial) -1.02 X62311 0.366 
Genes Up-regulated by ‘Low-zinc’ compared to ‘Optimal-Zinc’ (143 genes) 





Description GenBank ID p-value 
Apoptosis     
Bcl2-like (Bcl2l) 2.89 apoptosis    NM_009743 0.172 
Fas antigen (Fas) 1.23 apoptosis    NM_007987 0.077 




aortic preferentially expressed gene 1 
(Apeg1) 
 
Ste-20 related kinase (Spak-pending) 2.23 cell cycle    NM_016866 0.316 
p34SEI-1 (Sei1) 2.03    NM_018820 0.232 
NIMA (never in mitosis gene a)-related 
expressed kinase 3 (Nek3) 1.40 cell cycle 
   
NM_011848 0.168 
fibroblast growth factor 11 (Fgf11) cell cycle control    NM_010198 0.183 
pellino 2 (Peli2) mRNA, complete cds 1.20 G1 phase of mitotic cell cycle     AF302504 0.199 




M.musculus mRNA for synaptonemal 
complex protein 1 1.03 cell cycle       Z38118 0.092 
Cytoskeleton-related     
INGAPrP mRNA for INGAP related 
protein, complete cds 2.67 cell adhesion     AB028625 0.382 
mRNA for type 2 desmoglein 
0.212 




Growth and/or maintenance 
1.24 
   
1.74 cell adhesion     AJ000328 0.105 
stathmin-like-protein RB3 (Rb3) 1.70 cytoskeleton organization and biogenesis 
   
NM_019675 0.370 
fibrillin 2 (Fbn2) 1.61 cell adhesion    NM_010181 0.234 
vascular endothelial junction-associated 
molecule mRNA, complete cds 1.48 cell adhesion     AF255911 
mRNA for motor domain of KIF8, partial 
cds 1.21 microtubule-based process     AB001436 0.355 
cadherin 7 (Cdh7) 1.18 cell adhesion 
myosin XV (Myo15) cytoskeleton organization and biogenesis 
   
NM_010862 0.075 
selectin, platelet (Selp) cell adhesion    NM_011347 
    
transforming growth factor, beta induced, 
68 kDa (Tgfbi) 1.68 cell proliferation 
   
NM_009369 0.294 
mRNA fragment, clone S191 1.40 DNA transposition       M94296 0.203 
odd Oz/ten-m homolog 1 (Drosophila) 
(Odz1) 1.32 
negative control of cell 
proliferation 
   
NM_011855 0.300 
N-methylpurine-DNA glycosylase (Mpg) 1.27 DNA repair    NM_010822 0.050 
calpain 1 (Capn1) 1.27 positive control of cell proliferation 
   
NM_007600 0.081 
ELK3, member of ETS oncogene family 
(Elk3) 1.21 DNA binding 
   
NM_013508 0.140 
RAB33A, member of RAS oncogene 
family (Rab33a) 1.03 GTP binding 
   
NM_011228 0.141 
Metabolism     
phosphatidylcholine transfer protein (Pctp) 2.14 lipid metabolism    NM_008796 0.106 
neuraminidase 1 (Neu1) 1.98 cholesterol catabolism    NM_010893 0.396 
sulfotransferase-related protein SULT-X1 
(Sult-x1) 1.77 steroid metabolism 
   
NM_020564 0.203 
amine N-sulfotransferase (Sultn-pending) 1.70 steroid metabolism    NM_016771 0.283 
t-complex protein (Tcp-1x) mRNA, 3' end 1.31 fatty acid metabolism       M35797 0.167 
phosphatidylcholine-specific 
phospholipase D1b (mPLD1) mRNA, 
complete cds 
phospholipid metabolism       U87868 0.304 
immune-responsive gene 1 (Irg1) mRNA, 
3' end of cds 1.14 prostaglandin metabolism       L38281 0.279 
chondroitin 4-O-sulfotransferase (C4S-2) 1.09 coenzymes and prosthetic group metabolism 
   
NM_021528 0.063 
solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6 (Slc6a6) 1.08 amino acid metabolism 
   
NM_009320 0.225 
placental lactogen I (PL-I) mRNA, 
complete cds 1.05 lactation       M35662 0.085 
group X secreted phospholipase A2 
(Pla2g10) mRNA, complete cds 1.03 
membrane lipid 
metabolism     AF166097 0.104 
Protein processes     
tubulointerstitial nephritis antigen (Tinag) 1.92 proteolysis and peptidolysis 
   
NM_012033 0.107 





M.musculus nsk1 mRNA for putative 
receptor tyrosine kinase 1.75 
1.68 
protein tyrosine kinase       X86367 0.309 
block of proliferation 1 (Bop1) protein modification    NM_013481 0.268 
aldehyde oxidase 1 (Aox1) 1.53 proteolysis and peptidolysis 
   
NM_009676 0.219 
fibroblast growth factor receptor 3 (Fgfr3) 1.34 protein tyrosine kinase    NM_008010 0.301 
prostate kallikrein (mPK-1) mRNA, partial 
cds 1.19 
proteolysis and 
peptidolysis     AF019086 0.268 
mRNA for hepatocyte growth factor, 
complete cds 1.10 
proteolysis and 
peptidolysis       D10212 0.247 
E2 ubiquitin conjugating enzyme (UbcM8) 1.09 ubiquitin-dependent protein degradation 
   
NM_019949 0.061 
folate binding protein 1 (Folbp1) 1.09 post-translational membrane targeting 
   
NM_008034 0.266 
Signal transduction     
M.musculus mRNA expressed in islet cells 
(clone 40) 3.41 
tumor necrosis factor 
receptor ligand       Z47778 0.219 
small inducible cytokine subfamily A17 
(Scya17) 2.46 signal transduction 
   
NM_011332 0.208 
gap junction membrane channel protein 
beta 2 (Gjb2) 2.42 cell-cell signaling 
   
NM_008125 0.393 
f-box and leucine-rich repeat protein 8 
(Fbxl8) 2.01 signal transduction 
   
NM_015821 0.403 
endothelial differentiation sphingolipid G-
protein-coupled receptor 1 (Edg1) 1.76 
G-protein coupled 
receptor protein signaling 
pathway 
   
NM_007901 0.218 
5-hydroxytryptamine (serotonin) receptor 




   
NM_008311 0.357 
src homology 2 domain-containing 
transforming protein C3 (Shc3) 1.58 
EGF receptor signaling 
pathway 
   
NM_009167 0.119 
aggrecan mRNA exon 1.55 signal transduction       L07051 0.162 
fibroblast growth factor-related protein 
FGF-12A (Fgf12) mRNA, complete cds 1.38 signal transduction     AF020738 0.136 
TYRO protein tyrosine kinase binding 
protein (Tyrobp) 1.33 
intracellular signaling 
cascade 
   
NM_011662 0.306 
guanosine diphosphate (GDP) dissociation 
inhibitor 2 (Gdi2) 1.21 
small GTPase mediated 
signal transduction 
   
NM_008111 0.236 
EWS/FLI1 activated transcript 2 (Eat2) 1.20 signal transduction    NM_012009 0.097 
M.musculus mRNA for Mcf2 proto-
oncogene, partial 1.16 signal transduction       X57298 0.182 
wingless-related MMTV integration site 
7B (Wnt7b) 1.13 signal transduction 
   
NM_009528 0.160 
hypoxia inducible factor 3, alpha subunit 
(Hif3a) 1.07 signal transduction 
   
NM_016868 0.101 
sodium channel 2 (mBNaC2) mRNA, 
partial cds 1.01 signal transduction       U78179 0.258 
interleukin 4 receptor, alpha (Il4ra) 1.00 cell surface receptor linked signal transduction 
   
NM_010557 0.351 
Transcription regulation     
homeo box D1 (Hoxd1) 4.45 transcription regulation    NM_010467 0.414 
homeobox transcription factor NKX2-3 
(Nkx2-3) mRNA, complete cds 2.37 transcription regulation     AF202036 0.105 
downstream of tyrosine kinase 1 (Dok1) 2.02 
transmembrane receptor 
protein tyrosine kinase 
signaling pathway 





interferon dependent positive acting 
transcription factor 3 gamma (Isgf3g) 2.01 transcription regulation 
   
NM_008394 0.128 
SRY-box containing gene 13 (Sox13) 1.63 transcription regulation    NM_011439 0.172 
transcription regulation 
from Pol II promoter 
transcription regulation 





RNA-binding protein mHuC-L mRNA, 
complete cds 
signal transducer and activator of 
transcription 4 (Stat4) 1.55 
   
NM_011487 0.079 
Rel domain-containing transcription factor 
NFAT5 (Nfat5) mRNA, complete cds 1.16 transcription regulation     AF162853 0.214 
iroquois-class homeobox protein IRX2 
(Irx2) mRNA, complete cds 1.07 transcription regulation     AF295369 0.172 
zfh-4 mRNA for zinc-finger homeodomain 
protein 4, complete cds 1.07 transcription regulation     AB024499 0.281 
homeodomain protein (Nkx-1.2) mRNA, 
complete cds 1.03 transcription regulation     AF222444 0.302 
iroquois related homeobox 4 (Drosophila) 
(Irx4) 1.03 
   
NM_018885 0.141 
peroxisome proliferator activated receptor 
alpha (Ppara) 1.02 transcription regulation 
   
NM_011144 0.097 
Transport    
ADP-ribosylation-like 4 (Arl4) 2.75 intracellular protein traffic    NM_007487 
cytochrome P450, 2b9, phenobarbitol 
inducible, type a (Cyp2b9) 2.17 electron transport 
   
NM_010000 0.293 
small inducible cytokine subfamily C, 
member 1 (lymphotactin) (Scyc1) 
   
NM_008510 0.118 
non-gastric H,K-ATPase alpha 1 subunit 
(Atp1al1) mRNA, partial cds 1.54 hydrogen transport     AF100169 0.404 
SEC23B (S. cerevisiae) (Sec23b) 1.47 vesicle transport    NM_019787 0.219 
sodium bicarbonate cotransporter isoform 
3 (kNBC-3) 1.42 anion transport 
   
NM_021530 0.143 
klotho (Kl) 1.35 ion transport    NM_013823 0.228 
potassium large conductance calcium-
activated channel, subfamily M, beta 
member 4 (Kcnmb4) 
1.33 potassium transport    NM_021452 0.318 
selectively expressed in embryonic 
epithelia protein-1 (Eeg1) 1.25 potassium transport 
   
NM_021398 0.231 
synaptotagmin 10 (Syt10) 1.19 transport    NM_018803 0.312 
solute carrier family 30 (zinc transporter), 
member 3 (Slc30a3) 1.19 cation transport 
   
NM_011773 0.358 
beta globin mRNA, partial cds 1.16 transport     AF071431 0.348 
cytochrome P450, 2c37 (Cyp2c37) 1.13 electron transport    NM_010001 0.092 
adenylate cyclase 7 (Adcy7) 1.07 ion transport    NM_007406 0.204 
polycystic kidney disease 2 (Pkd2) 1.06 cation transport    NM_008861 0.277 
potassium large conductance calcium-
activated channel, subfamily M, alpha 
member 1 (Kcnma1) 
1.04 potassium transport    NM_010610 0.301 
transient receptor protein 6 (Trrp6) 1.01 ion transport    NM_013838 0.149 
Other    
M.musculus mRNA for TPCR09 protein 3.48 olfaction       X89681 0.298 
2.54 neurogenesis       U29148 0.123 
complexin 2 (Cplx2) 1.93 neurotransmitter release    NM_009946 0.211 





interleukin 7 receptor (Il7r) 1.66 lymph gland development    NM_008372 0.118 
mitochondrial capsule selenoprotein 
(Mcsp) 1.56 spermatogenesis 
   
NM_008574 0.260 
syntaxin1B (Stx1b) 1.52 neurotransmitter release    NM_019560 0.144 
retinal pigment epithelium derived 




   
NM_009102 0.268 
Kelch-like 1 protein (KLHL1) mRNA, 
complete cds 1.49 developmental processes     AF252281 0.098 
centrin 1 (Cetn1) 1.39 developmental processes    NM_007593 0.264 
M.musculus mRNA for fibronectin 1.36 acute-phase response       X93167 0.068 
neuronal calcium sensor-1 (Ncs1) 1.34 developmental processes    NM_019681 0.148 
tumor-associated antigen 1 (Taa1) 1.34 invasive growth    NM_009310 0.275 
protocadherin 8 (Pcdh8) 1.32 developmental processes    NM_021543 0.197 
testase 3 (Adam-26) mRNA, complete cds 1.29 fertilization     AF167404 0.107 
Musashi-1 homolog (Drosophila) (Msi1h) 1.26 neurogenesis    NM_008629 0.090 
mRNA, complete cds, clone:2-24 1.24     AB030190 0.129 
interleukin 1 receptor antagonist homolog 
1 (Il1hy1-pending) 1.22 immune response 
   
NM_019451 0.257 
CD3 antigen, gamma polypeptide (Cd3g) 1.22 developmental processes    NM_009850 0.054 
M-type mRNA for choline 
acetyltransferase, N-terminal 1.21 synaptic transmission       D12487 0.185 
hemogen-1 mRNA, complete cds 1.19 developmental processes     AF269248 0.288 
inhibitor of DNA binding 3 (Idb3) lymph gland development    NM_008321 0.310 
zinc finger protein 179 (Zfp179) 1.14 defense response    NM_009548 0.180 
serine protease inhibitor 17 (Spi17) 1.13 acute-phase response    NM_009250 0.055 
zinc finger protein 108 (Zfp108) 1.12 developmental processes    NM_018791 0.241 
solute carrier family 25 (mitochondrial 
carrier; adenine nucleotide translocator), 
member 10 (Slc25a10) 
1.10 gluconeogenesis    NM_013770 0.136 
transgene insert site 737, insertional 
mutation, polycystic kidney disease 
(TgN737Rpw) 
1.09 excretion    NM_009376 0.157 
Pendred syndrome homolog (human) (Pds) 1.07 histogenesis and organogenesis 
   
NM_011867 0.239 
testis specific protein kinase 1 (Tesk1) 1.07 spermatogenesis    NM_011571 0.097 
solute carrier family 35 (CMP-sialic acid 
transporter), member 1 (Slc35a1) 1.05 vision 
   
NM_011895 0.247 
FSHD region gene 1 (Frg1) 1.05 pathogenesis    NM_013522 0.230 
acetyl-Coenzyme A synthetase 1 (AMP 
forming) (Acas2) 1.04 physiological processes 
   
NM_019811 
dentin sialophosphoprotein (Dspp) 1.03 ossification    NM_010080 0.172 
cysteine proteinase inhibitor (MS3) mRNA 
sequence 1.02 inflammatory response       M92419 0.335 
Unknown Function     




at high levels in testis unknown 
K20D4 (K20D4) mRNA, complete cds 2.31 
      U09772 
      L33254 
    AF236125 
      M32073 
biological process 
unknown     AF313800 0.338 
decay accelerating factor (Daf) mRNA, 
alternative spliced product, partial cds 1.96 
biological process 
unknown     AF143539 0.346 
clone TSIP1 p53-induced apoptosis 
differentially expressed mRNA sequence 1.87 
biological process 





   
NM_019542 0.170 
NEDD-10 mRNA, partial sequence 1.73 biological process unknown       D10920 0.050 
SJL/j viral integration site (His-1) RNA 
transcript, exons 1, 2b and 3, alternatively 
spliced 
1.67 biological process unknown 0.257 
guanine nucleotide binding protein, alpha 
stimulating (Gnas) mRNA, alternatively 
spliced 5' flanking region 
1.60 biological process unknown     AF124383 0.148 




   
NM_021503 0.153 
hypertrophy-associated mRNA segment 1.39 biological process unknown 0.151 
mRNA for 3'UTR of Clc1 gene 1.25 biological process unknown     AJ011107 0.157 
putative neuronal cell adhesion molecule 
(Punc) mRNA, partial cds, alternatively 
spliced 
1.17 biological process unknown 0.134 
Mym mRNA, 5'UTR 1.13 biological process unknown     AF019615 0.277 
interleukin 2 receptor (IL 2R) mRNA, 
partial, homologous to human intron 6 1.12 
biological process 
unknown       M21982 0.245 
cholinergic receptor, muscarinic 4 (Chrm4) 1.08 biological process unknown 
   
NM_007699 0.195 




interferon alpha family, gene 8 (Ifna8) 1.03 biological process unknown 
   
NM_008335 0.217 
Genes Down-regulated by ‘Low-Zinc compared to ‘Optimal-Zinc’ (133 genes) 





Description GenBank ID p-value 
Apoptosis     
mRNA for death associated protein 3 
(DAP-3 gene) -2.26 apoptosis     AJ250375 0.300 




cyclin G2 (Ccng2) -1.81 cell cycle    NM_007635 0.377 
recombination activating gene 2 (Rag2) cell cycle    NM_009020 0.245 
adenylyl cyclase-associated CAP protein 
homolog 1 (S. cerevisiae, S. Pombe)   
iae (Cap1) 
-1.41 cell cycle control    NM_007598 0.180 
chaperonin subunit 4 (delta) (Cct4) -1.15 cell cycle control    NM_009837 0.348 
cyclin B1, related sequence 1 (Ccnb1-rs1) cell cycle control    NM_007629 0.215 
inner centromere protein (Incenp) -1.05 cell cycle    NM_016692 0.155 
checkpoint kinase 1 homolog (S. pombe) 
(Chek1) -1.00 cell cycle 
   
NM_007691 0.153 




-2.42 putative repair and recombination helicase RAD26L mRNA, partial cds DNA repair     AF217319 0.268 
Lps/Ran GTPase (lps(d)) mRNA, complete 
cds -2.22 
cell growth and/or 
maintenance     AF159256 0.236 
formin binding protein 17 mRNA, partial 
cds -2.14 
cell growth and/or 
maintenance       U40751 0.083 
A10 mRNA, partial cds -2.05 serine biosynthesis       L21027 0.292 
mRNA for SET-binding protein (SEB), 
partial cds -1.94 DNA packaging     AB015614 0.216 
upregulated by 1,25-dihydroxyvitamin D-3 
(Vdup1-pending) -1.91 
cell growth and/or 
maintenance 
   
NM_019751 0.107 
B lymphoid kinase (Blk) -1.82 ATP binding    NM_007549 0.192 
HGF-regulated tyrosine kinase substrate 
(Hgs) -1.56 
negative control of cell 
proliferation 
   
NM_008244 0.164 
selenium binding protein 2 (Selenbp2) -1.55 peroxidase reaction    NM_019414 0.257 
tetraspanin TM4-A homolog (LOC56434) -1.47 cell proliferation    NM_019793 0.287 
DNA polymerase delta 1, catalytic domain 
(Pold1) -1.36 DNA replication 
   
NM_011131 0.199 
cell division cycle 42 homolog (S. 
cerevisiae) (Cdc42) -1.34 
cell growth and/or 
maintenance 
   
NM_009861 
   
NM_007550 
      X74504 
      Z78162 
M. musculus mRNA for P1 protein (P1.m) DNA replication initiation       X62154 0.102 
0.052 
Bloom syndrome homolog (human) (Blm) -1.34 DNA repair 0.364 
M.musculus T10 mRNA -1.34 cytoplasm organization and biogenesis 0.304 
proteinase 3 (Prtn3) -1.33 positive control of cell proliferation 
   
NM_011178 0.155 
growth differentiation factor 8 (Gdf8) -1.33 cell growth and/or maintenance 
   
NM_010834 0.114 
M.musculus partial cochlear mRNA (clone 
260G4) -1.31 
cell growth and/or 
maintenance 0.193 
erythroblast macrophage protein (Ermp-
pending) -1.29 
cell growth and/or 
maintenance 
   
NM_021500 0.349 
-1.17 
nucleosome assembly protein 1-like 1 
(Nap1l1) -1.14 nucleosome assembly 
   
NM_015781 0.081 
thrombopoietin (Thpo) -1.11 cytokine    NM_009379 0.136 
ligase I, DNA, ATP-dependent (Lig1) -1.09 DNA repair    NM_010715 0.154 
metallothionein 4 (Mt4) -1.08 cell growth and/or maintenance 
   
NM_008631 0.084 
M.musculus mRNA for Ki-67 -1.07 cell growth and/or maintenance       X82786 0.067 
domesticus mRNA for tumor necrosis 
factor receptor p60 homologue 1 (Tnfrh1 
gene) 
-1.06 cell proliferation     AJ278264 0.119 
uracil-DNA glycosylase (Ung) -1.04 DNA repair    NM_011677 0.230 
translocase of outer mitochondrial 
membrane 40 homolog (yeast) (Tomm40) -1.04 
mitochondrial 
translocation 
   
NM_016871 0.213 
Cytoskeletion-related     
SH3 domain protein 5 (Sh3d5) -2.12 cell-matrix adhesion    NM_009166 0.201 
unknown mRNA -2.03 cytoskeleton organization and biogenesis     AF242319 0.151 
immediate early response 5 (Ier5) -1.84 cytoskeleton organization and biogenesis 
   
NM_010500 0.352 





catenin (cadherin-associated protein), delta 
2 (neural plakophilin-related arm-repeat 
protein) (Ctnnd2) 
-1.51 cell adhesion    NM_008729 0.306 
brain cDNA, clone MNCb-0783 -1.48 cytoskeleton organization and biogenesis     AB041650 0.380 
laminin B1 mRNA, complete cds -1.27 cell adhesion       M15525 0.325 
desmocollin 1 (Dsc1) -1.14 cell adhesion    NM_013504 0.246 
chromogranin B (Chgb) -1.13 cytoskeleton organization and biogenesis 
   
NM_007694 0.218 
Sid23p (Sid23p) -1.07 actin polymerization and/or depolymerization 
   
NM_019771 0.214 
cd164 antigen (Cd164) -1.05 heterophilic cell adhesion    NM_016898 0.316 
contactin 1 (Cntn1) -1.04 cell adhesion    NM_007727 0.285 
cadherin 16 (Cdh16) -1.04 cell adhesion    NM_007663 0.192 
dystrophin, muscular dystrophy (Dmd) -1.01 cell shape and cell size control 
   
NM_007868 0.139 
Metabolism     
carbonyl reductase 1 (Cbr1) -2.09 nitrogen metabolism    NM_007620 0.323 
olfactory UDP glucuronosyltransferase 
mRNA, complete cds -1.96 metabolism     AF184901 0.313 
M.musculus mRNA for iron responsive 
element binding protein -1.85 tricarboxylic acid cycle       X61147 0.179 
mannosidase 2, alpha B2 (Man2b2) -1.77 carbohydrate metabolism    NM_008550 0.360 
ferredoxin reductase (Fdxr) -1.58 glutamate biosynthesis    NM_007997 0.379 
liver carnitine palmitoyltransferase I 
mRNA, partial cds -1.54 fatty acid metabolism     AF017175 0.064 
platelet-activating factor acetylhydrolase, 
isoform 1b, alpha2 subunit (Pafah1b2) -1.40 
membrane lipid 
metabolism 
   
NM_008775 0.294 
molybdenum cofactor synthesis-step 1 
proteins A and B splice type I (Mocs1) 
mRNAs, partial cds, alternatively spliced 
-1.35 coenzymes and prosthetic group metabolism     AF214016 0.090 
glucose-6-phosphate dehydrogenase X-
linked (G6pdx) -1.28 
glucose 6-phosphate 
utilization 
   
NM_008062 0.350 
hypothetical proetin MNCb-4414, similar 
to NM_005827 UDP-galactose transporter 
related (Homo sapiens) (LOC58246) 
-1.23 glycolysis    NM_021435 0.231 
DXImx38e protein (DXImx38e) mRNA, 
complete cds -1.19 carbohydrate metabolism     AF229635 0.060 
cytidine monophospho-N-
acetylneuraminic acid hydroxylase (Cmah) -1.12 nitrogen metabolism 
   
NM_007717 0.235 
dihydropyrimidinase-like 4 (Dpysl4) -1.08 
nucleobase, nucleoside, 
nucleotide and nucleic 
acid metabolism 
   
NM_011993 0.183 
hydroxyacyl-Coenzyme A dehydrogenase, 
type II (Hadh2) -1.03 lipid metabolism 
   
NM_016763 0.087 
ornithine decarboxylase antizyme inhibitor 
(Oazi) -1.03 polyamine metabolism 
   
NM_018745 0.184 
hexosaminidase B (Hexb) -1.01 carbohydrate metabolism    NM_010422 0.132 
glucokinase activity, related sequence 1 
(Gk-rs1) -1.01 glycerol metabolism 
   
NM_010293 0.075 
Protein processes     




metalloproteinase (P-29 gene) peptidolysis 




   
NM_019709 0.079 
homeodomain interacting protein kinase 3 
(Hipk3) -1.42 protein phosphorylation 
   
NM_010434 0.212 
COQ7 protein mRNA, complete cds -1.34 ubiquinone biosynthesis [0006744]     AF098949 0.140 
non-catalytic region of tyrosine kinase 
adaptor protein 1 (Nck1) -1.33 
-1.01 
      U62908 
protein modification    NM_010878 0.188 
neural precursor cell expressed, 
developmentally down-regulated gene 8 
(Nedd8) 
-1.13 proteolysis and peptidolysis 
   
NM_008683 0.213 
M.musculus D11Bhm181e exon -1.13 protein biosynthesis       X81716 0.232 
eukaryotic translation initiation factor 4A2 
(Eif4a2) -1.01 protein biosynthesis 
   
NM_013506 0.144 
protein phosphatase 2a, catalytic subunit, 
beta isoform (Ppp2cb) -1.00 protein dephosphorylation 
   
NM_017374 0.106 
Signal transduction     
transforming growth factor beta 1 induced 
transcript 1 (Tgfb1i1) -2.12 signal transduction 
   
NM_009365 0.161 
phosphatidic acid phosphatase 2a (Ppap2a) -1.77 signal transduction    NM_008903 0.357 
Cdc42 GTPase-inhibiting protein (Cdgip-
pending) -1.51 
small GTPase mediated 
signal transduction 
   
NM_016788 0.225 
gap junction membrane channel protein 
alpha 4 (Gja4) -1.40 cell-cell signaling 
   
NM_008120 0.166 
WAVE-1 mRNA, complete cds -1.23 
G-protein signaling, 
coupled to cAMP 
nucleotide second 
messenger 
    AF290877 0.343 
phosphatidylinositol-4-phosphate 5-kinase, 
type 1 alpha (Pip5k1a) signal transduction 
   
NM_008846 0.282 
Transcription regulation     
fragile X mental retardation 2 homolog 
(Fmr2) -3.13 transcription regulation 
   
NM_008032 0.229 
nuclear receptor subfamily 0, group B, 
member 1 (Nr0b1) -3.11 transcription regulation 
   
NM_007430 0.204 
zinc finger protein (mkr5) mRNA, 3' end -1.87 transcription regulation       M36516 0.265 
Jun-B oncogene (Junb) -1.69 transcription regulation    NM_008416 0.346 
activating transcription factor 4 (Atf4) -1.60 transcription regulation    NM_009716 0.125 
zinc finger protein 29 (Zfp29) -1.57 transcription regulation    NM_009553 0.337 
mRNA for mszf75, partial cds -1.52 transcription regulation     AB010320 0.307 
LAG protein (Lag) mRNA, complete cds -1.48 transcription regulation     AF182040 0.129 
Max dimerization protein 5 (Mad5) -1.34 transcription regulation    NM_013720 0.362 
zinc finger protein 96 (Zfp96) mRNA, 
complete cds -1.33 transcription regulation 0.279 
human immunodeficiency virus type I 
enhancer-binding protein 2 (Hivep2) -1.25 transcription regulation 
   
NM_010437 0.074 
myeloid elf-1-like factor (Mef) -1.22 transcription from Pol II promoter 
   
NM_019680 0.057 
ash2 (absent, small, or homeotic)-like 
(Drosophila) (Ash2l) -1.14 transcription regulation 
   
NM_011791 0.191 
H6 homeo box 3 (Hmx3) -1.12 transcription regulation    NM_008257 0.178 
mRNA for mszf52, partial cds -1.10 transcription regulation     AB010345 0.070 




Transport     
Rab3D (rab3d) mRNA, complete cds -3.25 intracellular protein traffic     AF263365 0.393 
kanadaptin mRNA, complete cds -2.12 transport     AF035526 0.373 
zinc transporter like 1 (Zntl1) mRNA, 
complete cds -1.76 ion transport     AF233321 0.136 
M.musculus rab19 mRNA -1.56 intracellular protein traffic       X80473 0.195 
fidgetin (Fign) -1.42 intracellular protein traffic    NM_021716 0.304 
solute carrier family 11 (proton-coupled 
divalent metal ion transporters), member 1 
(Slc11a1) 
-1.29 transport    NM_013612 0.161 
adaptor-related protein complex AP-3, 
delta subunit (Ap3d) -1.28 intracellular protein traffic 
   
NM_007460 0.103 
Na+/H+ exchanger (NHE-4) mRNA, 
partial cds -1.27 sodium transport     AF139195 0.272 
0.328 
testicular antigen mRNA, partial cds -1.24 intracellular protein traffic       U69600 0.280 
intracellular calcium-binding protein 
(MRP8) mRNA, complete cds -1.22 chemotaxis       M83218 0.225 
solute carrier family 30 (zinc transporter), 
member 1 (Slc30a1) -1.16 cation transport 
   
NM_009579 0.146 
M.musculus mRNA for beta-chemokine 
receptor D6 -1.08 chemotaxis       Y12879 
Other     
CD8 antigen, beta chain (Cd8b) -2.18 defense response    NM_009858 0.275 
heat shock protein, DNAJ-like 2 (Hsj2) -2.14 heat shock response    NM_008298 0.268 
Notch gene homolog 4, (Drosophila) 
(Notch4) -1.89 neurogenesis 
   
NM_010929 0.372 
retinol binding protein 2, cellular (Rbp2) -1.80 epidermal differentiation    NM_009034 0.123 
cystic fibrosis transmembrane conductance 
regulator (CFTR) mRNA, complete cds -1.73 respiration       M60493 0.178 
proteoglycan 2, bone marrow (Prg2) -1.59 inflammatory response    NM_008920 0.160 
groucho-related protein (Grg2) -1.51 histogenesis and organogenesis 
   
NM_019725 0.315 
glutamic acid decarboxylase 1 (Gad1) -1.47 synaptic transmission    NM_008077 0.315 
myocilin (Myoc) -1.36 vision    NM_010865 0.234 
vanilloid receptor-like protein 1 (Vrl1) -1.32 sensory perception    NM_011706 0.336 
protoporphyrinogen oxidase (Ppox) -1.22 porphyrin biosynthesis    NM_008911 0.388 
tropomodulin 4 (Tmod4) -1.21 muscle contraction    NM_016712 0.145 
mlrq-like protein mRNA, partial cds -1.19 vision       U59509 0.187 
protein phosphatase 2A B'alpha3 
regulatory subunit mRNA, partial cds -1.14 neurogenesis       U59418 0.264 
probasin (Prbs-pending) -1.11 olfaction    NM_017471 0.135 
cytokine-dependent hematopoietic cell 
linker (Clnk-pending) -1.01 defense response 
   
NM_013748 0.168 
Unknown function     
brain cDNA, clone MNCb-1192, similar to 
Homo sapiens retinoic acid repressible 
protein (RARG-1) mRNA 
-2.35 biological process unknown     AB041566 0.181 
mRNA for a stretch regulated skeletal 
muscle protein (Usmg2 gene) -2.20 
biological process 
unknown     AJ290944 0.375 





sialyltransferase 1 (Siat1) gene, partial 
sequence -1.12 
biological process 
unknown     AF177147 0.070 




   
NM_019398 0.153 
mannoside acetyl glucosaminyltransferase 
3 (Mgat3) -1.06 
biological process 
unknown 
   
NM_010795 0.119 
parathyroid hormone precursor (Pthp) -1.03 biological process unknown 
   
NM_020623 0.123 
mRNA for GATS protein -1.00 biological process unknown     AJ296173 0.162 
 
 
Note1: In Table A.G.1, genes with defined threshold of more than two-fold differential expression are 
listed in terms of their known functions.  Each gene is represented with a common name, and the log 
(base 2) ratio of differential expression.  Abbreviations and brief descriptions are also added for most 
genes. 
Note2: Differential expression ratio based on ‘Cy5’ compared to ‘Cy3’, i.e., if ‘Cy5’ > ‘Cy3', “+”; if 






APPENDIX H: Clustering of Microarray Data 
            
To identify the more prominently regulated functions in the same test culture across 
different time-points, temporal (time-based) studies were carried out.  If the data could be 
successful clustered [Eisen et al., 1998], it could be used for cross-referencing with those 
obtained from the comparative studies between zinc- and insulin-supplemented cultures.   
Table A.H.1 (pre-screened data) shows that signal transduction and transcription-
related functions were prominently regulated in both zinc- and insulin-supplemented cultures 
across different time-points.  This is similar to results from the comparative studies shown in 
Section 4.4.  In contrast, very few apoptosis and cell cycle-related genes were differentially 
regulated.  This suggests that the apoptotic and cell cycle processes in the test cultures could be 
largely uniform throughout the 3-day culture period.  It could also mean that those processes 
were largely controlled in a post-transcriptional manner. 
‘k-means’ in Eisen’s Cluster and Treeview software was used to cluster the pre-
screened data, with starting nodes of 10, 50, 100, and 200 (arbitrary choices).  The results were 
ambiguous, as each of the resulting clusters contained genes of highly variant functions 
(clustering results not shown here).  This was contradictory to studies by Eisen et al. [1998], 
which has shown that genes of similar functions exhibited similar temporal transcription-
regulation profiles and could thus be clustered together.  While Eisen used a large number of 
sampling time points in his temporal studies, the effectiveness of such a set-up for batch 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Note1: Clustering of microarray data is used commonly in stimulation/starvation cell culture studies to 
group together genes with similar patterns of expression [Eisen et al. 1998, and references therein].  For 
effective clustering, the samples need to be collected with short intervals.  This is because the 
transcription of early-response genes is normally induced within a few minutes after addition of growth 
factors/stimulants [Lodish, 2001].   
The microarray samples used in this thesis had been maintained in many passages (3-50 
passages) in their respective test media, thus the differential expression profiles of the early-response 
genes could not be elucidated even if shorter sampling intervals were used.  Batch CRL1606 cultures 
could be maintained for a maximum of 3-4 days, while the samples for comparative studies were 
collected at one-day interval.  Thus with only 3 temporal points per test culture, the microarray elements 
(of 7524 genes) could be grouped into only 27 (= 33) clusters, based on ‘up-regulation (>2x)’, ‘non-
regulation (<2x)’, and ‘down-regulation (>2x)’.  This worked out to an expected average of nearly 300 
genes per cluster.  Such high numbers of genes per cluster would hinder subsequent data mining and 
analysis, as it was likely that each cluster would contain genes previously classified under vastly 
different functions.   
Furthermore, ‘Day-2 vs. Day-0’ experiments would be meaningless, as the cells have been 
passaged at 2-day intervals, and a Day-2 sample is just one passage ahead of a corresponding Day-0 
sample.  With a long adaptation period in the test media, the transcriptional profiles of ‘Day-2’ and 
‘Day-0’ cells could be nearly identical.  The abandoning of ‘Day-2 vs. Day-0’ experiments would 
further lower the number of possible working clusters to only 9 (= 32), and dramatically increase the 
number of genes that can be grouped into the same cluster.   
Note2: ‘Stimulation studies’ refers to studies conducted on the effects of an essential media component, 




APPENDIX I: Pathway Visualization of Zinc Dosage Response 
            
 
 
Figure A.I.1 GenMapp pathway visualization of data from the ‘low-zinc’ vs. ‘optimal-zinc’ 
comparative study [Section 4.5]. The value shown on the right of each gene label is the mean 
log2 ratio for that gene (n = 3, before screening).
 
Note: Pre-screened data was used in Figure A.I.1 as the process of screening filtered off most of the 





APPENDIX J: Sample Calculations 
            
 
Data for the following sample calculations originated from the comparative study of 
zinc- vs. insulin-supplementation.  The expression data of PUR-1 gene (Accession no.: 
L04649) in the study is used to demonstrate computations based on a single gene. 
A.J.1. Microarray Data Normalization 
The following shows sample calculations for microarray data normalization [Section 
3.2.6.3]: 
The mean comparative-expression ratio amongst all genes was assumed to be 1.0 in all 
of the replicates.  Using this approach, a normalization factor (Ntotal) was calculated by 





















where Ri and Gi were defined as the measured signal intensity minus background signal 
intensity of Cy5 and Cy3 channels respectively for the ith element, and Narray represents the 
total number of genes in the array (Narray = 7524). 
One of the intensities were then appropriately re-scaled using: 
0.528.2694.1' =⋅== itotali RNR  
(A.J.2) 












Compute log2 transformation of the normalized expression: 
49.18.2loglog 22 === ii TM  
(A.J.4) 
Compute the total intensity of that spot or hybridisation strength: 




The ‘M-A’ plot could be used to review intensity-specific artefacts in the log2(ratio) data 
[Figure A.J.1]: 
 
Figure A.J.1 An intensity distribution plot showing lowess 
normalization of intensity dependent dye bias 
 
Based on a quadratic line inserted into the ‘M-A’ plot, the lowess-normalized log2(ratio) could 
be computed: 
53.1]1794.096.40438.096.4001.0[49.1)( 2, =+⋅−⋅−=−= iiinorm AyMM  
(A.J.6) 




A.J.2 Pearson’s Coefficient 
The following shows sample calculations for Pearson’s correlation: 
( ) ( )( )



















r = Pearson’s coefficient 
n = number of paired observations = 7524 
X = variable in an array of independent values  
      = M a replicate in the zinc vs. insulin comparative study 
        = M another replicate in the zinc vs. insulin comparative study 
norm,i of 






A.J.3 Student’s t-test 
The following shows an alternative approach to Student’s t-test computation for 
statistical screening of microarray data, to the hypothesis-test based approach shown in Section 
3.2.7.   Both of these approaches should yield the same p-values, and thus one approach could 
be used to counter-check the p-values computed from the other approach.   
 




,, =++== ∑A inorminorm MAM  
(A.J.8) 
then calculate the sample standard deviation: 
 ∑ −−= i inorminormi MMAs 2,, )(11  
])15.190.0()15.153.1()15.101.1[(
13
1 222 −+−+−−=  
335.0=  
(A.J.9) 
















p-value (i.e. significance level) was then obtained by using normal transformation with 2-tailed 
t-distribution and (A-1) degrees of freedom.  This could be done by the Excel function 
‘TDIST(t-value,2,2)’.  For this gene, the p-value was 0.027. 
